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ABSTRACT 
SHEDDING LIGHT ON GENERAL ANESTHESIA: UNCOVERING THE 
MOLECULAR MECHANISMS OF PROPOFOL AND VOLATILE ANESTHESTICS 
Kellie A. Woll 
Roderic G. Eckenhoff 
 General anesthetics have played a pivotal role in the history of medicine. Despite 
accounts of their use within the earliest of human records, our understanding of anesthetic 
mechanisms remains unclear. Understanding these molecular mechanisms would be a 
significant advance toward enhanced drug design and optimal the clinical use of these 
potentially hazardous agents. Recent advances in chemical and molecular biology, 
including photoaffinity labeling, have allowed enhanced appreciation of the complex 
interactions anesthetic’s have with their macromolecular substrates. This work is 
dedicated to further define the protein interactions of the frequently administered volatile 
anesthetics sevoflurane and isoflurane, as well as the most commonly used intravenous 
anesthetic, propofol. A novel photoaffinity ligand for sevoflurane was validated and 
applied to uncover the unique mechanism of sevoflurane positive modulation of 
mammalian Shaker Kv1.2 channels. This novel sevoflurane photoaffinity ligand was in 
addition to a previously developed photoaffinity ligand for isoflurane, further applied to 
determine the anesthetic binding sites within a vital protein target, synaptic GABAA 
receptors. The molecular recognition elements for propofol-protein interactions were 
probed using a novel hydrogen-bond null derivative.  It was determined that the propofol 
1-hydroxyl is key for molecular interactions that contribute to anesthetic endpoints, such 
as synaptic GABAA receptor positive modulation, while less significant for other known 
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biological effects like decreasing muscle contractility. The range of propofol-binding 
proteins within synaptosomes was further defined with the synthesis of a novel 
photoaffinity tandem click chemistry-active ligand and the development of a quantitative 
affinity-based protein profiling workflow. Results of the investigation indicated a highly 
complex pool of propofol-specific proteins including an unbiased, selective binding of 
specific synaptic GABAA receptor subunits. The likely propofol binding cavities and the 
underlining molecular recognition features that contribute to the selective GABAA 
receptor subunit binding were examined using molecular dynamics simulations and 
photoaffinity protection studies. Together these series of studies suggest that general 
anesthetics bind a to range of molecular substrates that cumulatively result in general 
anesthesia phenotypes and that multiple, functionally distinct, binding sites can be 
present within a single protein target.   
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CHAPTER 1: INTRODUCTION TO GENERAL ANESTHESA RESEARCH AND 
PHOTOAFFINITY LABELING 
General anesthesia is among the oldest medical practices exercised by man. 
Despite this continual underlining application throughout our history, general anesthetics 
still maintain a strong stance as a ‘black-box drug’; our lack of understanding of their 
actual mechanisms of action, pharmacological endpoints and side effects is 
overshadowed by their current common use. Starting with joint hypothesis by Overton 
and Meyer in 1899 and 1901, which relates anesthetic potency with solubility in olive oil 
1,2, there has been a push to gain insight into how these drugs work in order to improve 
their design and/or administration. The movement to further our understanding has truly 
started to gain momentum within the last half-century resulting in the solidification of 
anesthesiology research as a field in medical science.  
The objective of this work is to add to this field by contributing a series of 
investigations focused on defining the molecular mechanisms of two inhalational or 
volatile anesthetics, sevoflurane and isoflurane, and one intravenous anesthetic, propofol. 
Photoaffinity labeling, a technique first introduced in the 1970s 3–5, has shown to be very 
useful in anesthesiology research. The first section of this chapter includes a concise 
summary on the historical background for general anesthetic development and discovery 
as well as short perspective. The second section examines all aspects of photoaffinity 
labeling within anesthesiology research, including the current methodologies and ligand 
design, characterization, and deployment. This section also includes points of 
consideration and highlights the future outlook as more photoaffinity ligands emerge 
within this field. 
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1.1. Brief Historical Sketch 
Behind every drug class is a story of ‘discovery’ and the individuals that 
contributed to each drug’s development. This holds true for general anesthetics 
particularly with their extensive, and rather turbulent, history. It is significant to have a 
fair understanding of a drug class’s history to grasp the background behind the current 
and the potential future understanding of drug mechanisms. Furthermore, it provides an 
appreciation for the achievements of these agents, and the persons that ultimately brought 
about modern medical practices as we see it today. 
1.1.1. An Ancient Realm 
General anesthesia, with the multiple components therein (eg. hypnosis, amnesia and 
immobility) 6, allows for a patient to undergo normally painful medical procedures 
without recall. The induced immobility enables the acting medical professional to 
conduct a procedure with considerably less physical hindrance. Because of our natural 
avoidance of pain, anesthesia’s ancient history is no surprise. Translations of cartiod in 
Greek (karotida) and Russian (sonnaya areteriya) are derived from ‘sleep’ or ‘stupor,’ 
suggesting that even our primitive ancestors may have applied compression to carotid 
arteries in order to physically produce a state similar to anesthesia. 
The ancient civilizations, from Egyptians to the early Greeks and Romans as well as 
the ancient Arabians, Hindus, and Chinese, all show records for inducing the anesthesia 
state with use of Indian Hemp, poppy, and/or mandrogora, alone or within complicated 
preparations 7,8. Pedanius Dioscorides, a pharmacologist, physician, and botanist of the 
Roman Empire describes a preparation within De Materia Medica (“On Medical 
Material”), the first pharmacopeia, using mandrogora and sweet wine. This preparation 
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that would cause a patient to be “thrown into a deep sleep, [where] they do not feel any 
pain.” 9 Records of anesthesia during surgical practices also exist for the Middle Ages, 
including inhalational administration with ‘spongia somnifera’, or the ‘sleeping 
sponge’10. Theordoric, the son of a 15th centenary Tuscan Physician, described that when 
applied over the nose and mouth, the sleeping sponge was so effective that some patients 
would not awaken for several days unless a countering medicinal agent like vinegar was 
used7,10.  
While recorded, the frequency in the use of general anesthesia in early history would 
be considered scarce compared to modern day. This could be attributed to a variety of 
reasons such as the lack of widespread knowledge, as well as poor availability. It is 
likely, however, that the main cause for the lesser use stemmed from the unpredictability 
in potency of the plant-based preparations7,8. Lord Nelson of the British Royal Navy 
provides an account of the variability when he requested that the surgeon had a pot of hot 
water ready so, if the anesthetic failed, at worst he would feel a warm knife during the 
amputation of his right arm during the French Revolutionary Wars11. Because of the lack 
of knowledge and inconsistency, general anesthesia would have likely faded from 
medical practice. If it were not for the advances that occurred mostly in the 1800’s now 
dubbed the ‘Chemical Era of General Anesthetics’, general anesthesia as we now see it 
would not exist. During this era, modern anesthetics started to emerge and these drugs 
were pushed to the forefront to eventually become amongst the most important advances 
within medicine. 
1.1.2. The Chemical Era of Empirical Domination 
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 The increased understanding of gases and vapors within the later 1700’s led to the 
isolation of nitrous oxide.  The discovery of the of the gas’s analgesic and anesthetic 
effects accredited to Humphry Davy 12,13.  Professor Thompson of Glasgow further 
demonstrated the anesthetic properties of nitrous oxide and sulpheric ether by 
administering the gases to volunteering students as a form of entertainment to his 
students (and himself) 7. However, application of these chemicals within practical 
medical purposes was not fully appreciated until almost half a century later.  
 Dentist Horace Wells is recognized as the leading advocate for the use of nitrous 
oxide as the earliest form of modern general anesthesia when he himself was treated 
while getting a tooth pulled by Dr. G.Q. Colton 7. However, foretelling future troubles 
with this class of drug, Dr. Wells was unable to successfully administer the agent during 
a formal medical demonstration. This unfortunate event resulted in the denouncement of 
nitrous oxide, the procedure, and Dr. Wells 14.  
 Years later the combined effort of Charles Jackson and W.T.G. Morton eventually 
accumulated to the first successful surgical operation demonstration with ether on Friday, 
October 16, 1946 at Massachusetts General Hospital 7,15. The amphitheater was packed 
with medical professionals and the success of the procedure, which took no more than 
five minutes, propelled general anesthesia and anesthetics into the limelight. The event is 
forever immortalized in the Robert Hinckley oil painting “First Operation Under Ether” 
and with the amphitheater being renamed the ‘Ether Dome’.  
 In the first few decades following ether’s acceptance into medicine, hundreds of 
other anesthetic gases were considered and many were tried. These attempts were all by 
trial and error with risks being particularly high. Two gases emerged with the highest 
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potential; chloroform and the re-discovered nitrous oxide, however both were very 
expensive, difficult to administer, and displayed many unwanted side effects 16.  
A third gas, cyclopropane, also showed promise as an anesthetic if not for the 
coinciding extremely high explosive property 17,18. Nevertheless cyclopropane, while in 
no way safe to use during surgical cautery and/or the age of electric monitoring, did 
provide vital insight for future drug chemotypes. John C. Krantz Jr. of the University of 
Maryland added his knowledge of halogenation, which decreases flammability relative to 
the hydrocarbon, and opened the door to a new series of compounds as potential general 
anesthetics 19. With shotgun empirical approaches led by various chemists, halothane 
emerged and gained worldwide acclaim as the prime general anesthetic in the mid-to-late 
1900s. Then, due to an associated side effect called ‘Halothane hepatitis’18, halothane 
decreased in favor allowing for fluorinated ethers to come forth as an optimal volatile 
anesthetic chemotype with isoflurane (1972), desflurane (1992) and sevoflurane (1994) 
being introduced into clinical use 16,20.  
 Parallel with the development of volatile agents, alternative routes for 
administering general anesthetics were also being considered. The first intravenous 
anesthetic, choral hydrate, was demonstrated in 1872, however the agent did not gain 
much popularity due to a relative mild anesthetic effect compared to the unwanted side 
effects 21. It was not until the concept of ‘balanced anesthesia’ proposed by Dr. John 
Lundy (i.e. administration of combinations of anesthetic agents at lower doses reduces 
undesired side effects), the discovery of sodium thiopental 20, and a push for agents that 
could be more readily transported and applied on the battle field11,22 that intravenous 
anesthetics became more conventional. The development of intravenous anesthetics 
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gradually progressed, much like their volatile counterparts, with the laborious synthesis 
of huge chemical libraries and empirically based pharmacological screening. Eventually 
agents including ketamine (1964) and later etomidate (1975) were discovered and 
administered to induce anesthesia 23–25 in combination with volatile agents to maintain 
anesthesia. It was not until propofol (1977) 26 that total intravenous anesthesia (or the 
“TIVA” method)27 was applied. Intravenous anesthetics also, to varying degrees, resulted 
in specific unwanted side effects compared to volatile agents, namely cardiovascular 
depression28.  
 From the use of the carotid artery to sevoflurane and propofol, the majority of the 
advances within general anesthetic development have been by serendipity and empiricism 
with no systematic evaluation of the actual molecular mechanism(s) or the state of 
general anesthesia. Indeed Professor James Simpson and his assistants would, after a long 
day of work, sit down and inhale vapors of their various compounds out of tumblers to 
eventually come across chloroform 7. The professor in the neighboring office commented 
on his fears of what he may find when he came in the next morning 7. Therefore it is not 
surprising that by this method various harmful drugs like phencyclidine (or PCP) 20 were 
exposed to wide populations or how acceptable drugs were dismissed, delayed, and/or 
stigmatized. Fortunately an alternative approach in anesthesiology research has arisen, 
with the science community focusing on furthering our understanding of what the 
anesthesia state entails and determining the underlining mechanisms.  
1.1.3.What’s the Point of a Molecular Hunt? 
 General anesthetics are used at least an estimated 200 million times per year in the 
United States alone 29. In total, undergoing general anesthesia is considered to be a 
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relatively safe experience when administered by the appropriate, highly trained medical 
professional, an anesthesiologist. As a result of this, in combination with the cost of drug 
development, there has been a lack of interest to invest in anesthesiology research, 
particularly in the pharmaceutical industry, adopting a natural viewpoint of, ‘Why fix 
what’s not broken?’   
 It still remains that general anesthetics are among the most dangerous drugs 
currently used in medicine. Even the modern clinical agents still display very narrow 
therapeutic indices (LD50/ED50) such as 6-12 and 2-4 for propofol and sevoflurane 
respectively 30,31. Much of the observed toxicity is from the overt acute side effects, 
notably respiratory and cardiovascular depression 28. Ample opportunities for improving 
administration and/or drug design exist to reconcile these known adverse effects. 
Furthermore, increasing evidence suggests other, lesser-known side effects might be 
present, including those on neurodevelopment and neurodegeneration 32–34. While 
research on these effects is not conclusive, these and other acute or chronic impacts on 
health -particularly within sensitive populations- are a cause for concern and warrant 
further investigation.  
An additional avenue to apply a further understanding of anesthetic mechanisms 
is within precision medicine, also known as personalized, predictive, preventive and 
participatory (‘P4’) medicine 35. While treatment strategies that account for individual 
variability are by no means a new concept, P4 medicine is gaining in popularity 
particularly with a large push for drug repurposing and the development of more robust 
personalized treatment predictions. Drug repurposing has already shown promise with 
general anesthetic ketamine, which has displayed signs as a useful antidepressant 36. 
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Finally, much within neurobiology remains a mystery, and given that general anesthetics 
are capable of inducing multiple interesting behaviors, likely through distinct pathways, 
these drugs can be applied to further probe the underlining molecular contributors. 
1.1.4. Conclusions 
 General anesthetics are considered very old drugs with a presence reaching the 
earliest recorded history 7,8. It is interesting how, regardless of this, we know so little of 
anesthetic mechanisms of action. In a sense our practiced expertize in administration of 
these difficult and dangerous agents has stalled investigations. However, the increasing 
concerns, a need for better care, as well as healthy scientific curiosity kindled a fire to 
extend our understanding. In combination with technological advances, we have the 
potential to gain insight into the workings of the ‘black-box’ that is general anesthesia 
and to further our understanding of neurobiology.  
1.2. Photoaffinity labeling: Shining-light on hidden binding sites 
Studying the interactions between general anesthetics and their macromolecular 
targets is crucial to the understanding of the biochemistry for these drugs. In recent years 
the application of photoaffinity labeling for this purpose has gained popularity. 
Traditionally the objectives of this method are to allow researchers to identify the binding 
site(s) within established targets (micro-level) and, to a lesser extent, determine novel 
binding molecules and distribution within a given biological system (macro-level).  
Within anesthesia research there has been significant advancement in the development of 
PALs (photoaffinity ligands), from the initial use of neat halothane 37 to complex 
syntheses of bifunctional PALs allowing for affinity-based protein profiling (ABPP) 38,39.  
1.2.1. Anesthetic-Photoaffinity Ligand Development: Making ‘a-PAL’ 
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In the current process of photoaffinity labeling, the chemical structure of the drug 
of interest (parent ligand) is modified to incorporate a photoreactive group that, upon 
ultra-violet (UV) irradiation, generates a highly reactive chemical intermediate. This 
intermediate then chemically ‘modifies’ or ‘labels’, by covalent insertion to a bond in 
close proximity, such as solvent components or an occupied macromolecule. In the 
instance of a PAL bound to a macromolecule, the covalent insertion acts as a traceable 
modification that can be used to investigate ligand-target interactions and/or ligand 
distribution within the organ or tissue. A critical advantage that PALs provide for general 
anesthetics is that they mitigate the relative lower binding affinities, generally 
micromolar, associated with this particular class of drugs. They accomplish this by 
dramatically prolonging drug unbinding rates -to irreversibility-, thereby providing a 
snapshot of these otherwise transient interaction(s). On the other hand, the inherent high 
dissociation constants of anesthetics remains an experimental hurdle chiefly by adding to 
the difficultly in validation of specific binding sites in photoaffinity labeling studies.  
Several factors are considered during the design of an anesthetic PAL or a-PAL; 
most notably that introduction of the photoreactive group into the anesthetic chemical 
structure does not significantly alter the biochemical and pharmacological properties of 
the parent drug. Diazirines are nearly universal as the photoreactive group incorporated 
within a-PALs (Figure 1). With UV irradiation, diazirines undergo photoactivation, 
resulting in the release of an inert dinitrogen molecule and the generation of carbene 
chemical species that indiscriminately inserts into the nearest molecule.  The popularity  
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of this particular photoreactive group can be largely attributed to the less damaging UV 
wavelength needed for photoactiviation, its relative stability and smaller size, and highly 
reactive intermediate product, the carbene. In combination, these attributes allow for 
lesser deviation of binding properties compared to the parent anesthetic. Past reviews 
further discuss the development and use of PALs and photoreactive groups 5,40–42 in 
detail. 
 
Figure 1. Chemical and spherical structures of general anesthetics and corresponding 
photoaffinity probes. With the exception of halothane, a diazirine serves as the photoactive group. 
Halothane and Haloethers (a); halothane (left), isoflurane (middle), aziisoflurane (right). Alcohols 
(b): octanol (left), 3-azioctanol (right).  Neurosteriods (c); pregnenolone (left), 6-azipregnenolone 
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(right). Alkylphenols (d); propofol (top left), meta-azipropofol (top right), para-4-aziC5-propofol 
(bottom left), ortho-propofol diazirine (bottom right). Barbiturates (e); pentobarbital (left), m-
TFD-mephobarbital (right). Imidazoles (f); etomidate (top), azietomidate (upper middle), pTFD-
etomidate (lower middle), TDBzl-etomidate (bottom) 
In practice, the design and synthesis of a-PAL to effectively mimic a general 
anesthetic can be arguably the most difficult process due to the challenging synthesis of 
stable molecules containing unstable photoreactive groups, and the lack of in-depth 
knowledge of molecular recognition elements between anesthetics and their important 
macromolecular targets. The small size and relatively featureless nature of most general 
anesthetics makes any chemical modification, even a diazirine, a relatively large 
perturbation.  As it stands, even the best-designed a-PAL requires considerable chemical 
deviation from the parent anesthetic structure (exception being halothane 37) and alone 
cannot definitively determine a binding target and/or site for the parent drug.  
After incorporation of the diazirine into the anesthetic chemical structure, the 
resulting changes in physicochemical properties require careful characterization before 
experimental deployment of the a-PAL. The stability and photoactivation efficiency of 
the diazirine (or any incorporated photoreactive group) are unique to each developed a-
PAL. The diazirine moiety should produce a distinctive and pronounced UV absorbance 
5,43 that decays with increasing exposure to the appropriate UV wavelength 44,45. The rate 
of decay provides an estimate of photoactivation efficiency within the given buffer. A 
basic equation (Eq. 1) 4 can give the half-life of photoactivation (T1/2) with relationship to 
the intensity of the lamp (I0) applied, molar extinction coefficient (ε) and quantum yield 
of photoactivation (Ψ).   
Equation 1. 4 
T1/2 = 0.3/ (ΨI0ε)        
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The chemical nature of the subsequent reactive intermediate generated by 
photoactivation is also unique to each a-PAL. The reactivity of the intermediate directly 
influences the propensity to covalently insert into near-by molecules or, depending on 
ligand chemical structure, itself (e.g. intramolecular reactions). For example, studies of 6-
azipregnanolone, an a-PAL derivative for pregnanolone, reported that major 
photoactivation products were likely generated from internal rearrangement or 
bimolecular insertion reactions 46. As a result, some macromolecular sites would not be 
sufficiently represented to allow for detection due to low to zero yield of adducted 
intermolecular products.  
 Assuming that a photoactivated ligand intermediate demonstrates sufficient 
probability for intermolecular interactions, it is generally considered that most carbenes 
do not demonstrate significant preference for covalent insertion. This includes solvent 
molecules that, under usual conditions, are in far greater abundance than a target 
macromolecule. For example, the singlet carbene intermediate is readily quenched by 
covalent insertion into adjacent water molecules 47. Similarly, amphipathic molecules of 
perhaps less interest than proteins, such as lipids and/or detergents, have also been shown 
to be readily adducted 42. Weiser et. al. demonstrated that the tritiated propofol derivative 
[3H]meta-azipropofol ([3H]AziPm), while showing preference towards synaptic dense 
regions (and therefore presumably protein), ubiquitously labeled whole rat brain, 
implying that lipids also act as a considerable photomodified product 48.   
Increasing evidence has suggested that proteins are a significant contributor to 
anesthetic mechanisms. As such, a-PALs have been applied toward understanding protein 
binding sites of anesthetics. Table 1 gives the list of photoadducted residues of halothane 
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and diazirine-containing anesthetic PALs with protein targets. To our knowledge, there 
has not been a systematic investigation on an anesthetic photoaffinity ligand that 
conclusively demonstrates preferential insertion into selected amino acids within a 
protein or polypeptide. Indeed previous work has demonstrated that, while the efficiency 
(defined as mole of PAL per mole of stationary pure amino acid) of labeling of specific 
amino acids may be greater for a given PAL (e.g. Cys, Trp, His, Phe), a carbene can 
covalently insert into all amino acids even within a transmembrane domain 42,49. It should 
be noted that backbone atoms within a protein, not just side chains, can act as potential 
insertion sites. Indeed, previous evidence with aziisoflurane modification of apoferritin 
(aF) implies that backbone atoms (such as the carbonyl oxygen) are suitable 
photomodification sites 50.  
An exception to preferential residue labeling arises with aliphatic-diazirines and 
their increased predisposition to undergo diazo isomerization, an alternative 
intramolecular rearrangement. The diazo isomerization of the diazirine can lead to the 
generation of a carbocation, rather than a carbene, an intermediate that preferentially 
undergoes electrophilic attack of electron dense (nucleophilic) residues 43. The fraction of 
the PAL generated by isomerization is specific to the chemical properties of the PAL, 
with the event being debated for some aliphatic-diazirines 51. Regardless, the propensity 
of labeling Asp, Glu, His, and Tyr by azietomidate 52,53 led to the development of the 
etomidate derivatives pTFD-etomidate 54 and TDBzl-etomidate 55, both of which contain 
trifluoromethyl diazirine and trifluoromethylaryl diazirine respectively. These additional 
chemical groups chemically favor carbene generation, rather than diazo isomerization,   
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Table 1. Summary of adducted residues by anesthetic photoaffinity ligands (a-PALs) using amino 
acid sequencing methods	  	  
Parent 
anesthetic 
Anesthetic 
photoaffinity 
ligand 
Amino acid 
sequencing 
methoda 
Protein Residue Ref. 
halothane halothane Edman 
degradation 
(14C) 
apo-ferritin Trp-15 56 
nAChR αTyr-213, γTyr-111, 
δPhe-206 δTyr-228 
57 
octanol 3-azioctanol Edman 
degradation 
(3H, 1H) 
nAChR αTyr-190, αTyr-198, 
αGlu-262, αHis-408, 
αCys-412 
53 
MS/MS adenylate kinase His-36 58 
neural cell adhesion 
molecule L1  
Glu-33, Tyr-418 59 
protein kinase Cδ Tyr-236, Lys-40, Glu-
2 
60 
protein kinase Cε Tyr-176, Tyr-238, 
Tyr-250 
61,62 
japanese firefly 
luciferase 
Glu-313 63 
isoflurane aziisoflurane MS/MS apo-ferritin Arg-59 50 
lymphocyte function 
associated antigen-1  
Leu-135, Glu-137, 
Tyr-257, Leu-302, 
Lys-304, Lys-305 
50,64 
platelet receptor integrin 
aIIbb3  
Asp-158, Lys-159 65 
etomidate azietomidate Edman 
degradation 
(3H) 
nAChR αTyr-98, αTyr-190, 
αGlu-262, αGlu-390, 
αCys-412, βAsp-268, 
δAsp-59, δSer-258, 
δCys-236, δSer-262, 
δGln-276  
52,66 
GABAA receptor α1Met-236, β1Met-
286  
67–69 
pTFD-
etomidate 
Edman 
degradation 
(3H) 
nAChR αLeu-251, αSer-
252,αVal-255, αLeu-
258, βLeu-257, βLeu-
261, δLeu-265, δVal-
269 
54 
TDBzl-
etomidate 
Edman 
degradation 
(3H) 
nAChR αLeu-251, αSer-252, 
αVal-255, γMet-299, 
δLeu-265, δVal-269, 
δLeu-272, δLeu-273, 
δGln-276 
70 
GABAA receptor α1Cys-234, α1Met-
236, β3Met-286, 
β3Cys-288, β3Val-290 
71 
barbituate (R)-(-)-mTFD-
mephobarbital 
Edman 
degradation 
(3H) 
nAChR αIle-231, αMet-242, 
αCys-412, βMet-249, 
βSer-254 βLeu-257, 
βVal-261, βLeu-265, 
γCys-252, γMet-299, 
δMet-257, δSer-258, 
72 
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δSer-262, δLeu-265, 
δVal-269  
GABAA receptor α1Ala-291, α1Tyr-
294, β3Met-227, 
β3Met-227, γ2Ser-301 
73 
pregnanolo
ne 
6-
azipregnanolon
e 
MS/MS tubulin Cys-354 46 
GABAA receptor β3Phe-301 74 
propofol meta-
azipropofol 
Edman 
degradation 
(3H, 1H) 
nAChR αSer-248, αSer-252, 
δArg-277, δPhe-232, 
δCys-236, δVal-269, 
δThr-274  
75 
GABAA receptor α1Met-236, α1Ile-239, 
β3Met-227, β3Met-
286 
76 
GLIC Met-205, Tyr-254, 
Met-261, Asn-307 
77 
MS/MS apo-ferritin Leu-24, Leu-81 78 
lymphocyte function 
associated antigen-1 
Ile-254, Tyr-257, Ile-
258, Lys-287, Leu-
302, Lys-304 
79 
SIRT2 deacetylase Tyr-139, Phe-190, 
Met-206 
80 
VDAC Gly-56, Val-184 81 
para-4-aziC5-
propofol b 
 nAChR  82 
ortho-propofol 
diazirine 
MS/MS human serum albumin Lys-41, Trp-111, Lys-
525, His-535, Lys-536  
83 
GABAA receptor βHis-267 83 
(nAChR) nicotinic acetylcholine receptor; (GABAA) γ-aminobutyric acid type A; (GLIC) 
gloeobacter ligand-gated ion channel; (SIRT2) sirtuin-2 ; (VDAC) voltage-dependent anion 
channel. a Noted in ( ) with Edman degradation amino acid sequencing method are the isotopes 
used for photoaffinity ligand detection. bpara-4-aziC5-propofol  was not applied in amino acid 
sequencing however displayed adduction to nAChR by gel electrophoresis and autoradiography 
 
leading to the desired indiscriminate covalent insertions 5,43,84.  The synthetic changes of 
etomidate a-PALs resulted in a broader range of labeled residues, including hydrophobic 
residues 55,85,86.  However whether these modifications were due to changes in 
photochemistry and/or to altered equilibrium binding due to the changes in chemical 
structure is unclear. 
 It is universally agreed that any novel anesthetic derivative, including a-PALs, 
requires a thorough investigation of biochemical and pharmacological activities to assure 
16 
 
retention of parent drug characteristics. These studies can be placed in three basic groups; 
1) equilibrium binding to anesthetic protein models, 2) isolated functional studies, and 3) 
in vivo demonstration of pharmacological endpoints.  
Initial determination of similar equilibrium binding to model proteins provides 
some evidence towards the retention of basic molecular recognition elements 
(hydrophobic forces, hydrogen bonding, van der Waals (vdW) volumes and electrostatic 
forces, etc.) between the parent drug and developed PAL. Well characterized anesthetic 
protein models previously crystalized in complex with the parent anesthetic at high 
resolution, such as apo-ferritin (aF)87,88 and human serum albumin (hSA) 89,90, are often 
used.  
 The a-PAL should demonstrate similar functional effect(s) within an established 
protein target as the parent general anesthetic. For many micro-level studies, the targets 
considered include the cys-loop pentameric ligand gated ion channels, such as the 
nicotinic acetylcholine receptor (nAChR) and γ-amino butyric acid type A (GABAA) 
receptor. Functional characterization therefore requires electrophysiology. Within these 
studies investigators often observe changes in potency and/or efficacy dependent on the 
type and position of chemical modifications made to turn the parent anesthetic into an a-
PAL, as observed with the meta- and ortho- trifluoromethyl-diazrine substitutions on 
propofol photoaffinity ligands 78,83. Similarly the different a-PAL derivatives of 
etomidate show altered activity on nAChR including approximately 5-fold differences in 
potency between azietomidate and pTFD-etomidate for inhibition 54,91. Because the 
contributions of these individual targets to the desired effect (anesthesia) is not known, it 
is not clear a priori how important these subtle changes in potency are for the 
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interpretation of photoaffinity labeling data. Regardless, these studies aim to demonstrate 
that the ligand retains the functional activity as the parent anesthetic. However this 
demonstration, while necessary, is not sufficient to indicate a shared binding site, 
particularly with these relatively lower affinity agents, in that the a-PAL may act as a 
functionally active ligand but at other distinct site(s).  
In addition to retention of activity in a reductionist system, retention of in vivo 
activity is also considered a necessary form of validation of the a-PAL. These studies 
usually include tadpole immobility assays or rodent loss of righting reflex. Since the 
mechanisms by which any of the general anesthetics produce their in vivo endpoints 
remain unclear, the retention of in vivo activity alone is insufficient evidence to support 
binding and action at specific protein targets. An interesting demonstration of this is 
TDBzl-etomidate, an etomidate a-PAL derivative. TDBzl-etomidate demonstrates 
comparable potency for tadpole immobility and more potent potentiation of the GABAA 
receptor relative to the parent anesthetic 55. However unlike etomidate, this a-PAL acts as 
a positive modulator of nAChR, 54 indicating that caution is required when attempting to 
correlate in vivo potency and a shared binding site within a specific target 
macromolecule. Additionally it should also be noted that the above noted in vivo models, 
and the overt endpoint(s) that are generally used (ie. immobility), do not represent the all 
components of anesthesia or adverse effects. 
Each of the biochemical and pharmacological investigations can be extended to 
provide evidence to confirm an a-PAL’s capabilities to successfully insert into the bound 
targets after photoactivation. For example photoaffinity labeling of model proteins with 
halothane 37, isoflurane 50, or propofol 78,83 a-PAL derivatives have demonstrated 
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insertion into residues lining the crystallographically confirmed site of hSA or aF. 
Irreversible enhancement of GABAA receptor gating and desensitization has been 
reported upon azietomidate photoactivation 92. Meta-azipropofol (AziPm) photoactivation 
in vivo has shown significant prolongation of emergence, nearly 10-fold, of tadpole 
immobility 93 suggesting successful covalent insertion into a sufficient mass or number of 
targets that contribute to an anesthetic endpoint. While the absence of this 
‘optoanesthesia’ feature does not negate the validity of an a-PAL, its presence is strong 
evidence for validity and utility. Evidence for reliable photomodification can be 
considered just as important as the studies demonstrating retention of biochemical and 
pharmacological activity in that this characteristic is directly responsible for the 
identification of novel binding partners. 
1.2.2. Micro-level Photoaffinity Labeling 
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Figure 2. Simplified schemes for the major methods used in micro-level anesthetic photoaffinity 
labeling; a) Edman degradation b) Tandem mass spectrometry (MS/MS).  a) Edman degradation; 
ia) enriched target protein is photoaffinity labeled with radiolabeled (*) anesthetic photoaffinity 
ligand (PAL) and protein(s) are separated and digested into peptides; iia) peptides are isolated and 
rigorously purified; iiia) the first amino acid from the N-termini is cleaved from purified peptide 
via Edman reaction; iva) the cleaved amino acid is isolated, quantified and separated into two 
pools for (top) radioisotope detection by scintillation counting and  (bottom) amino acid 
identification by chromatography; va) the cycle is repeated, gradually sequencing the entire 
purified peptide; via) the amino acid sequence is plotted against radioactivity (cpm, counts per 
minute, or dpm, disintegrations per minute) resulting in radioisotope release profile. b) Tandem 
mass spectrometry (MS/MS); ib) enriched target protein is photoaffinity labeled with anesthetic 
photoaffinity ligand (a-PAL) and protein(s) are separated and digested into peptides that are 
further separated by on- and/or offline chromatography methods; iib) peptides undergo ionization 
generally by electrospray ionization (ESI) or matrix-assisted laser desorption/ionization 
(MALDI); iiib) precursor ions are separated by mass/charge (m/z) within MS1 (aka. MS1 
precursor ion); ivb) MS1 precursor ion undergoes mass fragmentation often by collision-induced 
dissociation (CID) resulting in largely b or y fragment ions; vb) mass spectrometry software are 
used for data acquisition, database search analysis and representation.  
 
 The majority of studies currently represented in the literature use a-PALs to 
determine anesthetic binding sites within a specific pre-selected protein target, termed as 
a ‘micro-level’ approach. The identification and characterization of drug binding sites 
promotes increased understanding of the molecular mechanism(s) within 
pharmacological targets and, potentially, drug modifications to improve the drug safety 
profile. 
Two different methodologies of protein microsequencing are commonly used to 
identify protein binding sites photoaffinity labeled by an a-PAL. These include Edman 
degradation (ED) and mass spectrometry (MS), both of which determine binding sites to 
the amino acid level. Simplified schematics for both methods are shown in Figure 2A-B. 
ED and MS have been used extensively for multiple types of potential protein targets, 
soluble and insoluble, over the entire range of a-PALs (see Table 1) and much has been 
learned in terms of binding site location, specificity and actual mechanism of protein 
dysfunction. Depending on the characteristics and size of the investigated protein target, 
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both ED and MS can become complex. For example, larger multimeric membrane 
proteins may require additional steps of precipitation, separation and protease digestions 
in order to achieve sufficient coverage of the sequence to confidently reveal or exclude 
photomodified sites.  
While the fundamental endpoint result of either method is identical (e.g. 
identification of the photomodified amino acid), the means to gather the results are 
notably different. For ED, individual amino acids are sequentially and chemically cleaved 
(e.g. Edman reaction) from pools of purified peptide fragments from the digested target 
protein. The resulting pool of the cleaved amino acid is then separated into two smaller 
pools; one used for the identification of the amino acid using high-performance liquid 
chromatography (HPLC), the other to detect whether this amino acid contains a 
radiolabeled a-PAL modification. It should be noted that when a backbone atom is 
labeled by the radiolabeled a-PAL, the Edman reaction (or prior peptide cleavages) might 
be retarded. Although this has not been systematically studied, evidence in support of the 
possibility is the frequent observation that subsequent amino acid yield decreases after a 
radiolabeled amino acid. 
In contrast, in the MS approach, the a-PAL modification is detected by the change 
the label imparts to the molecular mass-to-charge (m/z) ratio of a peptide fragment. For 
amino acid level localization of the modification, second level (MS/MS) or higher order 
data is required. Most often ion traps, quadrupole mass filters, and mass analyzers are 
combined to the electrospray source for detection. The recent development of orbitrap 
and Fourier Transform Ion Cyclotron Resonance has resulted in very high mass accuracy, 
resolution, and dynamic range of detection for the MS method 94,95,63. These recent 
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advances in MS technology and the non-dependence on radioactivity have contributed to 
the increased use of MS as a method for detection in photoaffinity labeling studies.  
 The protein binding sites identified by a-PAL labeling require several levels of 
validation to have confidence that the revealed site is the same as that of the parent 
anesthetic. According to pharmacological convention, specific photoaffinity labeling 
would be irreversible labeling by the a-PAL, within a saturable protein binding site. For 
the purposed of this review, we define anesthetic-specific photoaffinity labeling as when 
this same labeled saturable site would be shared by the parent anesthetic. In contrast, 
nonspecific photoaffinity labeling is a result of random modification, such as to 
peripheral, solvent accessible, or lipid exposed regions of a protein. Nonspecific labeling 
could also occur with the migration of the reactive intermediate after photoactivation in 
solvent, lipid, or protein matrix to a random and remote site. All these forms of labeling 
will occur over the course of a single experiment, but in general nonspecific labeling is 
challenging to detect in most conditions due to the large number of potential modification 
sites, generally lower affinity and therefore lower occupancy, and random nature. 
Further, non-specific labeling should have lower reproducibility, so to categorize sites as 
‘specific’ requires several experiments. 
 Validation of an anesthetic-specific over an ‘a-PAL’-specific binding site is also 
required for a target protein. Notably, it should be recognized that both instances may 
contribute to a mechanism or component of ‘anesthesia’, however only parent anesthetic-
specific modified sites are of interest and relevance to clinical medicine. Generally the 
initial step includes reconciling the labeled residues against existing crystal structures or 
developed models to identify potential localization within a protein cavity, interface, or 
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pore site. The characteristics of these sites may indicate potential mechanisms as well as 
the likelihood for shared binding by the parent anesthetic. For example, the 
photomodified site of aziisoflurane in platelet receptor integrin αIIbβ3 resided near a 
calcium binding site, a critical region for regulation of the protein. This proximity 
immediately suggests a potential mechanism for isoflurane-induced attenuation of 
platelet aggregation 65.  
Another common form of validation is by mutagenesis of the photomodified 
residue(s), followed by functional studies and perhaps repeated photoaffinity labeling 
experiments. These studies, while indirect, allow association of the photomodified 
residue and site to the functional activity of the parent anesthetic within the protein. 
However, common to all mutagenesis investigations, the change in residue might also 
alter protein structure or dynamics, altering the protein’s response to the anesthetic 
instead of changing the affinity for the binding site. Furthermore, since the 
photomodification might be side chain independent, mutagenesis studies may not provide 
a clear interpretation of the site.  
Finally, direct evidence of a parent anesthetic-specific modified site would be 
represented by successful inhibition of PAL labeling through competitive binding, or 
‘protection’, by the parent anesthetic 4. Although intuitive, protection from photoaffinity 
labeling is complicated by the non-equilibrium nature of most photoaffinity labeling 
experiments. A kinetic mechanism for protection of a parent anesthetic-specific site from 
photoaffinity labeling is described in Figure 3, and is similar to that previously described 
for photoaffinity agents and other protection experiments for non-equilibrium systems 
4,96.  The model has simultaneous dependence on the two different affinities of the ligands 
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(e.g. protecting ligand and a-PAL) for the protein target, and the photoreactivity of the a-
PAL (which is highly dependent on the experimental conditions noted in section 2.2). 
Since the photoaffinity labeling event is irreversible, in contrast to the parent ligand, 
binding sites will be gradually depleted.  Further, the a-PAL will also be gradually 
depleted by solvent labeling.  Therefore, multiple consecutive and competing rates, 
unique to the target protein, protecting ligand and a-PAL, are present within a typical 
protection experiment. As a result, protection experiments require careful attention; 
otherwise, results can be misinterpreted.  
 
Figure 3. Schematic representation of the steps involved in the most basic mechanism of parent 
anesthetic protection of anesthetic photoaffinity labeling experiments. Highlighted region denotes 
the non-equilibrium reactions upon UV irradiation. (ksolvent ) Rate of solvent quenching of the 
ligand, given that carbenes are readily quenched by water the rate is limited by photoactivation of 
the ligand and therefore a first order rate constant.  (kadduct ) Rate of photoadduction represents 
two consecutive first order reactions, the photoactivation of the ligand and the insertion by the 
singlet carbene into the protein. 
 
Some physicochemical limitations of the a-PAL or the method for label detection 
may prevent quantitative assessment of protection. For example, a relatively high molar 
ratio of the parent anesthetic to a-PAL is generally required for protection (>100:1). 
However, such a high concentration may not be possible due to limitations in parent 
anesthetic solubility as reported previously 74 , making interpretation of protection 
experiments a challenge. Quantitative detection by MS also poses limitations, particularly 
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for label-free quantification that requires considerable protection for significance under 
most experimental conditions 97. However with continuing advancement of the technique, 
such as isobaric labeling methods 98,99, quantification of protection experiments by MS 
will be possible.    
 The potential for in-depth knowledge of the molecular mechanisms of anesthesia 
and/or drug side effects is reflected by the wide range of developed a-PALs and their 
numerous micro-level investigations. A previous published review 40 provides a 
comprehensive overview of all developed anesthetic PALs and studied protein targets. In 
addition Table 1 may be referred to for additional information. The following are selected 
significant findings that focuses on examples of insights given by the photoaffinity 
labeling. 
The majority of studies using volatile anesthetic a-PALs in micro-level 
investigations include neat halothane and aziisoflurane, the a-PAL for isoflurane. 
Permitted by 14C-labeled halothane, ED identified halothane modification of extracellular 
and transmembrane domains within Torpedo nAChR 57. In particular, isoflurane 
protected halothane photoaffinity labeling of Tyr-228 within the δ subunit in a state-
dependent manner. This finding highlighted a potential pocket formed within the 
receptor’s desensitized state that can accommodate either anesthetic and, through 
stabilization of the state, may contribute to the functional inhibition of nAChR. A similar 
trend of potential state-dependent binding was suggested by aziisoflurane labeling of 
lymphocyte function associated antigen-1 (LFA-1) 64. The labeling of Ile-135 and Glu-
137 within the LFA-1 β1 domain by aziisoflurane suggested a closed state-dependent 
binding. The stabilization of this conformation by the volatile anesthetic may contribute 
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to the impaired lymphocyte arrest and the anti-inflammatory actions displayed by 
isoflurane 100–102. 
The a-PAL derivative of mephobarbital, (R)-(-)-mTFD-mephobarbital, was 
shown to act as a particularly potent positive modulator of the GABAA receptor; 
approaching the potencies of etomidate and propofol 103. As such, (R)-(-)-mTFD-
mephobarbital was used to uncover binding sites of barbiturate anesthetics. When 
compared to azietomidate, photoaffinity labeling studies suggested distinct sites within 
the GABAA receptor for the two anesthetics 73. Both (R)-(-)-mTFD-mephobarbital and 
azietomidate labeled intersubunit sites, and at a similar depth within the transmembrane 
region; however, the different anesthetics targeted different subunit interfaces. mTFD-
mephobarbital selectively labeled γ-/α+ while azietomidate selectively labeled β-/γ+ or 
α+/β- with the GABAA receptors73. These studies demonstrate the heterogeneity of 
anesthetic chemical structures are reflected by different site locations within the same 
target. Indeed, with the likely joint use of multiple a-PALs, a progressive understanding 
of the molecular mechanisms for anesthetics within complex target proteins can be 
achieved. 
1.2.3. Macro-level Photoaffinity Labeling 
Macro-level photoaffinity labeling is a much less prevalent method compared to 
the application of micro-level photoaffinity labeling within anesthesiology research. 
Despite this, macro-level investigations are becoming recognized as a useful tool within 
chemical biology due to the increased need to uncover druggable targets, matched with 
the dawning awareness of how promiscuous many drugs are. Anesthetics can be 
considered a prime example of the current paradox in drug development in that there is 
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an urgent calling for optimized chemical designs in order to improve potency or decrease 
toxicity. Unfortunately, many of the molecular targets leading to any endpoints remain 
elusive. The following section overviews selected studies and perspectives of a-PALs in 
macro-level studies.  
 Previously the labeling of rat brain membranes with [3H]6-azipregnanolone 
provided an unbiased, affinity-based picture of neurosteroid targets within a complex 
biological system 104. Based on radioactivity of slices from a subsequent SDS-PAGE 
separation of proteins, specific labeling of a few gel bands was observed. Two proteins, 
tubulin and voltage-dependent anion channel-1 (VDAC-1), were subsequently identified 
and further investigated as potential protein targets. Micro-level studies found that 
photomodification of tubulin was at Cys-354 46, a residue within the colchicine binding 
site, and consistent with the ability of 6-azipregnanolone and pregnanolone to inhibit 
tubulin polymerization 46. Other work using the non-clinical a-PALs azidoanthracene has 
also implicated tubulin as a potential anesthetic target 105. Similarly, further work on 
VDAC-1 found that it was unlikely to be an important target in the VDAC-1/GABAA 
receptor interaction pathway 106. VDAC-1 might however be responsible for alternative 
pathways and/or anesthetic side effects. 
 VDAC-1 was also identified as a specific anesthetic binding protein target in a 
macro-level investigation using [3H]AziPm 93. The subsequent micro-level investigation 
found that VDAC gating was modulated by propofol, and two binding sites were 
identified 81. In addition to VDAC-1, synaptosomal-associated protein- 25kDa (SNAP-
25) was identified as a labeled protein within the macro-level investigation 107. The 
SNARE complex has potential as an anesthetic target, with volatile anesthetics and 
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propofol inhibiting neurotransmitter release by interactions with the complex 108,109. 
These few examples demonstrate how photoaffinity labeling has provided unexpected 
molecular targets that should provide opportunities for drug improvement when the 
associated physiology is understood. 
It is anticipated that many protein targets involved in anesthesia are low 
abundance integral membrane proteins such as ion channels and receptors. Both 
characteristics result in complications for macro-level detection using classical PAL 
techniques 104,107. However, over the past decade advancements in the photoaffinity 
labeling field has shown successful coupling of photoaffinity labeling and bioorthogonal 
reactions; a recent review 110 provides an excellent discussion of these developments in 
chemical biology methods. Recent tandem anesthetic photoaffinity-click chemistry 
conjugation involves the additional incorporation of a biologically inert alkyne into the a-
PALs structure 38,39. The additional chemical group allows for affinity-based protein 
profiling (ABPP) of the anesthetic. This technology has numerous powerful applications 
from micro- to macro-level protein profiling and imaging investigations within complex 
systems.  
General anesthetics are often considered to have low affinity for their targets 
relative to most other drugs. As such, the simplified view of ‘one drug, one target’ for 
these drugs is exceedingly improbable. While the diversity of targets opens up new 
avenues for further development, it also presents significant challenges with respect to 
characterization and validation. Challenges associated with these macro-level 
investigations are similar, if not greater, to that of micro-level investigations; sufficient a-
PAL development and validation of identified protein targets. As the science moves 
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towards systems biology and ‘P4’ medicine, the precise target-interaction profiles for 
each general anesthetic become increasingly necessary.  
1.2.4. Conclusions 
An ultimate the goal of anesthesiology research is to identify the biochemistry of 
these drugs that leads to the observed pharmacological phenotypes, both the desired and 
less desired effects. It is apparent that the popularity of photoaffinity labeling studies has 
increased in anesthesiology research and further progress is inevitable. A-PALs have 
contributed to this goal by providing evidence of molecular recognition elements for 
more informed design of future anesthetic agents as well as the identification of targets 
that may contribute to altered sensitivity within population groups. The obtained evidence 
has permitted refined hypotheses, and new directions with respect to molecular targets. 
This knowledge should allow educated improvements in drug design by enhancing or 
diminishing affinities for targets that lead to desired and adverse effects respectively 
and/or for selective administration of an anesthetic to distinct populations.  The 
mechanisms of anesthesia have remained elusive for nearly two centuries and increasing 
evidence has suggested a highly complex process.  In combination with other advancing 
techniques, the use of a-PALs continues to be a significant tool in shedding light on this 
puzzle in medicine. 
 
CHAPTER 2: SEVOFLURANE AND ISOFLURANE VOLATILE ANESTHETIC 
MECHANISMS 
Efforts to develop a safe, nonflammable volatile anesthetic started to gain 
momentum in the 1930s when it was found that the halogenation of compounds lowered 
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the boiling point, enhanced the solubility and generally decreased the toxicity of most 
agents111. In addition to Krantz Jr., Earl McBee of Purdue University applied his 
knowledge of fluorination, which he gained from his involvement in the “Manhattan” 
atomic bomb project, to develop a range of fluorine-containing compounds. 
Unfortunately none of these agents were appropriate clinical application 112,113. In 1951 
the synthesis of halothane by Charles Suckling lead to an increased push to develop better 
volatile anesthetic compounds 114.  Many of the halogenated inhaled agents that we 
associated with general anesthesia today were prepared in the 1960s from a library of 
over 700 compounds including enflurane, isoflurane, and desflurane17.  
The halogenated methyl ethyl ethers sevoflurane and isoflurane demonstrate 
many favorable pharmacological characteristics that were significant enough to 
eventually compensate for their alleged toxicity and relatively difficult synthesis at the 
time 115–117. However, both volatile anesthetics still require millimolar plasma 
concentrations to induce their desired pharmacological effects suggesting very rapid 
ligand-target protein off-times 118. Therefore, conventional binding assays are unlikely to 
confidently provide drug binding sites for these ligands and application of alternative 
techniques are required. The first section of this chapter focuses on the development of 
the first sevoflurane a-PAL called azisevoflurane(1a), and its application within a unique 
sevoflurane protein target, mammalian Shaker potassium (Kv1.x) channels.  The second 
section within this chapter centers on the application of azisevoflurane along-side a 
previously published isoflurane a-PAL, aziisoflurane50, in the identification of binding 
sites in synaptic γ-aminobutyric acid Type A (GABAA) receptors, a likely major general 
anesthetic target. 
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2.1.  Novel Photoaffinity ligand for sevoflurane reveals sites of voltage-gated ion 
channel modulation 
Sevoflurane (Figure 4) was first synthesized by Regan of Travenol Laboratories 
in 1968 and was later reported by fellow co-workers in 1971 119. The Travenol group 
continued on to animal studies and characterized the new anesthetic’s clinical properties. 
Despite some resistance brought on from claims of toxic effects (later shown to be a 
result of poor experimental design) as well as the drugs biotransformation in soda lime 
(used to remove CO2 from breathing gases), favorable clinical properties kept sevoflurane 
afloat as a potential clinical general anesthetic 115,116. Sevoflurane was finally accepted 
for clinical use in 1990 in Japan, later followed by approval by the Food and Drug 
Association. To date sevoflurane holds a spot as being amongst the youngest accepted 
volatile general anesthetics administered within the United States.  
 
Figure 4. Chemical structures of sevoflurane and azisevoflurane(1a) 
 
The favorable properties that sustained the interest in sevoflurane as a potential 
anesthetic included hemodynamic stability, rapid induction and emergence, as well as a 
marked decrease in pungency, or respiratory irritation 115. This combination of clinical 
properties has made sevoflurane the preferred anesthetic in pediatric care 120,121 where 
inhalational inductions are common. Most of the early reports on sevoflurane center on 
these pharmacokinetic observations, while the molecular mechanisms of sevoflurane 
anesthetic action remain unclear.  There has been growing concerns regarding adverse 
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effects of anesthetics on neurodevelopment and cognition, both being applicable for 
sevoflurane anesthesia due to their largely sensitive patient population.  
Here, the synthesis and characterization for the first PAL developed for 
sevoflurane, 3-{difluoro[(1,1,1,3,3,3-hexafluoropropan-2-yl)oxy]methyl}-3H-diazirine or 
azisevoflurane(1a) (Figure 4) is presented. Azisevoflurane (1a) displayed the same 
functional and pharmacological activity as sevoflurane. The use of azisevoflurane (1a) in 
the Shaker voltage-gated potassium channel Kv1.2, a unique target for this anesthetic 
chemotype, allowed for the unbiased identification of a sevoflurane active site, 
complementing previously suggested mechanisms of action. This result indicates that 
azisevoflurane(1a) will be useful to identify further contributing mechanism(s) for this 
important drug. 
2.1.1. Synthesis and characterization of azisevoflurane 
Scheme 1. 
 
The alkyldiazirine photoreactive group was used to generate azisevoflurane (1a) 
due to previous use in developing alkyldiazirine-based PAL derivatives for general 
anesthetics 50,78,122.  The synthesis of 3-(difluoro((1,1,1,3,3,3-hexafluoropropan-2-
yl)oxy)methyl)-3H-diazirine or azisevoflurane (1a) is shown in Scheme 1. The synthesis 
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started with the reaction between hexafluoroisopropanol and ethyl bromoacetate in the 
presence of anhydrous potassium carbonate. The resulting ester 2a is saponified and 
converted to acid chloride 4a using oxalyl chloride and a catalytic amount of DMF. 
Photochemical chlorination of 4a followed by reaction with methanol converts 4a to the 
dichloro-ester 5a. Fluorination of 5a using SbF3 with a catalytic amount of SbCl5 123 
converts it to octafluoro-ester 6a. A more direct route to 6a using the reaction between 
hexafluoroisopropanol and 2-iodo- or 2-bromo- or 2-chloro-2,2-difluoroacetic acid 
derivatives was unsuccessful under a wide variety of conditions. This is in contrast to the 
reaction between 3,3,3-trifluoroethanol and 2-chloro-2,2-difluoroacetic acid in the 
presence of aqueous base 124. 
Further conversion of methyl ester 6a to diazirine 1a followed standard 
procedures 125. Thus, reduction of ester 6a with DIBAL-H at low temperature followed 
by immediate condensation with tert-butylamine in refluxing benzene formed imine 7a. 
Treatment of 7 with hydroxylamine-O-sulfonic acid in ethanol in the presence of 
triethylamine produced diaziridine 8a which was converted to diazirine 1a using N-
bromosuccinimide in dichloroethane.  Final purification of 1a was accomplished using 
preparative gas chromatography. 
Table 2. Physicochemical properties of sevoflurane and azisevoflurane(1a) 
 MW (Da) Density  (22-
23°C; g/mL) 
Van Der Waals, 
(Å3) 
cLogP 
sevoflurane 200 1.51 123 2.42 
azisevoflurane (1a) 258 1.48 151 2.47 
 
The physiochemical properties of sevoflurane and azisevoflurane(1a) are reported 
in Table 2. Compared to sevoflurane, azisevoflurane(1a)  showed a modest increase in 
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hydrophobicity. The absorption spectrum of the alkyldiazirine shows the distinctive 
double-peak at 280-330 nm that decreased with increasing 300 nm exposure, indicating 
photoreactivity (Figure 5). The t1/2 of photoreactivity using a 300 nm RPR-3000 Rayonet 
lamp through a 295 nm glass cutoff filter was 6 min (in methanol). 
Despite the chemical modifications to incorporate the photoreactive group, 
azisevoflurane(1a) retained protein binding interactions and pharmacological activity of  
 
Figure 5. Photoactivation of azisevoflurane (1a). Absorbance spectrum of azisevoflurane (1a) 
diazirine with exposure to 300 nm UV light from t=0 (red line) and t=n (gray/black lines). 
 
sevoflurane. Previously it has been shown that aF serves as a soluble model for anesthetic 
binding to the four-helix bundles motifs found in consensus general anesthetic protein 
targets, such as the GABAA receptor 87,88. Multiple volatile general anesthetics have been 
crystalized within the aF ‘anesthetic site’ including the haloether anesthetic isoflurane 88. 
Equilibrium binding affinity of sevoflurane and azisevoflurane(1a) to aF was determined 
by 1-aminoanthracine (1-AMA) fluorescence competition 126 and isothermal titration 
calorimetry (ITC). Results from both methods were in agreement and are provided in 
Table 3 and in Figure 6A-B. Azisevoflurane (1a) demonstrates a small (50-70%) increase 
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in binding affinity relative to sevoflurane, consistent with the increased hydrophobicity 
88. 
Two animal models were employed to evaluate in vivo pharmacological activity 
of azisevoflurane(1a). Because of limitations imparted by low synthetic yield (~2%), the 
clinical route of administration (e.g. inhalation) was not feasible for azisevoflurane(1a). 
The common tadpole immobility assay 50,127 was employed to determine the potency of 
azisevoflurane(1a) as compared to sevoflurane. An Intralipid®-based formulation for  
Table 3. Apo-Ferritin (aF) sevoflurane and azisevoflurane (1a) binding parameters 
 sevoflurane  azisevoflurane (1) 
ITC Fluorescence 
Competition 
ITC Fluorescence 
Competition 
KD (µM; 95% 
CI) 
36 (23-49) 15 (9.5-24) 
 
 19 (13-24)   8.4 (5.2-14) 
 
Hill Slope 
(Mean ± SEM) 
- -1.0 ± 0.22 
 
  -   -1.5 ± 0.43 
 
 
intravenous (IV) administration of volatile anesthetics 128 was also employed to test 
anesthetic efficacy in mice. Sevoflurane and azisevoflurane(1a) displayed similar 
hypnotic potency in Xenopus laevis tadpoles with the induction of a reversible loss of 
spontaneous movement (Figure 7A). Azisevoflurane (1a) demonstrated a ~50% increase 
in potency relative to sevoflurane (Table 4) and no toxicity, again consistent with the 
small increase in hydrophobicity 2.  
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Figure 6. Sevoflurane and azisevoflurane (1a) binding to apoferritin. A) Equilibrium fluorescence 
competition from apoferritin (aF) anesthetic binding site using 1-aminoanthracene (1-AMA). 
Titration of the aF and 1-AMA combination with either sevoflurane (open diamonds) or 
azisevoflurane (1a) (red filled circles) produced inhibition of fluorescence indicating competition 
for binding. Graph values are given in Table 2. B) Isothermal titration calorimetry profiles of aF 
interaction with sevoflurane (left) or azisevoflurane (1a) (right) using sequential titrations. Top: 
time response heat change from addition of ligand. Bottom: best fit attained from a single site 
binding model (best χ2 statistic) fitted to a 1:1 stoichiometry for aF. 
 
Mouse IV administration of sevoflurane in 20% Intralipid® by bolus tail vain 
injection resulted in reversible hypnosis determined by Loss Of Righting Reflex (LORR). 
No toxic effects or irritation at injection site were observed. The EC50 and Hill Slope for 
emulsified sevoflurane were 0.36 g/kg (0.35-0.39 g/kg; 95% CI) and 11 ± 2.9 
respectively. The EC99 dose (based on sevoflurane) of azisevoflurane (1a) (0.51-0.53 
g/kg) was administered to two mice, resulting in reversible LORR with no observable 
toxicity. The time to regain righting reflex for emulsified azisevoflurane(1a) was longer 
(180 ± 21 s, mean ± SD, n=2) than for sevoflurane (40 ± 18 s, mean ± SD, n=4). The 
extended hypnotic times are consistent with azisevoflurane(1a) activity as a more potent 
anesthetic than sevoflurane, although the small cohort precluded statistical significance. 
At a minimum, azisevoflurane(1a) is a reversible anesthetic with potency and efficacy 
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similar to sevoflurane. 
 
Figure 7. Sevoflurane and azisevoflurane (1a) pharmacological activity. A) Tadpole immobility 
assay dose-response relationship for sevoflurane (open diamonds; n=80) and azisevoflurane (1a) 
(red filled circles; n=100). Lines represent best fit Hill slopes, constraining the bottom to 0% 
immobility. Graph values are given in Table 3. 
 
Table 4. Tadpole studies with sevoflurane and azisevoflurane (1a) 
 EC 50 (µM; 95% CI) Hill Slope (Mean ± SEM) 
sevoflurane  192 (166-221) 2.1 ± 0.26 
azisevoflurane (1a) 130 (120-141) 2.9 ± 0.26 
 
As a final means to evaluate azisevoflurane (1a) as a reliable PAL for 
sevoflurane, aF was photoaffinity labeled to determine whether the ligand could report 
sevoflurane binding site(s) at the residue level. Peptides accounting for 96.57% sequence 
coverage of aF light chain were detected by mass spectrometry (see appendix A.3.1). 
Azisevoflurane(1a) modifications were identified in 4 unique peptides on 4 different 
residues Arg-25, Arg-59, Leu-81 and Gln-82 (see appendix A.4.1). All residues were 
located within the	  crystallographically defined aF ‘anesthetic site’, with Arg-59 and Leu-
81 previously labeled by the isoflurane and propofol a-PAL derivatives 50,78. 
2.1.2. Photoaffinity labeling of purified Kv1.2 channels 
Sevoflurane at pharmacologically relevant concentrations, potentiates the Shaker-
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type Kv1.2 channel by left-shifting the conductance-voltage (G-V) curve and increasing 
the maximum conductance (Gmax) 129,130. The positive modulation of Kv1.2 channels by 
sevoflurane is in contrast to other anesthetic chemotypes that mainly show weak 
inhibitory activity 130 making Kv1.2 a uniquely specific target of this chemotype. 
Investigating such distinct differences in functional activity between general anesthetics 
is critical in understanding the multiple mechanisms that lead to the ‘same’ anesthesia 
endpoints. For example, previous studies have shown that characteristic burst suppression 
patterns observed during deep anesthesia differ between general anesthetics, including 
sevoflurane 131. Such findings strongly suggest that the various general anesthetics 
distinctly perturb molecular targets that influence neuronal excitability of which Kv1.x 
channels are known key regulators 132.  Indeed, previous studies have shown that 
inhibition of Kv1.x channels restored righting reflex in rodents under sevoflurane 
anesthesia 133,134.  
 
Figure 8. Photoaffinity labeling of mammalian Shaker Kv1.2 channel by azisevoflurane (1a). A) 
MS2 data for the peptide 313-GLQILGQTLK-322 peptide labeled with azisevoflurane (1a)(L*) 
(red: assigned b+ ions; blue: assigned y+ ions; green: assigned precursor ion). (B-C) Lowest 
energy sevoflurane docking pose viewed towards the S4-S5 linker and S6 cavity (B) and from the 
cytoplasm (C) of the lowest free energy docking pose of sevoflurane (stick/surface structure) 
within Kv1.2 (PDB code: 3LNM) transmembrane domain. S4 to S6 helixes, pore-helix (αP) and 
S4-S5 linker are denoted as the same subunit (Xi) or the adjacent subunit (Xii). The L317 
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(corresponding to L313 in 3LNM) photolabeled residue is represented in magenta stick structure. 
 
 Therefore, azisevoflurane(1a) was used to locate binding sites in this 
ubiquitously expressed central nervous system channel. Homotetrameric His-tagged rat 
Kv1.2 channels were heterologously expressed in Sf9 cells and purified before the 
introduction of 1 mM azisevoflurane(1a), with or without UV light. Mass spectrometry 
analysis resulted in the detection of peptides covering 74.0% of the full sequence; 57% of 
the 6 transmembrane domains (see appendix A.3.1). In the photolabeled sample, only 
Leu-317, part of the S4-S5 linker region, was identified as modified by 
azisevoflurane(1a) modification (Figure 8A; see appendix A.4.2).  
 
Figure 9. Lowest energy azisevoflurane(1a) docking pose viewed towards the S4-S5 linker and 
S6 cavity. (A-B) Lowest energy sevoflurane (A) and azisevoflurane (1a) (B) (stick/surface 
structure) docking pose viewed towards the S4-S5 linker and S6 cavity within Kv1.2 (PDB code: 
3LNM) transmembrane domain. S5 to S6 and the S4-S5 linker are denoted as the same subunit 
(Xi) or the adjacent subunit (Xii). The L317 (corresponding to L313 in 3LNM) photolabeled 
residue is represented in magenta stick structure. 
 
For further evaluation of the azisevoflurane (1a) photolabeled site within Kv1.2 
channels, docking simulations using sevoflurane and azisevoflurane (1a) were conducted 
with AutoDockVina 135. Mammalian Shaker K1.x channels consist of four α –subunits 
that are arranged to form a pore as tetramers. Each subunit contains six transmembrane 
helical segments (S1–S6), with a membrane-reentering loop (P-loop) and a ‘hinge’ helix 
39 
 
between the S4 and S5 called the S4-S5 linker 132. The simulations contained the entirety 
of the cavity formed by the S4-S5 linker and S4-S6 helixes of the same and adjacent 
subunit of a Kv1.2 homodimer (PDB ID: 3LNM). The lowest free energy value for the 
complex was -5 kcal mol-1 orienting the monofluoro- methyl group of sevoflurane 3.1-3.5 
Å from L317 (Figure 8 B-C). Azisevoflurane(1a) docking simulations revealed a lowest 
free energy value of  -5.9 kcal mol-1 with the diazirine carbon remaining 3.2-4.0 Å from 
Leu-317 (Figure 9). The highest scored poses placed the trifluoro-methyl moieties of both 
ligands in a pocket formed by the S4-S5 linker and the S5 and S6 helices of one subunit 
as well as the S6 from the adjacent subunit (Figure 8-9). 
2.1.3. Validation of sevoflurane Kv1.2 channel binding site by electrophysiology  
Compared to sevoflurane, azisevoflurane(1a) retained a unique ability to induce 
positive modulation of the Kv1.2 channel by significantly potentiating heterologously 
expressed Kv1.2 channels in X. leavis oocytes at 0.3 mM which corresponds to ~1 MAC 
(minimum alveolar concentration) (Figure 10A-B). Relative to sevoflurane, 
azisevoflurane(1a) is modestly more potent, a difference particularly evident when 
comparing the increase in Gmax.  
To assess the importance of L317 in the positive modulation of Kv1.2 by 
sevoflurane and azisevoflurane(1a), we investigated the electrophysiological properties 
of the Leu-317-Ala mutant. This mutation affected Kv1.2 gating by inducing a modest 
parallel G-V curve leftward shift of the order of -10mV. Furthermore, the Leu-317-Ala 
mutation dampened the sevoflurane- or azisevoflurane(1a)-induced leftward shifting of 
the G-V curve without affecting the Gmax increase (Figure 10). Accordingly, the effect of 
the anesthetics on the mutant half activation voltage (V1/2) was no longer significant 
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(Figure 11). The magnitude of the anesthetic effect and the impact of the Leu-317-Ala 
mutant can be directly assessed by examining the conductance ratio-plots for either 
ligand (Figure 10). At -30 mV, the anesthetics increase the Kv1.2 conductance ~1.5 – 
2.5-fold, and at positive membrane potentials corresponding to the Gmax, the increment 
decays and levels off at ~1.1 – 1.2-fold.  Whereas Leu-317-Ala reduces the fold change at 
biologically relevant negative voltages, it does not affect it at positive voltages (Figure 
10).  
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Figure 10. Positive modulation of Kv1.2 conductance by sevoflurane and azisevoflurane (1a) is 
dampened by the L317A mutation. (A) Kv1.2 wild-type currents in the absence and presence of 
sevoflurane, and the corresponding relative conductance-voltage plots. From a holding voltage of 
-100 mV, currents were evoked in 10-mV increments by step depolarizations from -90 to +50 
mV. Relative conductance is defined as the conductance G at a given voltage in the absence or 
presence of sevoflurane over the maximum conductance (Gmax) in the absence of the anesthetic. 
Solid lines represent the best-fit Boltzmann functions. (B) Kv1.2 wild-type currents in the 
absence and presence of azisevoflurane (1a), and the corresponding relative conductance-voltage 
plots. Each symbol and error bars represent the mean ± SEM (n = 13 and 9, for sevoflurane and 
azisevoflurane (1a), respectively). (C-D) Kv1.2 L317A mutant currents in the absence and 
presence of 0.3 mM sevoflurane and 0.3 mM azisevoflurane (1a), and the corresponding relative 
conductance-voltage plots. Each symbol and error bars represent the mean ± SEM (n = 6 and 5, 
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for sevoflurane and azisevoflurane (1a), respectively). (E-F) Conductance ratio-voltage plots of 
the ligands on wild-type and L317A mutant channels. At each voltage, these plots evaluate the 
fold conductance change (Ganesthetic/Gcontrol) induced by the anesthetic. Each symbol and error bars 
represent the mean ± SEM (n is the same as above). 
 
Cumulatively, the results indicate that Leu-317 and the S4-S5 linker, plays a 
significant role in the voltage-dependent aspect of the anesthetic-induced Kv 1.2 channel 
positive modulation, but a distinct site might be responsible for the increase in Gmax. 
These findings align with previous mutagenesis studies investigating anesthetic 
modulation Shaker-type Kv 1.2 channels 129,130,136–138 and suggest that the Gmax increase 
is governed by occupancy of a distinct site not detected in our photoaffinity labeling-
experiments (~25% of the sequence was not detected). More provocative mutations of 
Leu-317 (Leu-317-Ser or Leu-317-Thr) resulted in either no expression or conductance, a 
result consistent the critical role in of the S4-S5 linker in Kv1.2 dynamics 139–142. 
Therefore, the application of an unbiased experimental methodology based on 
photoaffinity labeling strongly supports the conclusion that the S4-S5 linker is part of an 
allosteric sevoflurane site through direct evidence of ligand binding, rather than a region 
of the channel highly sensitive to remote perturbations. 
 
Figure 11. The L317A mutation under basal conditions induces a parallel leftward shift in the G-
V curve. Solid lines represent the best-fit 4th power Boltzmann function. Each symbol and error 
bars represent the mean ± SEM (n = 22 and 11, for wild-type and L317A mutant, respectively). 
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A crystal structure of the closed-state Kv1.x channel has yet to be reported 
making it a challenge to determine the exact molecular mechanism of modulation. 
Current models suggest that, following the ‘upward’ movement of the S4 voltage sensor, 
the final cooperative transition to the open state involves an interaction between the S4-
S5 linker and the S6 tail, becoming more closely packed to create a cavity or pocket 
139,140. Based on our evidence and previous work, it is likely that sevoflurane binds to a 
pocket formed by the S4-S5 linker and the S6 helix and thereby stabilizes the open 
conformation in its conducting state 138.   
2.1.4. Conclusion 
 Understanding the unique mechanisms for sevoflurane is significant as it is the 
preferred anesthetic for children and concerns for anesthetic influences on 
neurodevelopment have arisen. However, identification of the molecular targets using 
conventional methods has been difficult due largely to the drug’s volatility and low 
binding affinities. Thus, a trifluoro-diazirine photoaffinity derivative of sevoflurane, or 
azisevoflurane(1a) was synthesized. Azisevoflurane(1a) was applied to investigate a 
pharmacological target distinct to sevoflurane, the voltage-gated Shaker Kv1.2 potassium 
channel, to identify the binding site(s) that lead to the observed positive modulation of 
the mammalian channel.  Further application of azisevoflurane(1a) should provide an 
improved understanding of the full- repertoire of sevoflurane protein targets and binding 
sites and thereby a further understanding of volatile anesthetic molecular mechanisms.   
2.1.5. Experimental methods 
General Synthetic Procedures- Reagents and solvents were all acquired from commercial 
sources. 1H, 13C NMR spectra were obtained on a Bruker DMX 500 MHz nuclear 
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magnetic resonance spectrometer and 19F NMR spectra were obtained on a Bruker DMX 
360 MHz nuclear magnetic resonance spectrometer.  
Physicochemical properties- The density of azisevoflurane(1a) was calculated using 
triplicate measurements of the volume/mass relationship within sealed vials. The UV 
spectrum and extinction coefficient (Σ305 nm = 115 M-1) of the diazirine absorption were 
determined from methanolic solutions of azisevoflurane(1a) at known concentration. The 
maximal water solubility (Sw = 1.25 mM) was determined by triplicate titrations into 
phosphate buffered saline (pH 7.4) and calculated from the extinction coefficient. The 
rate of photoactivation was determined by reduction of the azisevoflurane(1a) diazirine 
peak within a methanolic solution during the course of 300 nm UV light exposure using a 
1 cm pathlength quartz cuvette 5 cm from light source.  The octanol/water partition 
coefficients were calculated using XLOGP3 with default settings 143.  
Horse Spleen apo-Ferritin (aF) fluorescence competition- The affinity of 
azisevoflurane(1a) was determined by equilibrium binding of increasing amounts of 
sevoflurane in the presence of constant concentrations of 1-aminoanthracene (1-AMA) 
and aF. Total volume 200 µL of 10 µM aF, 10 µM 1-AMA and concentrations of 
sevoflurane or azisevoflurane(1a) (0.3 µM-1 mM) in phosphate buffered saline (PBS) pH 
7.4 were combined in 96-well plate on ice. The fluorescence spectrum of 1-AMA in each 
solution well was determined with 380 nm excitation and emission of 510 nm at 10°C. 
The fluorescence was corrected by simple math subtractions of baseline 1-AMA and aF 
fluorescence. Fluorescence intensity versus concentration data were fitted to variable 
slope Hill models. The Cheng-Prusoff equation was used to correct for the presence of 
the 1-AMA competitor 126.  
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Isothermal titration calorimetry (ITC)- ITC studies were generated using a MicroCal ™ 
iTC200 System (GE Healthcare Life Sciences). The calorimeter reference cell contained 
ddH2O. 25 µM of apoferritin (aF) dimer in 0.22 µm filtered 130 mM NaCl, 20 mM 
sodium phosphate (pH 7.0) was centrifuged for 10 min at 14, 000 x g before being added 
into the calorimeter sample cell (200 µL). Sevoflurane or azisevoflurane(1a) were 
solubilized to 0.8 mM concentration in the same buffer. Either sevoflurane or 
azisevoflurane(1a) were titrated into the sample cell horse spleen aF solution from a 39.9 
µL volume syringe. An initial 0.6 µL volume over 1.2 s was titrated followed by 2 µL 
volumes over 4 s thereafter with 3 min intervals between each injection.  The 
measurements were carried out at 25 °C and data was corrected for heats generated from 
buffer into buffer, sevoflurane or azisevoflurane(1a) into buffer and buffer into aF. 
Enthalpy measurements generated were fit using Origin 5.0 (MicroCal, Inc.) to a single 
set of independent sites 87,88.   
Tadpole immobility assay- Albino Xenopus leavis tadpoles were used to determine the 
relative anesthetic potency of azisevoflurane(1a) compared to sevoflurane.  Groups of 10 
tadpoles were placed in a 25 mL sealed glass Hamilton syringe containing 10mL of non-
drugged pond water. A sealed 25mL glass syringe containing 25 mL of either 1. 67 mM 
sevoflurane or 1 mM or azisevoflurane(1a) was connected using a two-way valve. Gently 
the tadpoles were exposed to set volumes of the drug-containing solution for 5 min. After 
5 min the tadpoles were assessed for spontaneous moment as defined previously 50,78.  
After final exposure the tadpoles were removed from the syringe and allowed to recover 
in petri dishes containing non-drugged water. Tadpoles were observed the following day 
for toxicity.  
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Preparation of emulsified volatile anesthetics- Neat sevoflurane or azisevoflurane(1a) 
was added to 20% Intralipid® using gas-tight Hamilton syringes. Emulsions were formed 
via shear stress provided by passing the solutions through a 26-gauge needle between two 
gas-tight Hamilton syringes 20-30 times at 20-22˚C. Emulsified sevoflurane and 
azisevoflurane(1a) were quantified using reverse phase-high performance liquid 
chromatography (rpHPLC) with a C-18 analytical column and a refractive index detector. 
Using an isocratic gradient (44:14:41.5 acetonitrile: isopropanol: 20 mM phosphate in 
ddH2O) with 1 mL/min flow rate (20-22˚C), sevoflurane had a retention time of 5.7 min. 
Emulsified azisevoflurane(1a) was quantified using diazirine UV absorbance at 305 nm. 
Azisevoflurane(1a) had a retention time of 19.2 min with an isocratic gradient (35:12:53 
acetonitrile: isopropanol: 20 mM phosphate in ddH2O) at 1 mL/min flow rate (20-22˚C). 
An initial preparation of 3.2 mg/mL azisevoflurane(1a) in Intralipid® provided 2.1 ± 
0.1% (v/v%; mean  ± SD) emulsified azisevoflurane(1a) determined by chromatography. 
Excess emulsified azisevoflurane(1a) from each rodent exposure was analyzed 
immediately after administration to confirm dosage.  
Rodent studies- Emulsified sevoflurane 2.0 ± 0.2% (v/v%; mean  ± SD) or 
azisevoflurane(1) 2.1 ± 0.1% (v/v%; mean  ± SD) in 20% Intralipid® were introduced 
into 8-14 week CD-1 male mice via tail vein bolus injection. The hypnotic effects of 
emulsified anesthetics were measured using the loss of righting reflex (LORR) assay 
immediately after injection. Mice were placed in a supine position within a mouse 
chamber and the time at which the mice were able to right themselves was recorded. 
Mice were observed for 24-48 hr for toxicity.  
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Photolabeling of Horse spleen apoferritin (aF)- 50 µg of aF was suspended to 1 mg/mL 
in phosphate buffered saline (pH 7.4) with 0.5 mM azisevoflurane(1a). Samples were 
equilibrated in the dark for 5 min prior to being exposed to 300 nm RPR-3000 Rayonet 
lamp in 1-mm path length quartz cuvettes at through a WG295 295 nm glass filter 
(Newport Corporation) for 15 min. An exclusion list was generated from separate 
experiment where a sample was exposed to same filtered UV light without the presence 
of azisevoflurane(1a).  
Shaker Kv1.2 channel plasmid construction and expression- A C-terminal Arg-Gly-Ser-
His10 tag was appended to the sequence of rat Kv1.2 using PCR, and the resulting gene 
was subcloned into the EcoRI and NotI sites of pFastBac1. This plasmid was then used to 
generate recombinant baculovirus. Kv1.2, which were both expressed in Sf9 cells by the 
Protein Expression Facility of the Wistar Institute (Philadelphia, PA, USA). Cells were 
incubated for 48-60 h post-infection. 
Shaker Kv1.2 channel purification- All purification steps were carried out at 4 °C. A cell 
pellet from a one-liter growth was rapidly thawed and resuspended in 50 mL of lysis 
buffer (250 mM KCl, 25 mM imidazole, 50 mM potassium phosphate, 10 mM 2-
mercaptoethanol, pH  7.6) containing 5 mM MgCl2, 2 mM tris(2-carboxyethyl)phosphine 
(TCEP), 1ug/mL each of DNAse and RNAse, and 1x protease inhibitor cocktail (Sigma-
Aldrich). Cells were lysed by three strokes in a Potter-Elvehjem homogenizer. 10% (w/v) 
dodecyl-maltoside (DDM) was then added to the lysate to a final concentration of 1.5%, 
and the suspension was stirred for 1hr. Cell debris and insoluble material were removed 
by ultracentrifugation (164,000 x g, 1 hr). The resultant supernatant was syringe-filtered 
twice, first with a 5 µm PVDF filter and then with a 0.45 µm MCE filter. The doubly 
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filtered supernatant was loaded at 1 mL/min onto a 1 mL HiTrap IMAC HP column (GE 
Healthcare) equilibrated with buffer A (250 mM KCl, 25 mM imidazole, 50 mM 
potassium phosphate, 10mM 2-mercaptoethanol, 0.2% DDM, pH 7.6). The column was 
washed with 15 mL of 5% buffer B (identical to buffer A, except with 325 mM 
imidazole), followed by 15 mL of 15% buffer B.  Protein was then eluted from the 
column with a 25 mL gradient from 15-100% buffer B. The column was washed with 25 
mL of 100% buffer B to complete protein elution.  
Fractions were analyzed by Western blotting, using HRP-conjugated anti-His 
antibody (Proteintech).  Positive fractions were pooled and dialyzed against IEX start 
buffer (20 mM Tris-Cl, 0.1% DDM, 10 mM 2-mercaptoethanol (βME), pH 8). The 
dialyzed protein was loaded at 1 mL/min onto a 1mL HiTrap Q HP column (GE 
Healthcare) previously equilibrated with IEX start buffer. The column was washed with 
20 mL of IEX start buffer, and then eluted with a 50 mL gradient from 0-100% IEX 
elution buffer (start buffer + 500mM KCl). The column was washed with 20 mL of 100% 
IEX elution buffer.  Fractions were analyzed by SDS-PAGE, using both Western blot 
analysis and Coomassie staining. Fractions containing protein were pooled and 
concentrated using 50-100kDa MWCO concentrators. 
Photolabeling of Shaker Kv1.2 channel.- 25 µg of Kv 1.2 were diluted to 0.5 mg/mL 
containing final concentrations of 20 mM TrisHCl, pH 7.2, 5 mM KCl, 5 mM βME 
containing 1.75% DDM with or without 1 mM azisevoflurane (1a). Samples were 
equilibrated in the dark for 5 min prior to being exposed to 300 nm RPR-3000 Rayonet 
lamp in 1-mm path length quartz cuvettes through a WG295 295nm glass filter (Newport 
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Corporation) for 15 min. Exclusion lists were generated using samples exposed to same 
filtered UV light without the presence of azisevoflurane(1a).  
In-solution digestion of proteins- 20 µg of protein was participated with chilled acetone 
and air dried for 3-5 min. Proteins were solubilized and digested with ProteaseMax ™ 
Surfactant trypsin enhancer using product instructions. For detailed methods, see 
supporting information. Pellet was first solubilized in 20 uL 0.2% (w/v %) ProteaseMax 
™ Surfactant in 50 mM NH4HCO3 for 1 hr at room temperature and then diluted with 
73.5 uL 50 mM NH4HCO3. Following 1 uL 0.5 M DTT was added and sample was 
incubated at 56° C for 20 min. 2.7 uL of 0.55 M iodoacetamide was then added and 
protein sample was incubated at room temperature in the dark for 15 min.  After 1 uL of 
1% (w/v%) ProteaseMax ™ Surfactant was added followed by CaCl2 to 1 mM final 
concentration. 1.8 uL of 1 µg/µL porcine sequencing trypsin (Promega) was added and 
samples were incubated at 37 °C for 3 hr with mild agitation.  Samples were centrifuged 
for 10 min at 16, 000 x g, the supernatant was removed and trifluoroacetic acid (TFA) 
was added to a final concentration of 0.5% (v/v %). Samples were incubated at room 
temperature for 5 min.  Samples were snap frozen with dry ice and stored at -80 °C until 
further processing. 20 µg of sample was desalted using C18 stage tips prepared in house 
and the elution was dried by speed vac. Prior to MS analysis the peptide digestion was 
resuspended in 0.1% formic acid. 
Mass spectrometry- Digested protein preparations were analyzed by Orbitrap EliteTM 
Hybrid Ion Trap-Orbitrap Mass Spectrometer (MS) coupled to an Easy-nanoLC 1000 
system with a flow rate of 3 µL/min. Data dependent acquisition mode was applied with a 
dynamic exclusion of 45 s. in every cycle, one full MS scan was collected with a scan 
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range of 350 to 1500 m/z. An exclusion list of MS1 precursor ions of non-photolabeled 
protein sample was imported into the precursor mass parameter in Xcalibur allowing for 
a 10 min retention window. Spectral analysis was conducted using Thermo Proteome 
Discoverer 2.0 (Thermo Scientific) and the Mascot Daemon search engine using horse 
ferritin light chain sequence provided by UniProt database (UniProtKB: P02791) or a 
customized database containing the sequence for the expressed rat Kv1.2 with appended 
Arg-Gly-Ser-His10 tag. All analyses included dynamic oxidation of methionine 
(+15.9949 m/z) and static alkylation of cysteine (+57.0215 m/z; iodoacetamide 
alkylation). Photolabeled samples were run with the additional azisevoflurane(1a) 
modification (+230.0559 m/z), the false discovery rate of 0.01% allowing for up to 2 
missed cleavages and setting a fragment ion mass tolerance of 0.500 Da and a parent ion 
tolerance of 10 ppm.  
Docking . Horse spleen apo-ferritin (aF)-  The biological assembly of the aF dimer 
complex with pentobarbital (PDB code: 3RAV) solved at 1.9 Å resolution was used for 
docking simulations. Prior to docking pentobarbital, sulfate, and Cd+ were removed using 
PYMOL. For docking the protein, hydrogens and Kollman charges were added and 
nonpolar hydrogens were merged using AutodockTools4. Molecular coordinates for 
sevoflurane were downloaded from the ZINC small molecule library144 using provided 
physical representations. The molecular coordinates for azisevoflurane(1a) were 
generated using MarvinSketch version 16.3.28.0. In AutodockTools4 Geisteiger charges 
were added and nonpolar hydrogens were merged. A maximum of 4 and 5 torsions were 
allowed for sevoflurane and azisevoflurane(1a) respectively (i.e., ligands were fully 
flexible). Residue side chains projecting towards the cavities were flexible during 
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docking runs with AutoDock Vina. The grid box was centered within the aF monomer 
interfacial region or within the aF dimer interface sized to 22x24x22 points with 1 Å 
resolution for both experiments. For either ligand, 30 docking results were generated 
using and exhaustiveness of 300, other genetic algorithm search parameters and docking 
protocol were set as default. Scores were evaluated based off the upper bound RMSD 
values. Images and distance measurements were prepared using PYMOL. 
Docking Kv1.2 transmembrane region. The biological assembly of rat F233W 
mutant of the Kv2.1 paddle-Kv1.2 chimera channel crystal structure (PDB code: 3LNM) 
solved at 2.9 Å resolution was used for docking simulations. Prior to docking water, 
NADP+, potassium and phosphatidylglycerol were removed using PYMOL. To focus on 
the transmembrane domain of Kv1.2 subunit interfaces within docking studies, we 
removed L36-E120 from the B chain and the full A, C and D chains and joined two 
subunits in the same biological assembly provided 145 before loading into AutoDockTools 
146. AutodockTools4146 preparation of the Kv1.2 assembly and sevoflurane for docking 
were competed as mentioned above. For docking, the grid was targeted the S4-S5 linker 
and S6 interaction region at the interface of the two subunits. Flexible residue side chains 
and Autodock Vina147 were programed as mentioned above. 
Heterologous Kv1.2 channel expression in Xenopus oocytes.  Plasmid maintenance, 
mutagenesis, sequence, RNA synthesis and oocyte microinjection were carried out as 
previously described 130. Briefly, defolliculated stage V-VI Xenopus laevis (X. laevis) 
oocytes were microinjected with in vitro transcribed cRNA (mMessage mMachine kit, 
Ambion, Austin, TX). Oocytes were incubated at 18˚C for 1-2 days before 
electrophysiological characterization.  All animal care and experimental procedures 
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involving were carried out according to a protocol approved by the IACUC of Thomas 
Jefferson University. 
Electrophysiological characterization of Kv1.2 expressed in Xenopus oocytes-  Whole-
oocyte currents were recorded at room temperature (21-23˚C) under two-electrode 
voltage-clamping conditions (OC-725C, Warner Instrument, Hamden, CT). The 
microelectrodes were filled with 3 M KCl and recordings were completed as previously 
reported 130. Briefly, a stable current baseline was determined by repeating voltage steps 
to +40 mV from a holding potential of -100 mV while oocytes were bathed in ND96 (in 
mM: 96 NaCl, 2 KCl, 1 MgCl2, 1.8 CaCl2, 5 HEPES, 2.5 Na-Pyr, pH 7.4 with NaOH). 
Reponses were collected once currents reached a stable level. ND96-based solutions of 
sevoflurane or azisevoflurane(1a) were freshly prepared by sonication under gas-tight 
conditions. Solution delivery was conducted with a gas-tight syringe and Teflon tubing. 
Data acquisition, leak subtraction and initial analysis were performed using pClamp 10.3 
(Molecular Devices, Sunnyvale, CA).   
G-V curves were described by assuming this form of the 4th order Boltzmann 
equation: 
Equation 2. 
𝐺 = 𝐺𝑚𝑎𝑥1+ 𝑒 !!!!!! ! 
Where G is the peak chord conductance; Gmax is the maximum conductance; k is the slope 
factor; Vc is the command voltage; and Vs is the activation midpoint voltage of a single 
subunit. V1/2, the midpoint voltage of the peak conductance curve, was calculated as 
follows: 
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Equation 3.  𝑉1/2 = 1.665  𝑘 + 𝑉s 
The equivalent gating charge (z) was calculated as follows: 
Equation 4.  
z=RT/Fk=25.5/k 
Where R, T and F are the gas constant, absolute temperature and Faraday constant, 
respectively. 
        To display the results from different oocytes and estimate the magnitude of relative 
changes, individual G-V relations were normalized to the control Gmax before exposure to 
sevoflurane/azisevoflurane(1a) because all data were obtained from paired experiments 
(same oocyte in the absence and presence of the anesthetics). Accordingly, a relative G = 
1, <1 and >1 indicates no change, inhibition and potentiation, respectively. Data analysis, 
plotting and curve fitting were performed in OriginPro 9.1 (OriginLab, Northampton, 
MA). 
Statistics- GraphPad Prism 7, unless otherwise noted, was used for preparation and 
statistical data analysis. 
Study Approval- All animal care and experimental procedures involving X. laevis 
tadpoles and rodents were carried out according to a protocol approved by the IACUC of 
University of Pennsylvania. All animal care and experimental procedures involving 
Xenopus frogs were carried out according to a protocol approved by the IACUC of 
Thomas Jefferson University. 
2.2. Mechanistic basis for GABAA receptor modulation by volatile general anesthetics 
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γ-aminobutyric acid (GABA) is well established as the major inhibitory 
neurotransmitter within the adult mammalian brain. The majority of GABA inhibitory 
activity is a consequence of binding to the GABA Type A (GABAA) receptors, a member 
of the pentameric ligand-gated channel (pLGIC) superfamily.  GABAA receptors are 
largely heteromeric protein complexes composed of five homologous subunits. These 
subunits are expressed in a pseudosymmetric manner to form a chloride-selective pore. 
Numerous investigations have indicated that synaptic GABAA receptors are vital in for 
postsynaptic hyperpolarization and contribute to presynaptic neurotransmitter release 148–
151. Synaptic GABAA receptors are predominately a 2α(1-3):2β(1-3):1γ(1-3) stoichiometry 
152,153 organized in an alternating order (e.g. γαβαβ anti-clockwise as seen from synaptic 
cleft) 152–154. As a consequence, numerous potential ligand binding sites exist including at 
least four distinct subunit interfaces; α+/γ-, α+/β-, β+/α-, and γ+/β-.  
Since the mid-20th century, mounting evidence has suggested that GABAA 
receptors are significant functional protein targets involved general anesthetic 
mechanisms 155–158. The majority of general anesthetics enhance receptor activity at 
clinically relevant concentrations 6. Within the past decade the focus has largely been on 
identifying binding sites for intravenous anesthetics, such as propofol and etomidate 159; 
however the sites for volatile anesthetics remains unclear.  Sevoflurane and isoflurane 
(Figure 12) are volatile anesthetics widely used in clinics. Both anesthetics have been 
shown to effect synaptic transmission within the central nervous system and enhance 
synaptic GABAA receptor activity 156,160. It has been reported that α1 mutations can 
influence isoflurane and sevoflurane positive modulation of the receptor 160. Isoflurane at 
clinical concentrations has shown to prolong both fast and slow forms of phasic GABAA 
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receptor-mediated inhibition in mouse hippocampal neurons161 and ‘knock-in’ mutations 
within α1 or β3 subunits within mice have resulted in, to varying degrees, right-shifts of 
anesthesia endpoints for volatile anesthetics162,163. These studies, while providing 
evidence for the role of synaptic GABAA receptors in sevoflurane and isoflurane 
mechanisms of action, do not define the direct binding site(s) of these ligands within the 
receptor. Indeed, it is unclear whether the mutated proteins provide suitable model 
systems and/or the inhibition is a product of allosterically perturbing the binding site(s). 
Furthermore mutagenesis leaves some ambiguity to the location of the anesthetic binding 
cavity relative to the mutated residue; therefore complementary methodologies are 
necessary.  
 
Figure 12. Chemical structures of volatile anesthetics and corresponding anesthetic-photoaffinity 
ligands. 
 
It is critical to define these sites for volatile agents in synaptic GABAA receptors 
due to 1) the likely significant contribution that these and other pLGICs within volatile 
anesthetic mechanisms and 2) to determine underlining mechanisms that may lead to 
potential receptor subunit selectivity of these agents. Within the following investigation 
two a-PALs for the volatile anesthetics sevoflurane and isoflurane, azisevoflurane(1a) 
and aziisoflurane50 respectively (Figure 12), were applied to identify binding sites within 
human α1β3γ2L and α1β3 GABAA receptors. Azisevoflurane(1a) and aziisoflurane labeled 
multiple sites within α1β3γ2L and α1β3 GABAA receptors largely located within the 
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transmembrane domain (TMD). Photoaffinity labeled residues strongly suggests a shared 
volatile anesthetic binding site within the β+/α- interface that overlaps with a previous 
positive modulatory site identified for intravenous anesthetics.  Selective interfacial 
photoaffinity labeling within the α+/β- interface aligns with previous mutagenesis studies 
implicating this interface as a volatile anesthetic binding site. Potential intra- and/or 
interfacial volatile anesthetic binding within γ subunit-containing sites were identified, 
however functional contributions of the occupancy of these sites remain to be further 
defined.  
2.2.1. Purified α1β3γ2L GABAA receptor generation and volatile a-PAL competition for 
photoaffinity radiolabeling 
α1β3γ2L GABAA receptors are considered among the most abundant synaptic 
GABAA receptors within the adult mammalian brain 148. These receptors are also noted to 
be difficult to heterolgously express as functionally active receptor, in particular the γ2 
subunit has been reported to be difficult to incorporate during assembly 164,165. A 
previously successful tetracycline-inducible HEK293 cell line was applied that includes a 
(GGS)3GK (or L3) linker and 1D4 epitope to the C-terminus of the γ2L GABAA receptor 
subunit 164. The additional 1D4 epitope within the FLAG- α1β3γ2L-(L3)-1D4 GABAA 
receptor allows for enhanced affinity purification and validation of γ2L  containing 
receptor. The full, assembled FLAG- α1β3γ2L-(L3)-1D4 GABAA receptor was validated 
by the proper stoichiometry (2:1) of [3H]muscimol (a GABA-mimetic that shares binding 
sites within the two β+/α- interfaces per receptor) and [3H]flunitrazepam (a 
benzodiazepine that binds within a single α+/γ- interfacial binding site per receptor) 
binding. The additional affinity tags have shown to have no significant effect on the 
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functional activity of the receptor, including response to positive modulators 164. To 
solubilize the receptors from membrane preparations, n-dodecyl-β-D maltopyranoside  
(DDM) was used164. The receptors were then purified with anti-FLAG and/or anti-1D4 
affinity columns before reconstitution directly from the beads with washes using 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS)/ asolectin. 
Approximant specific activity and purification were determined by [3H]muscimol 
binding. 
Previously, photoaffinity radiolabeling with radioactive isotope-containing a-
PALs has been used to demonstrate photomodification(s) of proteins93,57,80, unfortunately 
due to significant synthetic challenges, a radioactive isotope could not be incorporated 
into the volatile a-PAL structures. Protection from or competition for photoaffinity 
radiolabeling using various anesthetics or a-PALs have also been used to gather further 
evidence for protein binding sites166,69,76. Indeed propofol and the corresponding PAL 
meta-azipropofol (AziPm) inhibit [3H]azietomidate photoaffinity radiolabeling within 
α1β3  GABAA receptors and likely have shared and/or overlapping binding site(s) within 
α1β3γ2L GABAA receptors159,76. Similarly it has been shown that isoflurane was able to 
protect from [3H]azietomidate photoaffinity radiolabeling of GABAA receptor purified 
from bovine brain 69. Likely due to the differences in binding affinity as well as the 
multiple factors that interplay during photoaffinity labeling protection (see section 1.2.2.), 
such studies utilizing volatile anesthetics and [3H]AziPm have not been realized for 
GABAA receptors. Therefore we applied azisevoflurane(1a) and aziisoflurane as 
competing a-PALs during the [3H]AziPm  photoaffinity radiolabeling of purified α1β3γ2L 
GABAA receptors.  
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FLAG- α1β3γ2L-(L3)-1D4 GABAA receptors were equilibrated with 1:25 molar 
ratio of [3H]AziPm: azisevoflurane(1a) or aziisoflurane in the presence of GABA. 
Receptors were simultaneously irradiated with two UV lamps with two optimal 
transmission wavelengths, 300 nm (associated with a 295 nm low pass filter) and 350 nm 
(associated with a 305 nm low pass filter) for volatile a-PAL and [3H]AziPm 
photoactivation respectively. The irradiated receptors were separated by SDS-PAGE and 
excised bands were counted for radioactivity. With the addition of the low pass filters no 
overt damage to the FLAG- α1β3γ2L-(L3)-1D4 GABAA receptor subunits by the UV 
irradiation was observed as displayed by SDS-PAGE. Predominate bands spanning above 
the 50kDa molecular weight marker were present corresponding with the expected 
molecular weight for subunits are 52-55kDa 164.  
 
Figure 13. Inhibition [3H]AziPm photoaffinity radiolabeling of FLAG- α1β3γ2L-(L3)-1D4 GABAA 
receptor by azisevoflurane(1a) and aziisoflurane.  Competition radiolabeling labeling assay with 
[3H]AziPm, azisevoflurane(1a) and aziisoflurane photoaffinity labeling of FLAG- α1β3γ2L-(L3)-
1D4 GABAA receptor  subunits separated by SDS-PAGE. Dpm represents disintegrations per 
minute, intensity was measured as the optical density of the coomassie blue stained bands 
multiplied by the band area (mm2). Results were analyzed by 2way-ANOVA with Dunnett’s 
multiple comparisons test comparing photoaffinity competition samples to [3H]AziPm control, 
(*,p<0.05; **,p<0.01; ns, not significant). Error values are represented as mean ± SEM 
 
 Azisevoflurane(1a) and aziisoflurane both inhibited [3H]AziPm 
photoincorporation into FLAG- α1 and β3 subunits of FLAG- α1β3γ2L-(L3)-1D4 GABAA 
receptors (Figure 13). Within bands at molecular weight corresponding to the FLAG- α1 
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subunit, aziisoflurane significantly decreased the [3H]AziPm radiolabeling by ~41% (p-
value = 0.0280; two-way ANOVA Dunnett’s multiple comparisons test). A ~30% 
inhibition in [3H]AziPm photoaffinity radiolabeling was observed when 
azisevoflurane(1a) was included however these results did not reach significance (p-value 
= 0.1167; two-way ANOVA Dunnett’s multiple comparisons test). Within bands 
corresponding to the molecular weights of the β3 subunit, both azisevoflurane(1a) and 
aziisoflurane significantly decreased [3H]AziPm photoincorporation by ~27% (p-value = 
0.0275; two-way ANOVA Dunnett’s multiple comparisons test) and ~36% (p-value = 
0.0030; two-way ANOVA Dunnett’s multiple comparisons test) respectively. Neither 
volatile a-PALs significantly inhibited [3H]AziPm photoincorporation into the γ2L-(L3)-
1D4 subunit (Figure 13); although considering the relative lower levels of photoaffinity 
radiolabeling by [3H]AziPm and/or potential alternative unshared binding site(s), this 
study does cannot rule out potential azisevoflurane(1a) or aziisoflurane photoaffinity 
labeling of the γ subunit residues. 
 Together the inhibition of [3H]AziPm photoaffinity radiolabeling indicates 
successful photoaffinity labeling of FLAG- α1 and/or β3 subunit residues by the volatile 
a-PALs. Furthermore the competition for [3H]AziPm photoaffinity labeling aligns with 
previous evidence suggesting shared and/or overlapping binding sites between the 
intravenous and volatile anesthetics within synaptic GABAA receptors 160,69,76. While 
providing an initial assessment for volatile a-PAL binding to α1β3γ2L GABAA receptors, 
the results from this study cannot be fully extended to localization of or affinity for 
volatile anesthetic binding sites. The observed competition by azisevoflurane(1a) and 
aziisoflurane for [3H]AziPm photoaffinity radiolabeling, albeit considered unlikely due to 
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the low EC50s 118, might be a result of an allosteric mechanism resulting in decreased 
[3H]AziPm binding. Furthermore the differences in quantum yield of photoactivation or 
Ψ (see section 1.2.1) between all three a-PALs as well as the effect of the cumulative 
exposure of multiple UV wavelengths prevents accurate quantitative evaluation of 
binding affinity. Protein microsequencing would be necessary to identify the volatile a-
PAL photomodified residues and provide evidence for potential volatile anesthetic 
binding sites within α1β3γ2L GABAA receptors.  
2.2.2.Volatile a-PAL photoaffinity labeling of α1β3γ2L & α1β3 GABAA receptors 
For the micro-level identification of volatile a-PAL photomodification sites 
reverse phase High Performance Liquid Chromatography coupled tandem mass 
spectrometry (rpHPLC-MS/MS) for protein microsequencing was employed. Purified 
FLAG- α1β3γ2L-(L3)-1D4 GABAA receptors were prepared as above. Azisevoflurane(1a) 
or aziisoflurane were directly solubilized into the receptor containing sample and allowed 
time to equilibrate within the system before UV irradiation with 300 nm UV lamp with 
the addition of a 295 nm low pass filter. After irradiation, receptors were concentrated 
and subjected to either in-solution or in-gel sequential trypsin/chymotrypsin protease 
digests. The resulting spectra from rpHPLC-MS/MS were analyzed using a customized 
database containing the heterologously expressed receptor sequences 167.  
There was sufficient coverage of each GABAA receptor subunit with 95:85:78% 
(FLAG- α1:β3:γ2L-(L3)-1D4 % coverage) for azisevoflurane(1a) and 95:88:84%(FLAG- 
α1:β3:γ2L-(L3)-1D4 % coverage) for aziisoflurane photoaffinity experiments (see 
appendix A.3.3.-A.3.4.). Within azisevoflurane(1a) photoaffinity labeled receptor, a total 
of eight residues within seven unique peptides were identified to contain the mass to 
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charge (m/z) change indicative of the a-PAL photomodification. The FLAG-α1 subunit 
contained the highest relative degree of photomodification by azisevoflurane(1a) with 
five residues demonstrating modification (Ser-276/241, Arg-290/255, Val-295/260, Thr-
296/261 and Thr-300/265; residues corresponding FLAG/non-FLAG tagged α1 subunit) 
within four unique peptides. The β3 subunit displayed the least detected 
azisevoflurane(1a) photomodified residues with the single Ala-248 detected as containing 
photomodification. Within the γ2L-(L3)-1D4 subunit,  two azisevoflurane photomodified 
residues, Leu-268 and Gly-269, on two unique peptides were identified (see appendix 
A.4.3.). A total of nine aziisoflurane modified residues within seven unique peptides were 
detected in photoaffinity labeled FLAG- α1β3γ2L-(L3)-1D4 GABAA receptors. 
Comparatively the β3 subunit displayed the highest number of modified residues detected 
with five residues (Ile-222, Gln-224, Trp-226, Ile-255, and Ile-264) on three unique 
peptides. Three modified residues were detected within the FLAG- α1 subunit (Glu-
285/250, Ser-311/276, and Pro-313/278; residues corresponding FLAG/non-FLAG 
tagged α1 subunit) on three unique peptides. Finally only one residue within the γ2L-(L3)-
1D4 subunit (Trp-241) was detected with an aziisoflurane modified residue (see appendix 
A.4.4.). 
It should be noted that in the case of the γ2L subunit, relative to the other subunits, 
showed the least protein coverage (~4-18% less than the FLAG-α1 or β3 subunits) within 
both azisevoflurane(1a) and aziisoflurane photoaffinity labeled receptor; therefore some 
photomodified residues might not be represented. Multiple factors could have contributed 
to the decrease including the relative subunit abundance, protease digest efficiency and/or 
the photomodifications themselves as discussed in section 1.2.2.  Notably the γ2L subunit 
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third transmembrane domain (TMD) helix (γM3) consistently was not detected within 
photoaffinity labeled receptors with ~40-78% coverage. This is in contrast to FLAG-α1 
and β3 subunits that showed 100% and 93-100% coverage despite being within the same 
experiments and having fair homology. As such we cannot rule out further photoaffinity 
labeled residues within this region of the subunit.  
A difficulty when evaluating potential photoaffinity labeled sites within a 
complex oligomer is that single protein interface can be present in multiple distinct 
binding cavities. Within α1β3γ2L GABAA receptors, the α+ and β- subunit interfaces are 
present in two of three separate interfacial sites (α+/β- and α+/γ- or γ+/β-). In order 
further resolve these sites, heterologously expressed α1β3  GABAA receptors were 
photoaffinity labeled with azisevoflurane(1a) or aziisoflurane. Removing the γ subunit 
from the system provides evidence for of α+/β- interfacial binding without interference 
from α+/γ- or γ+/β- interfacial binding. Purified and functionally active human FLAG- 
α1β3 GABAA receptors were generated using a previously published tetracycline-
inducible HEK293 cell line with receptor solubilization and purification methods similar 
to that described above 167. The FLAG-tagged receptor maintains a stable cell line with 
concentration dependent response to GABA comparable to that of α1β3 GABAA receptors 
and positive modulation by anesthetics is also retained by the FLAG-tagged receptors 167. 
The system composition used during photoaffinity labeling and downstream sample 
preparation and MS microsequencing of photoaffinity labeled FLAG- α1β3 GABAA 
receptors was the same as FLAG- α1β3γ2L-(L3)-1D4 GABAA receptors noted above. 
Both FLAG-α1 and β3 GABAA receptor subunits displayed ample coverage with 
92: 89% (FLAG-α1 : β3 % coverage) for azisevoflurane(1a) and 91: 81% (FLAG-α1: β3 % 
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coverage) for aziisoflurane photoaffinity labeling experiments (see appendix A.3.5- 
A.3.6). A total of four residues on four unique peptides within the FLAG-α1 subunit 
(Gly-139/104, Cys-269/234, Pro-288/253, and Val-292/257; residues corresponding 
FLAG/non-FLAG tagged α1 subunit) and five residues on four unique peptides within the 
β3 subunit  (Glu-179, Pro-184, Trp-241, Ala-249, Thr-256, and Leu-417) were 
photolabeled by azisevoflurane(1a) (see appendix A.4.5.). Seven aziisoflurane 
photomodified residues (Asn-138/103, Thr-265/230, Ile-274/239, Leu-275/240, Val-
287/252, Ile-306/271 and Ser-307/272; residues corresponding FLAG/non-FLAG tagged 
α1 subunit) on five unique peptides were detected within FLAG-α1 subunit of FLAG- 
α1β3 GABAA receptors.  Within the β3 subunit three residues (Ala-45, Thr-266 and Val-
290) on three unique peptides were detected with aziisoflurane photomodifications (see 
appendix A.4.6.).   
2.2.3. Volatile anesthetic binding in α1β3γ2L GABAA receptor homology models 
 
Figure 14. Locations of the photomodified residues by azisevoflurane(1a) and aziisoflurane from 
FLAG- α1β3γ2L-(L3)-1D4 and/or FLAG- α1β3 GABAA receptor photoaffinity labeling studies. 
Detected photomodified residues (spherical structure) by azisevoflurane(1a) (A-B; red) or 
aziisoflurane (C-D; teal) within α1β3γ2L-(L3)-1D4 (A-D) and FLAG- α1β3 (B,D) GABAA 
receptors. 
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 The locations of the photomodified residues by azisevoflurane(1a) and 
aziisoflurane from all GABAA receptors photoaffinity labeling studies are shown in 
Figure 14 using a previously published homology model of the α1β3γ2 GABAA receptor 
168 based-off the glutamate-gated chloride channel (GluCl) of Caenorhabditis elegans 
(PDB ID: 3RHW). For each FLAG- α1β3γ2L-(L3)-1D4 or FLAG- α1β3 GABAA GABAA 
receptor the 8-10 residues were detected to contain volatile a-PAL photomodification. It 
is likely that the multiple but largely localized photomodifications reflects the high 
motility and lower binding affinities of these volatile anesthetics within protein cavities 
87,88. Volatile anesthetics and a-PALs generally show higher flexibility with more 
rotatable bonds compared to their nearest sized intravenous anesthetic counterparts. 
Therefore it is likely for the volatile a-PALs to insert into a range of potential residues 
within a single binding site.  
The majority of detected photoaffinity labeled residues by the volatile a-PALs 
appear to be within or near the membrane spanning helices of each subunit. Previous 
evidence has indicated that the majority of the likely pharmacologically relevant binding 
sites for intravenous anesthetics are likely located in TMD of GABAA receptors159 and 
the selective photoaffinity labeling of the TMD residues by azisevoflurane(1a) and 
aziisoflurane extends this hypothesis to volatile anesthetics. To investigate the potential 
of the anesthetics to occupy the cavities within the TMD, docking experiments with 
sevoflurane and isoflurane were conducted for each of the binding cavities provided by 
the four distinct GABAA receptor subunit dimers (α/γ, α/β, β/α, and γ/β) using AutoDock 
Vina147. Docking included the one intersubunit and two intrasubunit cavities present 
within the dimer and all cavity-facing residues made flexible.  
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 Views of sevoflurane and isoflurane docking poses within α/γ cavities are shown 
in (Figure 15) with corresponding a-PAL labeled residues within the interfacial cavity 
forming helixes (Figure16A). All of the generated docked poses for sevoflurane were 
located within the α+/γ- interfacial cavity (Figure 15B-C). Docking experiments appeared 
to correlate well with FLAG- α1β3γ2L-(L3)-1D4 GABAA receptor photoaffinity labeling 
experiments with poses being within at least 3 Å of at least one residue labeled by  
 
Figure 15. Sevoflurane and isoflurane docking poses in the α1β3γ2L GABAA receptor at the α+/γ- 
TMD interface with photoaffinity labeled residues. Sequences (A) of α+/γ- TMD interfacial 
helixes (α1 M2-M3 and γ2L M1-M2) are shown with corresponding residues (bold, underlined) 
labeled within α1β3γ2L GABAA receptors by azisevoflurane(1a) and aziisoflurane highlighted in 
red and cyan respectively. Views of the α+/γ- TMD interface of an α1β3γ2L GABAA receptor 
homology model168 based-off the glutamate-gated chloride channel (GluCl) of Caenorhabditis 
elegans (PDB ID: 3RHW) from the lipid (B,D, F,H) or the base of the extracellular domain 
(C,E,G,I) with the α and γ subunit shown in green and blue respectively and TMD helices labeled 
within colored circles. Five scored docking poses are shown in spherical representations for 
sevoflurane (B-C; salmon) and isoflurane (F-G; purple). The highest scored docking pose for 
sevoflurane (D-E) and isoflurane (H-I) are shown as spherical representations with carbon, 
oxygen, fluorine, and chloride colored as gray, red, cyan, and orange respectively.  
Corresponding azisevoflurane(1a) labeled residues within α1β3γ2L (red dashed boxes) GABAA 
receptors are shown as red stick representations at highest scored docking poses. Corresponding 
66 
 
aziisoflurane labeled residues within α1β3γ2L (cyan dashed boxes) GABAA receptors are shown as 
teal stick representations at highest scored docking poses and labeled in dashed boxes. 
 
azisevoflurane(1a). This included the lowest energy pose for sevoflurane (Figure 15D-E) 
that was < 2.5 Å from the azisevoflurane(1a) modified residue γLeu-268. The majority of 
isoflurane docking poses were also located within the α+/γ- interfacial cavity (Figure 
15F-G) including the lowest energy docking pose (Figure 15H-I). However is should be 
noted that the second highest scoring pose was located at the exterior of the dimer 
situated within a small cavity formed by the γM1 and γM4 helices. In contrast to the 
sevoflurane docking experiments, generated docking poses for isoflurane were a relative 
fair distance > 5 Å from any detected aziisoflurane photomodified residue. 
 
Figure 16. Sevoflurane and isoflurane docking poses in the α1β3γ2L GABAA receptor at the γ+/β- 
TMD interface with photoaffinity labeled residues. Sequences (A) of γ+/β- TMD interfacial 
helixes (γ2L M2-M3 and β3 M1-M2) are shown with corresponding residues (bold, underlined) 
labeled within α1β3γ2L GABAA receptors by azisevoflurane(1a) and aziisoflurane highlighted in 
red and cyan respectively.Views of the γ+/β- TMD interface of an α1β3γ2L GABAA receptor 
homology model168 based-off the glutamate-gated chloride channel (GluCl) of Caenorhabditis 
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elegans (PDB ID: 3RHW) from the lipid (B,D, F,H) or the base of the extracellular domain 
(C,E,G,I) with the α and γ subunit shown in green and blue respectively and TMD helices labeled 
within colored circles. Five scored docking poses are shown in spherical representations for 
sevoflurane (B-C; salmon) and isoflurane (F-G; purple). The highest scored docking pose for 
sevoflurane (D-E) and isoflurane (H-I) are shown as spherical representations with carbon, 
oxygen, fluorine, and chloride colored as gray, red, cyan, and orange respectively.  
Corresponding azisevoflurane(1a) labeled residues within α1β3γ2L (red dashed boxes) GABAA 
receptors are shown as red stick representations at highest scored docking poses and labeled in 
dashed boxes. Corresponding aziisoflurane labeled residues within α1β3γ2L (cyan dashed boxes) 
GABAA receptors are shown as teal stick representations at highest scored docking poses. 
 
 Docking within the γ/β GABAA receptor TMD dimer is shown in Figure 16. 
Compare to the α/γ dimer, the generated poses for sevoflurane in the γ/β dimer were 
further (> 5.5 Å) from detected azisevoflurane photomodified residues (Figure 16A-E) 
however all were still within the interfacial cavity. Two of the five generated poses 
(second and fifth lowest relative energy) for isoflurane were situated within the γ 
intrasubunit region (Figure 16A,F-I). The intrasubunit sites were in closest proximity 
(<2.5 Å) to an aziisoflurane labeled residue within the γM1 helix, γTyr-241 (Figure 15A). 
Previously intrasubunit binding within pLGICs has been associated with inhibition 169. It 
is unclear whether this identified site within the γ subunit represents a competing 
antagonistic action within synaptic GABAA receptors, however this finding does provide 
an interesting prospect for volatile anesthetic molecular mechanisms. The lowest energy 
pose generated for isoflurane was located within the γ+/β- interfacial cavity (Figure 16H-
I). The interfacial poses for isoflurane were a fair distance (<4.0 Å) of a detected 
aziisoflurane photomodified residue within the β3 subunit, namely βGln-224.  
It is necessary to consider that the portion of the γM3 helix (γTyr-292/Val-300 to 
γIle-305; see appendix A.3.5- A.3.6) that consistently displayed poor coverage within 
both a-PAL photoaffinity labeling experiments would be included within γ+/β- interfacial 
binding cavity. Anticipated alterations by the volatile a-PALs to this peptide segment (ex. 
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increased hydrophobicity) could be responsible for the continual lack of coverage within 
this region. Ultimately volatile anesthetic binding within the γ+/β- interfacial cavity 
cannot be excluded from consideration due to potential of unrepresented photoaffinity 
labeled residues within the γM3 helix. Indeed binding by intravenous anesthetics has 
been suggested within the γ+/β- interfacial cavity159,170, with an (R)-(-)-mTFD-
mephobarbital photomodification detected on γSer-301 of the γM3 helix 73.  
 
Figure 17. Sevoflurane and isoflurane docking poses in the α1β3γ2L GABAA receptor at the β+/α- 
TMD interface with photoaffinity labeled residues. Sequences (A) of β+/α- TMD interfacial 
helixes (β3 M2-M3 and α1 M1-M2) are shown with corresponding residues (bold, underlined) 
labeled within α1β3 (*) or α1β3γ2L GABAA receptors by azisevoflurane(1a) and aziisoflurane 
highlighted in red and cyan respectively. Views of the β+/α- TMD interface of an α1β3γ2L GABAA 
receptor homology model168 based-off the glutamate-gated chloride channel (GluCl) of 
Caenorhabditis elegans (PDB ID: 3RHW) from the lipid (B,D, F,H) or the base of the 
extracellular domain (C,E,G,I) with the α and γ subunit shown in green and blue respectively and 
TMD helices labeled within colored circles. Five scored docking poses are shown in spherical 
representations for sevoflurane (B-C; salmon) and isoflurane (F-G; purple). The highest scored 
docking pose for sevoflurane (D-E) and isoflurane (H-I) are shown as spherical representations 
with carbon, oxygen, fluorine, and chloride colored as gray, red, cyan, and orange respectively.  
Corresponding azisevoflurane(1a) labeled residues within α1β3 (bold boxes) or α1β3γ2L (dashed 
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boxes) GABAA receptors are shown as red stick representations at highest scored docking poses. 
Corresponding aziisoflurane labeled residues within α1β3 (cyan bold boxes) or α1β3γ2L (cyan 
dashed boxes) GABAA receptors are shown as teal stick representations at highest scored docking 
poses. 
 
 Figure 17 displays the docking poses for the volatile anesthetics within the β/α 
TMD dimer. The β/α dimer is expected to form the β+/α- interface that represents two of 
the five potential interfaces within most native synaptic α1β3γ2L GABAA receptors and in 
photoaffinity labeled FLAG- α1β3γ2L-(L3)-1D4 and FLAG- α1β3 GABAA receptors 
(Figure 17A). Sevoflurane docking poses were located within the β+/α- interface (Figure 
17B-E) with the lowest energy docking poses agreeing (< 2.5 Å distance) with αM1 
(αCys-234), αM2 (αThr-261 and/or αThr-260) or βM2 (βThr256) helical residues 
photomodified by azisevoflurane(1a) (Figure 17D-E). Isoflurane docking poses were also 
near (<2.5 Å distance) aziisoflurane photomodified residues detected within the αM1 
(αIle-239 and/or αLeu-240), βM2 (βIle-255) or βM3 (βVal-290) helices (Figure 17A, F-
I).  
The β+/α- interfacial site has been implicated as a likely positive modulatory site 
for the comparatively more potent intravenous anesthetics propofol and etomidate 159. 
Indeed residues previously labeled by these intravenous a-PALs are in close proximity to 
residues labeled by the volatile a-PALs. This includes residues photoaffinity labeled by 
aziisoflurane that were also detected to contain a photomodification by AziPm (αIle-
239)76 and TDBzl-etomidate (βVal-290) 71. Together with previous protection studies69,76 
and above photoaffinity radiolabeling competition studies with [3H]AziPm, the evidence 
suggests a shared or overlapping general anesthetic binding site within the β+/α- interface 
of synaptic GABAA receptors. Based off published mutagenesis studies and the binding 
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of more potent modulators, it is likely that the β+/α- interfacial site contributes to the 
positive modulation of GABAA receptors by the volatile anesthetics sevoflurane and 
isoflurane. 
 The docking results and photoaffinity labeled residues within the α/β subunit 
dimer are shown in Figure 18. As the α+ and β- interfaces are present within α+/β- and  
 
Figure 18. Sevoflurane and isoflurane docking poses in the α1β3γ2L GABAA receptor at the α+/ β- 
TMD interface with photoaffinity labeled residues. Sequences (A) of α+/β- TMD interfacial 
helixes (α1 M2-M3 and β3 M1-M2) are shown with corresponding residues (bold, underlined) 
labeled within α1β3 (*) or α1β3γ2L GABAA receptors by azisevoflurane(1a) and aziisoflurane 
highlighted in red and cyan respectively. Views of the α+/β- TMD interface of an α1β3γ2L GABAA 
receptor homology model168 based-off the glutamate-gated chloride channel (GluCl) of 
Caenorhabditis elegans (PDB ID: 3RHW) from the lipid (B,D, F,H) or the base of the 
extracellular domain (C,E,G,I) with the α and γ subunit shown in green and blue respectively and 
TMD helices labeled within colored circles. Five scored docking poses are shown in spherical 
representations for sevoflurane (B-C; salmon) and isoflurane (F-G; purple). The highest scored 
docking pose for sevoflurane (D-E) and isoflurane (H-I) are shown as spherical representations 
with carbon, oxygen, fluorine, and chloride colored as gray, red, cyan, and orange respectively.  
Corresponding azisevoflurane(1a) labeled residues within α1β3 (red bold boxes) or α1β3γ2L (red 
dashed boxes) GABAA receptors are shown as red stick representations at highest scored docking 
poses. Corresponding aziisoflurane labeled residues within α1β3 (cyan bold boxes) or α1β3γ2L 
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(cyan dashed boxes) GABAA receptors are shown as teal stick representations at highest scored 
docking poses. 
 
the α+/γ- or γ+/β- interfacial sites within α1β3γ2L GABAA receptors, photoaffinity 
labeling of FLAG- α1β3γ2L-(L3)-1D4 GABAA receptor alone cannot fully distinguish 
photomodified residues within the α+/β- interface. To examine the α+/β- interfacial site 
under further isolation, FLAG- α1β3 GABAA receptors were photoaffinity labeled with 
the volatile a-PALs. The detected photomodified residues by azisevoflurane(1a) and 
aziisoflurane from both experiments are shown in Figure 18A. The docking poses for 
sevoflurane within the α/β subunit dimer were in agreement with photomodified residues 
that were detected in both GABAA receptors (Figure 18B-E). Accordingly the selective 
photoaffinity labeling by azisevoflurane(1a), in particular those residues photomodified 
within the FLAG- α1β3 GABAA receptors (αPro-253, αVal-257, βTrp-241, βAla-249 and 
βThr-256), suggests binding within the lower region of the α+/β-  interface. Similarly the 
residues photomodified with aziisoflurane were in good agreement with docking poses 
generated within the α/β subunit dimer with poses within close proximity (< 3 Å) of 
αSer-272 and αIle-271 that were detected with photomodifications within FLAG- α1β3 
GABAA receptors (Figure 18F-I).   
Previously mutations of αSer-270, which is located within the αM2 helix and 
projects into the α+/β- interface, to either Trp and Ile has shown to enhance receptor 
sensitivity to GABA. Furthermore αSer-270 mutations have been shown to significantly 
decrease the positive modulation by volatile anesthetics including sevoflurane and, to a 
greater extent, isoflurane. Based on things findings, the α+/β- interface, specifically this 
region of the interface, had been put forth to contain volatile anesthetic binding site(s). 
The volatile a-PAL photoaffinity labeling experiments largely complement this 
72 
 
hypothesis, particularly for the site identified with aziisoflurane. Residues photomodified 
by azisevoflurane(1a) are located near the final residues of the αM2 helix and the final 
and leading residues of the βM2 and βM3 respectively (Figure 18A). Mutations near the  
αSer-270 residue will likely influence the conformation and/or dynamics of the 
surrounding protein structure. Given the lower inhibition of positive modulatory activity 
by αSer-270 mutations for sevoflurane compared to isoflurane160, it is reasonable to 
conclude that regions identified by azisevoflurane(1a) photoaffinity labeling located 
within the same interface could be more selective for sevoflurane binding. 
 Some photomodified residues by the volatile a-PALs were detected outside the 
TMD of the FLAG- α1β3 GABAA receptors. A total of three extracellular domain (ECD) 
residues, one within the FLAG- α1 (αGly-139/104; residues corresponding FLAG/non-
FLAG tagged α1 subunit) and two within β3 (βGlu-179 and βPro-184) subunit, were 
detected with an azisevoflurane(1a) photomodification. Two extracellular domain 
residues were detected with an aziisoflurane photomodification, αAsn-138/103 (residues 
corresponding FLAG/non-FLAG tagged α1 subunit) and βAla-45. Within the applied 
homology model of the α1β3γ2 GABAA receptor 168 all the volatile a-PAL photomodified 
residues are focused within a single site at the α+/β- interface of ECD (Figure 14). This 
ECD site is distinct from the GABA and benzodiazepine binding sites that are located at 
the β+/α- and α+/γ- interfaces respectively. These photomodified residues correspond 
with the ketamine binding site crystalized within bacterial homolog of pLGICs from 
Gloeobacter violaceus (GLIC) 171. Both ketamine and volatile anesthetics inhibit GLIC 
171,172, however the functional relevance of this site for GABAA receptors (i.e. whether it 
may act as a potential functional site within all pLGICs) is unclear. One residue (βLeu-
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417) located within the intracellular loop between the βM3 and βM4 helices was detected 
as an azisevoflurane(1a) photomodified residue. This residue is located near the clathrin 
adaptor 2 protein (AP2) binding motif that acts as a vital phosphorylation site that 
regulates GABAA receptor endocytosis 173. Whether a potential anesthetic binding cavity 
exists within the intracellular loop is not apparent and the potential effect it may have in a 
biological system is unclear; however, this finding opens the possibility for potential 
alternative anesthetic molecular mechanisms, other than direct modulation of ion flux, 
that could affect receptor activity.  
2.2.4. Conclusions 
General anesthetics have long been shown to enhance the GABAA receptor 
activity at clinically relevant concentrations.  The bulk of recent investigations to 
determine the mechanism(s) behind the positive modulation have been focused on 
intravenous anesthetics while studies for inhaled anesthetics have been, in comparison, 
limited. In this study two a-PALs for sevoflurane and isoflurane to identify binding sites 
within human α1β3γ2L and/or α1β3 GABAA receptors. In total, the multiple localized 
photomodified residues by either volatile a-PAL exemplifies the motility of these 
comparatively highly flexible and mobile ligands within these cavities and likely 
contributes to their lower protein binding affinity.  The labeled residues suggested that 
the a-PALs likely bind within both α+/β- and β+/α- subunit interfaces, with the β+/α- 
interfacial site overlapping with previously suggested intravenous anesthetic binding site. 
Azisevoflurane(1a) and aziisoflurane demonstrated potential preferential labeling, and 
therefore occupancy of the α+/β- interface. Labeling of γ subunit residues suggests 
binding within γ-containing interface(s) and the potential for an intrasubunit site. Further 
74 
 
studies are required to determine the functional significance of detected binding sites. 
However photoaffinity experiments do support previous investigations suggesting 
binding site(s) within the α+/β- and β+/α- subunit interfaces that likely contribute to 
volatile anesthetic positive modulation of synaptic GABAA receptors.  
2.2.5. Experimental methods  
Construction and stable cell line generation. The genes encoding GABAA receptor α1, β3, 
and γ2L subunits were respectively cloned into expression vectors containing independent 
antibiotic selection. Preparation of the plasmids FLAG–bGABAAR α1/pcDNA4/TO– 
Zeocin, hGABAAR β3/pcDNA3.1/TO–Hygro1 and hGABAAR γ2-(GGS)3GK-
1D4/pACMV/TO–blasticidin was performed as previously described164,167. Transfection 
using 293fectin and colony selection and amplification were conducted as previously 
reported. Optimal inducible cell lines were validated and chosen based on quantitative 
reverse-transcription polymerase chain reaction (RT-PCR), Western blotting, growth rate 
and the number of [3H]muscimol and/or [3H]flunitrazepam sites.   
Immunoaffinity purification of GABAA receptor. Protein purification and reconstitution 
were performed as previously described164,167. Briefly stably transfected HEK293-TetR 
cells were grown, induced with tetracycline and 5 mM sodium butyrate, harvested and 
lysed, and membrane suspensions were collected. Membrane pellets were solubilized by 
dropwise addition of (in mM) 50 Tris-HCl (pH 7.4), 150 NaCl, 2 CaCl2, 5 KCl, 5 
MgCl2, and 4 EDTA supplemented with 10% (v/v%) glycol, protease inhibitors and 
DDM (final concentration 1.5% m/v%) to a final protein concentration of 1 mg/mL. 
Insoluble material was removed by ultracentrifugation and the supernatant was loaded on 
to prepared anti-FLAG or anti-1D4 affinity columns. CHAPS/asolectin replaced DDM by 
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repeated washes and 1 hr equilibration. The columns were then washed with asolectin 
(0.025-0.86 mM as required) and CHAPS (5 mM) prior to elution by 90 min equilibration 
in one column volume of the same solution supplemented with 0.1 mM FLAG or 0.15 
mM 1D4 peptide. The eluate was collected and the elution process was conducted a total 
of 3 to 4 times. The eluted protein fractions were frozen in liquid nitrogen and stored at -
80 °C. 
Radiophotoaffinity labeling of purified FLAG-α1β3γ2L-L3-1D4 GABAA receptor. 1250:1 
(ligand:protein molar ratio) of azisevoflurane(1a)  or aziisoflurane and 50:1 
(ligand:protein molar ratio)  [3H]meta-azipropofol was added to 1 µg FLAG-α1β3γ2L-L3-
1D4 GABAA receptor in 200 µM 2:1 (asolectin: cholesterol), 5 mM CHAPS and 1 µM 
GABA using methanol vehicle (<0.5% v/v%). The sample was equilibrated on ice in the 
dark for 5 min prior to being simultaneously exposed to 350 nm and 300 nm RPR-3000 
Rayonet lamp in quartz cuvettes through a WG305 305 nm glass filter (Newport 
Corporation) at the 350 nm face and WG295 295 nm glass filter (Newport Corporation) 
at the 300 nm face for 30 min. Samples were concentrated to ~15-20 µL using 10kDa 
MWCO Amicon Ultra Centrifugal Filters (Millipore). An equal volume of SDS loading 
buffer was added to the sample containing a final concentration 80 mM DTT, samples 
were vortexed vigorously then incubated at room temperature for 60 min before 
separation by 7.5% SDS-PAGE. The gel was stained by Coomassie Blue G250 (BioRad), 
destained and washed with ddH2O. Identified bands spanning from ~60-50kDa were 
excised. Prior to band cutting, gels were scanned on a Bio-Rad GS-800 calibrated 
densitometer with quantitation performed using the accompanying Quantity One 
Software. Mean background was subtracted with a box drawn between 50- 60 kDa 
76 
 
molecular mass marker.  The mean optical density multiplied by the band area (mm2) was 
recorded. Each excised band was placed into scintillation vials containing 2 mL 30% 
hydrogen peroxide (v/v%) and incubated at 65 °C to digest the polyacrylamide. Samples 
were allowed to cool to ambient temperature before 10 mL of scintillation fluid was 
added. The disintegrations per minute (dpm) from each vial were corrected with a non-
UV irradiated control and normalized to the corresponding optical density measurement. 
Values are represented as the mean ± SEM of four replicate experiments. 
Photoaffinity labeling of FLAG-α1β3 or FLAG-α1β3γ2L-L3-1D4 GABAA receptor for 
protein microsequencing.  1250:1 (ligand:protein molar ratio) of azisevoflurane(1a)  or 
aziisoflurane was added to 4 µg FLAG-α1β3γ2L-L3-1D4 and/or 6 µg of FLAG-α1β3 
GABAA receptor in 200 µM 2:1 (asolectin: cholesterol), 5 mM CHAPS and 1 µM GABA 
using DMSO vehicle (<0.01% v/v%). The sample was equilibrated on ice in the dark for 
5 min prior to being exposed to 300 nm RPR-3000 Rayonet lamp in 1-mm path length 
quartz cuvettes at through a WG295 295nm glass filter (Newport Corporation) for 25 
min.  
In-Solution Protein Digestion. Photolabeled samples were concentrated to ~15-20 µL 
using 10kDa MWCO Amicon Ultra Centrifugal Filters (Millipore). ProteaseMAX™ 
Surfactant (Promega) was added to 0.2% and the samples were vortexed vigorously for 
30 s. Samples were diluted to 93.5 µL to a final concentration of 50 mM NH4HCO3. 
Following 1 µL 0.5 M dithiothreitol (DTT) was added and samples were incubated at 56 
°C for 20 min. 2.7 uL of 0.55 M iodoacetamide was then added and protein samples were 
incubated at room temperature in the dark for 20 min.  After, 1 µL of 1% (w/v%) 
ProteaseMax ™ Surfactant was added followed by CaCl2 to 1 mM final concentration. 
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Sequencing grade-modified trypsin (Promega) was added to a final 1:20 protease: protein 
ratio (w/w). Proteins were digested overnight at 37°C. Trypsin digested peptides were 
diluted to 200 µL with final concentration of 100 mM NH4HCO3 and 0.2% ProteaseMAX 
Surfactant prior to the addition of sequencing grade chymotrypsin (Promega) to a final 
1:20 protease:protein ratio (w/w). Proteins were digested overnight at 37°C.  
Trifluoroacetic acid (TFA) was added to 0.5% (v/v) and the peptide digests were 
incubated at room temperature for 10 min prior to centrifugation at 16, 000 x g for 20 min 
before desalting using C18 stage tips prepared in house. Samples were dried by speed vac 
and resuspended in 0.1% formic acid immediately prior to mass spectrometry analysis. 
In-Gel Protein Digestion. Photolabeled receptor samples were concentrated to ~20 µL 
using 10kDa MWCO Amicon Ultra Centrifugal Filters (Millipore). SDS loading buffer 
was added to the sample containing a final concentration 80 mM DTT, samples were 
vortexed vigorously then incubated at room temperature for 45 min before the entire 
sample was separated by SDS-PAGE. Resulting gels were stained with Coomassie Blue 
G250 (BioRad). Gels were destained and washed with ddH2O; identified protein bands 
between ~50-60kDa, corresponding to FLAG-α1, β3, or γ2L-(L3)-1D4 GABAA receptor 
subunits, were excised. Excised bands were destained, dehydrated and dried by speed vac 
before proteins were reduced by incubation at 56° C for 20 min in 5 mM DTT and 50 
mM NH4HCO3. The DTT solution was removed and proteins were then alkylated by the 
addition of 55 mM iodoacetamide in 50 mM NH4HCO3 and incubation at room 
temperature in the dark. Bands were dehydrated and dried by speed vac before 
resuspension in 100 µL 0.2 % ProteaseMAX™ surfactant, 1 mM CaCl2 and 50 mM 
NH4HCO3 solution containing trypsin at a 1:20 protease:protein ratio (w/w). Proteins 
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were digested overnight at 37°C. After, samples were diluted to 200 µL with final 
concentration of 100 mM NH4HCO3 and 0.2% ProteaseMAX™ Surfactant prior to the 
addition of sequencing grade chymotrypsin (Promega) to a final 1:20 protease:protein 
ratio (w/w). Proteins were digested overnight at 37°C.  To increase hydrophobic peptide 
retrieval from the gel, multiple peptide extractions were performed. First the initial 
peptide digest solution was removed and 100 µL 30% acetylnitrile and 5% formic acid in 
ddH2O (v/v%) was added. Samples were sonicated for 20 min. The second peptide 
extraction was removed before 100 µL 70% acetylnitrile and 5% formic acid in ddH2O 
(v/v%) was added. Samples were sonicated for 20 min. All peptide digests were pooled 
and dried by speed vac before resuspension in 0.5% TFA and desalting using C18 stage 
tips prepared in house. Samples were dried by speed vac and resuspended in 0.1% formic 
acid immediately prior to mass spectrometry analysis. 
Mass spectrometry. Desalted peptides were analyzed on an Orbitrap EliteTM Hybrid Ion 
Trap-Orbitrap Mass Spectrometer (MS) coupled to an Easy-nanoLC 1000 system with a 
flow rate of 300 nL/min. Peptides were eluted with 100 min with linear gradients from 
2% to 40% ACN (85 min), from 40% to 85% ACN (5 min) and finally 85% (10 min) 
ACN in 0.1% formic acid (v/v). Data dependent acquisition mode was applied with a 
dynamic exclusion of 45 s, in every 3 s cycle, one full MS scan was collected with a scan 
range of 350 to 1500 m/z, a resolution of 60K and a maximum injection time was 50 ms 
and AGC of 500000. Then MS2 scans were followed on parent ions from the most 
intense ones. Ions were filtered with charge 2-5. An isolation window of 1.5 m/z was 
used with quadruple isolation mode. Ions were fragmented using collision induced 
dissociation (CID) with collision energy of 35%. Iontrap detection was used with normal 
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scan range mode and rapid iontrap scan rate. AG was set to be 10000 with a maximal 
injection time of 100 ms. 
Mass spectrometry analysis. Analysis was performed similar to as previously reported 
174. Spectral analysis was conducted using Thermo Proteome Discoverer 2.0 (Thermo 
Scientific) and the Mascot Daemon search engine using a customized database containing 
GABAA receptor protein sequences supplied for heterologous expression or the human 
proteome UniProt database (UniProtKB: P28472). All analyses included dynamic 
oxidation of methionine (+15.9949 m/z) and N(Q) deamidation (+0.98402 Da, when 
PNGase F-specific, defined as N(Q) deglycosylation) as well as static alkylation of 
cysteine (+57.0215 m/z; iodoacetamide alkylation). Photolabeled samples were run with 
the additional dynamic azisevoflurane (+230.0559 m/z) or aziisoflurane (+195.97143 m/z) 
modifications. A mass variation tolerance of 10 ppm for MS and 0.8 Da for MS/MS were 
used. Both the in-solution and in-gel sequential trypsin/chymotrypsin digests were 
searched without enzyme specification with a false discovery rate of 0.01%. Samples 
were conducted in triplicate and samples containing no photoaffinity ligand were treated 
similarly to control for false positive detection of photoaffinity ligand modifications.  
Docking. α1β3γ2 GABAA receptor transmembrane interfaces.  A homology model of the 
α1β3γ2 GABAA receptor was built by mutating 31 residues in the β subunits from an 
α1β1γ2 GABAA Model 3 reported in Hénin et al., 2014 168.   The mutations were made 
using the MUTATOR plugin of VMD 175. Molecular coordinates for isoflurane and 
sevoflurane were downloaded from the ZINC small molecule library144 using provided 
physical representations. The maximum torsions were allowed (i.e., ligands were fully 
flexible). Each unique subunit dimer (ie. α/γ, α/β, β/α, or γ/β) underwent individual 
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docking runs with each ligand with docking runs using AutoDock Vina 147. Grid boxes 
were set to contain the two intrasubunit and single intersubunit cavities present in the 
dimer and all residue side chains projecting towards the intra- and interface cavities were 
made flexible. Each dimer docking experiment was set to output 5 docking modes, all 
other setting were assigned with default parameters. Figures and measurements were 
generated using PYMOL.   
Statistics- GraphPad Prism 7, unless otherwise noted, was used for preparation and 
statistical data analysis. 
 
CHAPTER 3: PROPOFOL AND ALKYLPHENOL-BASED ANESTHETIC 
MOLECULAR MECHANISMS 
Propofol, or 2,6-diisopropylphenol, was the 31st of 51 alkylphenols synthesized 
and tested as candidate general anesthetic compounds within a primary structure-activity 
assessment by Dr. R. James in 1980 176.  Since then propofol has become the most widely 
used intravenous general anesthetic for the induction and maintenance of anesthesia. 
Although considered a more potent agent compared to the volatile anesthetics discussed 
within the previous chapter, the micromolar EC50 concentrations still suggest very 
transient interactions with molecular targets. The first section of this chapter contains a 
study on the key molecular feature(s) that contribute to propofol biological effects 
including the introduction of the novel hydrogen-bonding null propofol derivative called 
fropofol(1b). The second section introduces a novel bioorthoganol a-PAL for propofol 
termed AziPm-click(1c) that, coupled with a quantitative mass spectrometry workflow, 
allows the identification of propofol and alkylphenol-based general anesthetics binding 
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proteome within synaptosomes. The third and final section of this chapter focuses on 
propofol and alkylphenol binding within a suggested major target, synaptic GABAA 
receptors. 
3.1. Role for the propofol hydroxyl in anesthetic protein target molecular recognition 
The first major proposal for a mechanism of anesthetic-induced hypnosis arose 
when a relationship between anesthetic lipophilicity and potency was independently 
observed by Meyer and Overton 1,2. This correlation led to various hypotheses for 
membrane mediated mechanisms of anesthesia; however, evidence that anesthetics bind 
and cause functional effects through specific sites on multiple protein targets has steadily 
emerged. Crystallized anesthetic-protein complexes 88,90,177, recognition of highly specific 
and selective responses by ion channels 6,178, and elucidation of receptor binding site 
character using a-PALs 40,179 have propelled the concept of protein-mediated mechanisms 
to general acceptance.  
The binding affinity of a drug for a protein site is generally mediated by multiple 
specific non-covalent interactions in a process known as molecular recognition. Drug 
occupancy of a target protein site results in alteration(s) in protein conformation and/or 
dynamics that reflect (or produce) changes in the protein’s activity. General anesthetic 
ligands are a unique class of drugs in that they share only broad physicochemical 
features, such as low molecular weight and hydrophobicity. While causing similar 
desired endpoints including hypnosis, immobility, and amnesia, and adverse effects 
including cardiovascular depression, nausea, and hyperthermia, the drug concentrations 
to achieve the effects can be considerably different between anesthetics.  These 
observations suggest that a penchant of an individual anesthetic for a pharmacological 
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effect may be reliant on distinctive chemical features giving rise to a relative higher 
affinity for particular protein target(s). It is therefore essential to characterize the 
molecular interactions between proteins and anesthetics to successfully design new 
anesthetic agents that selectively cause the desirable effects through specific targets. 
While a fairly simple compound, propofol contains a particular feature within its 
chemical structure, a 1-hydroxyl, that is capable of distinctive intermolecular interactions 
180–182. The hydrophilic group permits hydrogen bonding to both aqueous solvent and to 
amino acids within protein targets, which contribute to solvation and specific molecular 
recognition, respectively. Solvation is critical for hydrophobic ligands to gain access to 
protein target(s) 183. Previous studies that examined various substitutions on the 
alkylphenol backbone could not rigorously attribute the changes in ligand efficacy to 
molecular recognition or to solvation 184,185.  To achieve this, a modification of propofol 
that removes hydrogen bonding propensity while retaining solvation properties, and then 
a comparison of both ligand activity and binding, is essential. 
 
Figure 19. Chemical structures of propofol and fropofol(1b) 
 
Thus, the 1-hydroxyl of propofol was substituted with a fluorine atom to produce 
2-fluoro-1,3-diisopropylbenzene, or fropofol(1b) (Figure 19). This otherwise 
physicochemically similar analogue to propofol allowed us to explicitly link the 1-
hydroxyl to protein affinity and, most importantly, to multiple in vivo consequences. The 
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investigation indicates that hydrogen bonding plays a surprisingly dominant role in 
molecular recognition for propofol-protein interactions that contribute to hypnosis, 
whereas the loss of the hydrophilic feature did not prevent binding to targets that lead to 
less favorable endpoints. 
3.1.1. Synthesis and characterization of fropofol(1b) 
To directly evaluate the contribution of the 1-hydroxyl in propofol molecular 
recognition an analogue that selectively weakens the hydrogen bond capability while 
retaining other physiochemical properties of propofol was designed. The synthesis of 
fropofol involved the diazotization of 2,6-diisopropylaniline, precipitation of the 
tetrafluoroborate salt, and dediazotization-fluorination under mild vacuum overnight 
(Scheme 2). 
Scheme 2. 
 
 
The physiochemical properties of propofol and fropofol(1b) are reported in Table 
5. The calculated van der Waals molecular volumes were similar between the two 
compounds with fropofol(1b) (189 Å3) being marginally smaller than propofol (192 Å3). 
Based on the Meyer-Overton rule, the increase in hydrophobicity by calculated 
octanol/water partition coefficients for fropofol(1b) (3.96) relative to propofol (3.79) 
predicted a modest increase in the compound’s anesthetic potency1,2. Consistent with the 
cLogP value, the measured maximum aqueous concentration achieved by fropofol(1b) 
was 116 ± 4.4 µM, approximately 5-fold less than propofol; however, the solubility of 
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fropofol(1b) exceeded or was within the same range of halogenated alkylphenols that 
retain activity;  2,4-diethylphenol bromide and 4-iodo-2,6-diisopropylphenol 185.  
Initial studies started with comparing propofol and fropofol(1b) binding to two 
model proteins. Previously, anesthetic binding to horse spleen apoferritin (aF) had been 
found to correlate strongly with GABAA receptor potentiation and tadpole loss of righting 
reflex (LORR) 87,186.  Anesthetic binding to a single site on aF is exothermic and 
mediated by electrostatic and hydrophobic interactions 87; a hydrogen bond was not 
apparent in the crystal structure of the complex with propofol. Propofol and fropofol(1b) 
bound aF with low micromolar KD values (Figure 20A-B; Table 5); however, 
fropofol(1b)  had a 4 to 5-fold increase in affinity (KD= 1.7 µM (0.5 - 2.9) (95% CI)) 
relative to propofol (KD= 9.0 µM (7.1 - 11) (95% CI)). 
Table 5. Physicochemical parameters and binding properties of propofol and fropofol(1b) 
 † Values are represented as mean (95% CI); ∫ Stoichiometry of aF sites were fixed at 
N=1;  ‡ KD Fluorescence data derived from Cheng–Prusoff equation 
 
 Propofol Fropofol(1b) 
Physicochemical Properties (2,6-diisopropylphenol) (2-fluoro-1,3-
diisopropylbenzene) 
Molecular Weight 178.27Da 180.26Da 
van der Waals Volume 192 Å 189 Å 
cLogP 3.79 3.96  
Density 0.96g/cm3 0.9 g/cm3 
Protein Affinities (µM) † aF∫ hSA aF∫ hSA 
ITC 9 (7.1 - 11) 43 (36 - 50) 1.7 (0.5 – 2.9) 91 (72-110) 
1-AMA Competition 10 (7-15) - 0.7 (0.3 -1.5 ) - 
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Figure 20. Propofol and fropofol(1b) horse spleen apoferrition (aF) binding. Isothermal titration 
calorimetry profiles of aF(A-B) interaction with propofol (A) or fropofol(1b) (B) using sequential 
titrations. Top: time response heat change from addition of ligand. Bottom: best fit attained from 
a single site binding model (best χ2 statistic) fitted to a 1:1 stoichiometry for aF. Drug affinities 
(KD) for HSAF site were 9µM and 1.7µM for propofol and fropofol(1b) respectively. (C) aF 
fluorescence competition using 1-aminoanthracene with titrations of either propofol (PfL; black 
circles) or fropofol(1b) (FfL; blue circles). Intensity was corrected for ambient ligand and protein 
fluorescence (see table 5). 
 
The propofol a-PAL meta-azi-propofol (AziPm) has been shown to photolabel the 
crystallographically-determined propofol site on aF 187. Therefore, [3H]AziPm was used 
in photoradiolabeling with and without competing ligands to definitively determine the 
fropofol(1b) -aF binding site. 1 µM propofol or fropofol(1b)  caused a 31% and 61% 
reduction in [3H]AziPm binding to aF, respectively. 1-Aminoanthracine (1-AMA) also 
binds the same site on aF 126. 1-AMA decreases in fluorescence when displaced from the 
aF site, and this feature allows calculation of ligand KD values through competition 
experiments. Calculated KD values from 1-AMA fluorescence competition (Figure 20A) 
correlated well with ITC and photoradiolabel competition studies for both propofol (KD= 
10 µM (7 - 15) (95% CI)) and fropofol (KD= 0.7 µM (0.3 - 1.5) (95% CI)).  
Cumulatively, the data show that propofol and fropofol(1b) bind within the same 
hydrophobic cavity on aF 87; however, fropofol(1b) consistently demonstrated an 
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approximately 3- to 5-fold increase in affinity, presumably due to the modest increase in 
hydrophobicity. 
 
Figure 21. Propofol and fropofol(1b) human serum albumin (hSA) binding. Isothermal titration 
calorimetry profiles of hSA interaction with propofol (A) or fropofol (B) using incremental 
titrations. Top: time response heat change from addition of ligand. Bottom: best fit attained from 
a single site binding model (best χ2 statistic) resulting in roughly 1:2 stoichiometry for hSA for 
fropofol(1b) (n=1.3 ± 0.9) and propofol (n=1.4 ± 0.5). Affinity (KD) for the hSA sites were 43µM 
and 91µM for propofol and fropofol(1b) respectively (see table 5). (C) Protection binding assay 
with [3H]AziPm photoradiolabeling of hSA hSA CNBr  14.9-12.1 kDa domain III digestion 
fragment with DMSO control or 75µM propofol (PfL) or fropofol(1b) (FfL) protection. 
Quantitation of dpm was normalized to averaged relative lane intensities of Coomassie blue (CB) 
stain. Data sets are represented as normalized mean ± normalized SEM and were analyzed by 
one-way ANOVA with Bonferroni’s post hoc test (p<0.05) comparing significance in protection 
to fragment control (*). 
 
Propofol has also been shown with crystallography to bind two sites within 
domain III of human serum albumin (hSA) 188.  Within each site there resides hydrogen 
bonding partners that facilitate propofol binding188.  Similar to aF, ITC measurements 
showed propofol and fropofol(1b) bound to hSA exothermically (Figure 21A-B; Table 
5). The cumulative KD of propofol binding to hSA was determined as 43 µM (36-50) 
(95% CI), with stoichiometry being dominated by the higher affinity complex 189. 
Fropofol(1b) demonstrated similar stoichiometry but with a cumulative KD of 91 µM (72-
110) (95% CI). 
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[3H]AziPm photoradiolabeling protection experiments were also performed with 
hSA, and these experiments were supplemented with CNBr digestion to specifically 
study binding to domain III.  Within the isolated domain III fragments, propofol 
significantly decreased radiolabel incorporation to about 67 ± 5% of the control 
[3H]AziPm photolabeling, while fropofol(1b) inhibited it by only half as much  (37 ± 
12% (mean ± SEM); Figure 21C). This suggests that the substitution of the 1-hydroxyl 
results in lower affinity to the specific propofol hSA binding sites that contain hydrogen 
bonding partners.  
Together, our data with aF and hSA demonstrate a contribution of the propofol 
hydroxyl for specific molecular recognition of model proteins. Our results demonstrate 
that propofol binds with higher affinity than fropofol(1b) to sites that contain hydrogen 
bond interactions, but that in the absence of hydrogen bond partners, fropofol(1b) binds 
with higher affinity. The relatively high affinities of these interactions also suggest that 
this result is independent of the solubility of the ligands.  
It bears mentioning that substitution for the 1-hydroxyl would also result in 
electronic changes that could modulate binding.  It is very difficult to entirely separate 
this possibility from the hydrogen bonding hypothesis, but it seems an unlikely 
explanation for the large differences measured and the generally weaker van der Waals 
interactions that would be influenced. Halogens can also serve as weak hydrogen bond 
acceptors. However fluorine, due to its high electronegativity and lack of polarizability 
190,191, is generally excluded from this form of interaction 192. 
3.1.2. Fropofol(1b) pharmacological and functional activity 
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Next, to characterize the relevance of the hydroxyl on pharmacological activity, 
several in vivo experiments were performed. The pharmacological activity of 
fropofol(1b) within albino X. laevis tadpoles was evaluated over the course of 60 and 90 
min exposure periods. When administered 3-100 µM fropofol, none of the X. laevis 
tadpoles within any dose group exhibited the standard loss-of-mobility endpoints. In 
contrast, excitatory phenotypes 193  were observed in some tadpoles (~11%) at 40-60 min 
with greater than 30 µM concentrations, and longer (80-90 min) exposures to these high 
concentrations produced this behavior in ~70% of the tadpoles. This excitatory behavior 
included continuous tight circular and/or ‘darting’ swimming patterns, previously 
reported as indicators of lower class seizures in X. laevis 193. When fropofol(1b)-
containing water was exchanged for fresh pond water, normal swimming behaviors 
resumed within 10-15 min. 
 
Figure 22. Propofol and fropofol(1b)in vivo activity. (A) EEG recording 1.75-2.4min after 
injection of 200 mg/kg fropofol(1b).  Phenotypical seizure activity observed within frontal 
association (FrA), primary motor (M1), medial parietal association area (MPAA), primary 
somatosensory (S1) and primary auditory (A1) traces. Postictal state (PI) was observed after 
seizing activity. (B) Propofol dose-response curves with the co-administration of 0 µM (black 
circles), 5µM (violet triangles), 25 µM (green squares) and 100µM (red diamonds) of 
fropofol(1b) within X. laevis tadpoles. Immobility was measured as loss of spontaneous 
movement. 
 
The excitatory activity was similarly observed within a mammalian model. Wild 
type C57/Bl6 mice were given bolus tail vein injections of fropofol(1b) dissolved in 10% 
lipid emulsion. At low dose (96 mg/kg), no observable effects were noted.  At higher 
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dose (180 mg/kg), electroencephalography (EEG) recordings and physical observation 
showed generalized tonic-clonic seizure-like activity 2 min post injection (Figure 22A), 
after which a lethargic postictal state was observed. Mice resumed normal activity within 
2-3 hr, and no toxicity was observed within the following days post-injection. Loss of 
righting reflex, the standard endpoint for general anesthetics was produced with 20 mg/kg 
of propofol, but not with even the highest doses of fropofol(1b).   
 To assure that fropofol(1b)  accessed the brain, some mice were euthanized at 45 
s and at 10 min after IV bolus injection of 96 mg/kg and 200mg/kg respectively. After 
perfusion and removal, the fropofol(1b) content in the brain was assayed by reverse 
phase-high performance liquid chromatography. At both time points, fropofol(1b)  was 
detectable within processed brain samples at 38 µg/gram of brain tissue and 51 µg/gram 
of brain tissue for the lower and higher doses, respectively. These concentrations are 
higher than propofol concentrations that result in hypnosis 194. When combined with the 
obvious central nervous system-derived behavioral change, this confirms that exclusion 
by either the blood-brain-barrier or through active pumps does not explain the absence of 
a fropofol(1b)  hypnotic action. 
Finally, in order to determine whether fropofol(1b)  has subhypnotic activity 195,  
tadpoles were exposed to increasing concentrations of propofol in the presence of four  
fixed concentrations of fropofol(1b)  (0, 5, 25 and 100 µM). Rather than demonstrating 
an additive effect, fropofol induced a right-shift in the propofol dose-response curve 
(Figure 22B) indicating antagonism towards propofol induced hypnosis at all 
concentrations.  
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Figure 23.  Propofol and fropofol(1b) GABAA receptor activity. (A) Effect on current by 
concentrations of propofol (PfL; n=3), fropofol(1b) (FfL; n=5) or propofol and fropofol(1b) 
(n=5) without GABA EC10 and propofol (n=5), fropofol (n=8), or propofol and fropofol with 
(n=6) GABA EC10 within X. laevis oocytes expressing α1β2γ2L GABAA receptor. GABA 
represents initial control EC10 exposure for modulation studies (n=19). Data is normalized to 
maximum GABA response and represented as mean ± SEM. Data were analyzed by one-way 
ANOVA with Bonferroni’s post hoc test (p<0.05) showing significant differences in fropofol(1b) 
or propofol or propofol and fropofol(1b) modulation (*) or significance from EC00 (†). (B) 
Propofol (PfL; black circles), fropofol(1b) (FfL; blue circles), or propofol with 50µM 
fropofol(1b) (green squares) concentration-response curves for α1β2γ2L GABAA receptor positive 
modulation in the presence of GABA EC10. Each point represents individually tested oocytes.  
Lines represent polynomial (PfL/black solid; PfL+ 50 µM FfL/ green solid) and linear (FfL/ blue 
dash) best fit curves. (C) Response to fropofol (FfL) concentrations in the presence of 5 µM 
propofol represented as mean ± SEM (n=3-6). (D) Representative traces of evoked current by 
GABA EC10 control and following combined of GABA EC10 and 5 µM propofol (PfL; left); 
GABA EC10 control and following combined of GABA EC10 and 50 µM fropofol(1b) (FfL; 
middle); GABA EC10 control and following combined of GABA EC10, 5 µM propofol and 50 
µM fropofol(1b) (PfL+FfL; right) exposures within individual X. laevis oocytes expressing 
α1β2γ2L GABAA receptor. 
 
 To test the hypothesis and determine a potential mechanism for fropofol(1b)  
excitatory activity and antagonism of propofol induced hypnosis, the influence of these 
agents on recombinantly-expressed GABAA receptors was investigated. Propofol has 
been shown to be a strong positive modulator of GABAA receptors 196, which likely 
contributes to its hypnotic action.   Perfusion with propofol in the absence of GABA 
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caused minor direct activation, consistent with previous literature (Figure 23A) 196. Also 
consistent with previous studies, co-exposure to propofol and GABA resulted in a 
concentration-dependent increase in current up to 80 µM (Figure 23B); positive 
modulation began to decline at propofol concentrations of 100 µM 196,197. In contrast, 5 
µM and 50 µM fropofol(1b)   elicited no significant direct activation of the receptor 
(Figure 23A). Furthermore fropofol(1b)  , at any concentration, demonstrated no 
significant modulation or inhibition of the α1β2γ2L GABAA receptor at solubility 
permitted concentrations (Figure 23).  
To determine whether the antagonistic action of fropofol(1b) on propofol 
hypnosis was mediated through GABAA receptors, recombinant ion channels were 
exposed to all three ligands (GABA, propofol and fropofol(1b) ). The introduction of 50 
µM fropofol(1b)  resulted in no significant change of propofol positive modulation of the 
GABAA receptor (Figure 23A-B, D), and exposure of saturating concentrations of 
fropofol(1b)  displayed no significant alteration of 5 µM propofol potentiation of GABAA 
receptor currents (Figure 23C-D).  
In total, fropofol(1b) had no influence whatsoever on propofol positive 
modulation of the α1β2γ2L GABAA receptor. Because propofol has shown similar potency 
across most synaptic GABAA receptor subtypes 197,198, these data suggest that 
fropofol(1b)  in vivo excitatory activity and antagonism of propofol hypnosis were via a 
non-GABAergic mechanism.  However, we examined only a single sub-type, and thus 
cannot completely rule out GABAergic antagonism as underlying fropofol(1b)  
excitation. Fropofol(1b)  might be a useful tool to characterize GABAA receptor 
specificity. In addition, these data suggest that our previous demonstration of the 
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correlation of affinity for aF “anesthetic site”, GABAA receptor potentiation, and LORR 
87 represents only a portion of the molecular recognition features required for transducing 
a likely major component for the pharmacological effect. While aF provides a convenient 
model amenable to high throughput screening, which is a considerable improvement over 
previous approaches, like the Meyer-Overton rule 1,2, these fropofol(1b) data strongly 
indicate an additional requirement for a hydrogen bond within synaptic GABAA receptor 
site(s). 
As fropofol(1b) does not partake in the molecular recognition features that lead to 
hypnosis, we decided to examine whether the propofol 1-hydroxyl was similarly vital for 
mechanisms resulting in an alternative pharmacological endpoint. A known adverse 
effect of propofol is cardiovascular depression, which previous reports suggest is at least 
partially caused by a direct effect on myocardial contraction 199,200. The influence of 
propofol and fropofol(1b) on myocardial contractility was measured by the change in 
 
Figure 24. Influence of propofol and fropofol(1b) on trabecular muscle force generation. 
Force development by intact trabecular muscle over a range of propofol (PfL; n=8) and 
fropofol(1b)  (FfL; n=3) concentrations. Force development was normalized to initial force 
development without agent exposure. Values are represented at normalized mean ± SEM. 
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force development of isolated, intact rat trabecular muscle. 100 µM propofol depressed 
maximum force development by 49 ± 4% (Figure 24), and 100 µM fropofol(1b)  
exposure resulted in a similar effect with a 35 ± 1% reduction (Figure 24).  These results 
suggest that the molecular interactions that lead to the decrease in myocardial 
contractility are less dependent on the 1-hydroxyl, and likely hydrogen bond interactions, 
in contrast to GABAA receptor potentiation. These data indicate that fropofol(1b) would 
be an effective tool to dissect interactions within these different molecular targets and 
tissues.  
The cardiovascular and excitatory activity of fropofol(1b) emphasizes the 
importance of distinguishing different forms of molecular recognition involved in the 
pharmacology of propofol. Our evidence suggests that more degenerate, apolar binding 
sites may transduce either no effect or are associated with certain adverse effects. 
Furthermore, we demonstrate that these alternative non-hydrogen bonding dependent 
pathways that fropofol(1b) unveils are probably non-GABAergic. By expanding the 
repertoire of recognized propofol targets, and relating molecular recognition features with 
the functional effect, further progress in anesthetic development is possible. 
3.1.3. Conclusion 
 In summary, we synthesized a propofol analogue with fluorine replacing the 1-
hydroxyl to result in the loss of hydrogen bond capabilities. The compound, fropofol(1b), 
displayed analogous physiochemical properties and specific binding to commonly 
employed anesthetic-site protein models.   Within a protein site defined primarily by 
hydrophobic forces, fropofol(1b) showed greater affinity than propofol. However, within 
a model containing cavities with clear hydrogen bonding residues, fropofol(1b) 
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demonstrated lower affinity. Within animal models, fropofol(1b) administration resulted 
in no hypnotic activity, but rather weak excitatory activity. The excitatory activity and 
antagonism of propofol efficacy was determined not to be mediated by direct 
postsynaptic GABAergic signaling. On the other hand, fropofol(1b) induced myocardial 
depression like that of propofol. These data indicate that hydrogen bonding is a critical 
molecular recognition feature for propofol protein binding sites that transduce hypnosis, 
and that fropofol(1b) may be used to identify and distinguish these sites. 
3.1.4. Experimental methods 
General Synthetic Procedures- Solvents and reagents used were purchased from 
commercial sources unless otherwise noted. Proton and 13C NMR spectra were recorded 
using Bruker DMX 500 MHz NMR spectrometer and19F NMR spectra was recorded 
using Bruker DMX 360 MHz NMR spectrometer.  Purity of fropofol(1b) was determined 
using reverse phase-high performance liquid chromatography (rpHPLC) with C-18 
analytical column. An isocratic gradient (67:28:5:0.1 acetonitrile: ddH2O: isopropanol: 
trifluoroacetic acid) with a 1 mL/min flow at ambient temperature (21-22˚C) was applied, 
and fropofol(1b) was monitored for UV-vis absorbance at 210 nm and 205 nm. The 
retention time for fropofol(1b) was observed at 8.5 min with a purity of >98%. 
Physicochemical Properties- The density of fropofol(1b) was determined from triplicate 
measurements of the volume/mass relationship. The extinction coefficient 
(Σ270=10611/M) was calculated through the UV (Varian Cary 300 Bio UV-vis 
spectrophotometer) benzene absorption at 270 nm within a methanolic solution of known 
concentrations. The maximal water solubility (116 ± 4.4 µM; mean ± SD) was calculated 
from the extinction coefficient after 24 hr titration and incubation in double distilled 
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water (ddH2O). Octanol/water partition coefficients were calculated using XLOGP3143. 
Molecular volume was calculated using NAMD program developed by the Theoretical 
Biophysics Group in the Beckman Institute for Advanced Science and Technology at the 
University of Illinois at Urbana-Champaign201.  
Isothermal Titration Calorimetry- Isothermal titration calorimetry (ITC) permits the 
calculation of the binding affinity and entropy based on measurement of binding 
enthalpy.  Propofol and fropofol(1b) injections into the soluble protein models horse 
spleen apoferritin (aF) and human serum albumin (hSA) were conducted similar to 
previously reported procedures 87 and were resolved using a VP-ITC microcalorimeter 
(MicroCal, Inc., Northampton, MA, U.S.A). For all ITC studies, 20 mM sodium 
phosphate buffer containing 130 mM NaCl (pH 7.0) was used and referenced against 
ddH2O.  The sample cell (1.43 mL) contained either 5 µM or 2.5 µM HSAF or 20 µM 
hSA solution at 20˚C or 26˚C based on pilot studies respectively. The injectate solution 
(286 µL) was either propofol (160 µM) or fropofol(1b) (75 µM). Injections were titrated 
(15 µL) into the sample cell for aF.  Because of the low-affinity interaction(s) with hSA, 
and the limited solubility of the ligand(s), sequential titrations were performed to achieve 
near complete occupancy of the binding site(s). This was accomplished by loading and 
titrating (10-40 µM) with the same ligand, propofol (0.55 mM) or fropofol(1b) (85 µM) 
without removal from the sample cell until the titration signal was near constant.  The 
titrations were linked together prior to data analysis using ConCat32 software provided 
by MicroCal, Inc. The signals of buffer into buffer, ligand to buffer, and buffer to protein 
were subtracted after separate titrations. Origin 5.0 software was used to best fit 
thermodynamic parameters to the heat profiles.   
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Fluorescence competition with aF- A fluorescence competition assay utilizing 1-
aminoanthracine (1-AMA) allowed comparison of ligand-protein binding in aF. The 
extent of 1-AMA fluorescence inhibition has been previously reported as a reliable 
measurement of anesthetic occupation of hydrophobic protein cavities 126,186. All 
solutions were prepared in 20 mM sodium phosphate buffer containing 130 mM NaCl 
(pH 7.2) in 1 mL quartz cuvettes. For competition with the aF anesthetic site87, samples 
containing 5 µM aF and 5 µM 1-AMA were mixed with increasing concentrations of 
propofol (1-350 µM) or fropofol(1b) (1-100 µM). The 1-AMA fluorescence was 
determined with 380 nm excitation and emission monitoring between 400 nm and 700 
nm. The fluorescence curves were corrected by subtraction of the 1-AMA/protein, 
ligand/protein and ligand/ 1-AMA baseline emission post acquisition. The fluorescence 
intensity versus concentration data were fitted to variable slope Hill models to obtain the 
IC50 and Hill slope. The KD was calculated using the Cheng-Prusoff equation 126 to 
correct for the presence of the 1-AMA competitors.  
[3H]meta-Azipropofol Photolabel Competition with aF- In addition to 1-AMA, we 
employed radiophotolabel competition using tritiated meta-Azipropofol ([3H]AziPm) to 
confirm occupancy of  the aF propofol site.  In 1 mm quartz cuvettes, 3 µM aF and 1 µM 
[3H]AziPm respectively in ddH2O were combined with 10 µM fropofol(1b) or propofol, 
or vehicle control (DMSO). After 5 min equilibration, the sample was irradiated for 
10min with ~340-375 nm light generated by filtering a 100 W arc mercury lamp through 
broadband (~340-625 nm) and UV bandpass (~250-375 nm) filters (lamp and filters from 
Newport, Stratford, CT). After precipitation with 4X volume cold acetone and two 
additional cold  acetone washes (1 mL each), the dried pellet was suspended in 1% SDS, 
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1% Triton-X, and 5 mM Tris (pH 7.6) to achieve 12 µM aF (BCA Protein Assay Kit 
using aF as standard). A sample volume of 5 uL was scintillation counted using Ecolite 
(+) liquid scintillation cocktail (MP Biomedicals) with a PerkinElmer Tri-Carb 2800TR 
instrument. The final dpm were normalized to protein content.  
[3H]meta-Azipropofol Photolabel Competition with hSA- Similar competition 
experiments were used for hSA, except that CNBr protein digestion was used after 
photolabeling.  Thus, after irradiation of 5 µM hSA (>98%; Fluka) and 2 µM [3H]AziPm  
with 75 µM fropofol(1b) or propofol or vehicle control (DMSO), samples were diluted to 
1.5 µM hSA with 0.1 M Tris-HCl (pH 8.0) and 3% SDS. DTT was then added to achieve 
2 mM and samples were heated for 2 min at 96˚C.  CNBr and formic acid were added to 
produce a 9 mM CNBr, 70% formic acid solution. These samples were left at room 
temperature for 24 hr, followed by the addition of 200 µL N-ethylmorpholine (97%, 
Sigma). Following acetone precipitation and drying under nitrogen, the pellets were 
resuspended in 1.5% SDS, 50 mM Tris pH 7.0. Protein content was determined with the 
BCA Protein Assay Kit using hSA as standard.  A total of 30 µg of digested protein was 
separated on 4-15% SDS-gels. After electrophoresis, the gel was stained with Coomassie 
blue G-250 and imaged using Kodak Image Station 4000mm Pro. Bands were excised 
and the polyacrylamide dissolved with 30% H2O2 for ~ 3 hr at 65-70˚C. The sample 
volume was scintillation counted using Ecolite (+) liquid scintillation cocktail with a 
PerkinElmer Tri-Carb 2800TR instrument. The final dpm were normalized to the 
Coomassie blue stain intensity relative to the total sample lane. In a parallel study, bands 
were excised and submitted to the Proteomics Core Facility at the University of 
Pennsylvania for mass spectrometry to verify band peptide content.  
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Activity in Tadpoles- Behavioral activity was initially determined in albino X. laevis 
tadpoles (stages 45-47) as previously described 187,193.   Tadpoles (n= 240) were 
incubated in Petri dishes (10 tadpoles/dish) with concentrations (3 µM, 30 µM, 70 µM 
and 100 µM) of fropofol(1b) dissolved in pond water, containing <0.01% DMSO vehicle, 
for 60 or 90 min. Because loss of righting was not observed with any fropofol(1b) 
concentration, fropofol(1b) was co-administered with propofol to look for 
pharmacological additivity.  Tadpoles (n= 630) were incubated with varying 
concentrations of fropofol(1b) (0 µM, 5 µM, 25 µM and 100 µM) and propofol (0.25-3 
µM) dissolved in pond water containing <0.01% DMSO vehicle and were evaluated after 
30 min. Hypnosis was defined as the percentage of tadpoles that did not demonstrate 
spontaneous movement over the course of a 30 s period preceding each time point.  After 
both study conditions, the tadpoles were transferred to fresh pond water and observed 
overnight for signs of toxicity. The water temperature remained between 21-22˚C 
throughout the experiments. All animal care and experimental procedures involving X. 
laevis tadpoles were carried out according to protocol approved by the IACUC of 
University of Pennsylvania. 
Pharmacological Activity in Mice. Fropofol(1b) was dissolved in 10% lipid emulsion to 
30 g/L and two dosages, 96 mg/kg (n= 2) and 180 mg/kg (n= 2), were introduced into 12-
20 week C57/B6 mice via tail vein bolus injection. Mice were then monitored for 
changes in behavior immediately and over the following days post injection. Some mice 
were euthanized by cervical dislocation within 45 s or 10 min post injection, and the 
brain was rapidly removed and frozen for subsequent fropofol extraction.   Fropofol(1b) 
extraction proceeded according to methods published for propofol (41). Briefly, 2 
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volumes of 0.22 µm filtered PBS buffer was added to weighed brain samples. The brain 
was homogenized for 5 s using a Polytron PT 1300D handheld homogenizer 
(Kinematica), vortexed for 30 s, and centrifuged for 20 min at 14,000 x g. The 
supernatant was removed and 2 volumes of HPLC-grade acetonitrile was added. Samples 
were vortexed for 30 s and centrifuged for 20 min at 14,000 x g. Fropofol(1b) amount 
was quantified using the same rpHPLC method as mentioned above. All brain tissue 
extractions were conducted within 12 hr of rpHPLC quantification and the fropofol(1b) 
peak was clearly distinguishable from tissue peaks with the determined retention time of 
8.5 min. Generated standard curves with neat fropofol(1b) in methanol provided absolute 
concentration values. Based on an average (n= 4) of fropofol spiked brain tissue samples, 
recovery from tissue was determined to be 4.8 ± 0.2% for both 210 nm and 205 nm 
wavelengths (similar for propofol).  
Electroencephalography (EEG) recording. 12-20 week C57/B6 male mice (n= 2) were 
placed under general anesthesia maintained with isoflurane and implanted with 5 right-
sided chronically indwelling silver ball EEG electrodes over frontal association cortex 
(2.6 mm anterior to bregma, 1.0 mm lateral), primary motor cortex (2.0 mm anterior to 
bregma, 2.0 mm lateral), the medial parietal association area (1.7 mm posterior to 
bregma, 1.2 mm lateral), primary somatosensory cortex (2.0 mm posterior to bregma, 2.6 
mm lateral) and primary auditory cortex (2.3 mm posterior to bregma, 4.0 mm lateral); 
the leads were secured with dental cement. After a minimum of a two-week recovery, a 
tail vein catheter was placed in the lateral tail vein of an implanted mouse and secured. 
After recording a 5 min baseline EEG, 200 mg/kg fropofol(1b) in 10% lipid emulsion 
was injected over 3 s through the catheter, and the catheter was flushed with 100 uL 
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normal saline. Acqknowledge (Biopac Systems Inc., Golea, CA) was used for processing 
with a 0.8-59 Hz software bandpass filter. All animal care and experimental procedures 
involving mice were carried out according to protocol approved by the IACUC of the 
University of Pennsylvania. 
Electrophysiology. α1β2γ2L γ-Aminobutyric acid type A (GABAA) receptor expression 
within oocytes- cDNAs for GABAA receptor α1, β2, and γ2L subunits were kindly 
provided by Dr. Robert Pearce (University of Wisconsin). Defolliculated stage V-VI 
Xenopus laevis (X. laevis) oocytes were microinjected with 2.8 ng of in vitro transcribed 
cRNA (mMessage mMachine kit, Ambion, Austin, TX) of α1/β2/γ2L subunits at a 1:1:10 
weight ratio respectively. Oocytes were incubated at 18˚C in a gentamycin supplemented 
ND96 solution (in mM: 96 NaCl, 2 KCl, 1 MgCl2, 1.8 CaCl2, 5 HEPES, 2.5 Na-Pyr, pH 
7.4 with NaOH) for 16-24 before use.  All animal care and experimental procedures 
involving X. laevis frogs were carried out according to a protocol approved by the 
IACUC of Thomas Jefferson University.  
Occyte Electrophysiology Recordings- GABAA receptor whole-oocyte currents were 
recorded at room temperature (21-23˚C) under two electrode voltage clamp (TEVC) 
conditions (OC-725C, Warner Instrument, Hamden, CT). All recordings were made at a 
holding voltage of -80 mV. Oocytes were continuously perfused with ND96-based 
solutions using gravity-driven perfusion system with an approximate perfusion rate 2-4 
mL/min. The perfusion system was outfitted with Teflon® tubing for drug exposure 
studies. γ-Aminobutyric acid (GABA; Sigma) solutions were prepared daily in ND96. 
Propofol and fropofol(1b) were directly dissolved in ND96 facilitated by sonication. 
Initially each oocyte was exposed to 2.5-5 µM GABA for the effective concentration 
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(EC) 7-13 of maximum GABAA receptor activation. Maximum GABA response was 
determined by a 10 mM GABA perfusion post drug exposure and washout. To determine 
modulatory activity oocytes were perfused for 20 s with the test compound(s) 
immediately followed by 20 s perfusion with the test compound and GABA at 
determined EC10.  Oocytes continuously perfused in ND96 solution or fropofol ND96 
based solution prepared as noted above. Data acquisition and initial analysis were 
performed using pClamp 9.2/10.3 (Molecular Devices, Sunnyvale, CA). Macroscopic 
currents were low-pass filtered at 1 kHz and digitized at 2 kHz. Expression of α1β2γ2L 
cRNA within X. laevis oocytes generated GABAA receptors that demonstrated a GABA 
EC50 of 33 µM (95% CI, 29 - 38) with a Hill coefficient of 0.87 ± 0.04 (mean ± SEM)  
within 18-24 hr post microinjection. 
Trabeculae preparation- Drug effects on myocardial contractility were conducted as 
previously reported 202. Briefly LBN/F1 rats (250–300g, Harlan Laboratories, 
Indianapolis, IN) were anesthetized by intra-peritoneal injection of pentobarbital (100 
mg/kg); the heart was exposed by sternotomy and rapidly removed. After transfer to a 
dissection dish, the aorta was cannulated and the heart perfused in a retrograde fashion 
with dissecting Krebs-Henseleit (K-H) solution (in mM: 120 NaCl, 20 NaHCO3, 5 KCl, 
1.2 MgCl2, 10 glucose, 0.5 CaCl2, and 20 2,3-butanedione monoxime (BDM) (pH 7.35–
7.45); equilibrated with 95% O2 and 5% CO2). The trabecular muscle was dissected from 
the right ventricle and mounted between a force transducer and a motor arm. The muscle 
was superfused with K-H solution without BDM at ~10 ml/min, and stimulated at 0.5 Hz. 
A transducer (KG7, Scientific Instruments GmbH, Heidelberg, Germany) was used to 
measure the developed force, and expressed as millinewtons per square millimeter of 
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cross-sectional area.  The muscles underwent isometric contractions with a set resting 
muscle length that was set at 15% of the total force development corresponding to resting 
sarcomere length of 2.20-2.30 µm as determined by laser diffraction 203.  Propofol or 
fropofol(1b) were added to non-BDM containing K-H solution at desired concentrations 
during the experiments. Similar force depression was observed at both 37˚C and room 
temperature (20-22˚C); the experiments reported herein were performed at room 
temperature. Animal care and experimental protocols were approved by the Animal Care 
and Use Committee of The Johns Hopkins University School of Medicine. Data is 
represented as mean ± SEM of experiments normalized to initial force development 
without drug exposure. 
Statistics- GraphPad Prism5, unless otherwise noted, was used for preparation and 
statistical data analysis. Details are given in the figure legends. 
3.2. Novel bifunctional alkylphenol anesthetic allows identification of the alkylphenol 
binding synaptic proteome 
While demonstrating higher potency compared to volatile anesthetics, propofol 
still requires micromolar plasma concentrations to induce observable behavioral effects 
40. Evidence suggests the likelihood of protein targets as major contributors towards the 
mechanisms of propofol with in vitro studies demonstrating functional influence at 
pharmacologically relevant concentrations 6,178. Regardless, direct identification of 
propofol interactions with protein targets in more physiologically relevant biological 
systems has been a scientific challenge. Forming an understanding of likely binding sites 
of potential clinical relevance within protein targets is vital for the characterization of 
propofol. Therefore a development of a means to study a biological system that 
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demonstrates physiologically relevant protein distribution and molecular environment is 
significant.  
 
Figure 25.Chemical structures of propofol and AziPm-click(1c) 
 
Herein an affinity-chemoproteomic strategy is presented to expand the current 
range of approaches for anesthetic protein target identification within non-recombinant 
tissue.  A novel propofol analogue, ortho-alkynyl-meta-azipropofol or AziPm-click(1c) 
(Figure 25), was synthesized this compound contains two chemically-active groups; 1) a 
photoactive group for direct and immediate labeling of protein targets and 2) a ‘click 
chemistry’ partner for designed attachment of affinity tags for target protein enrichment. 
Within this study an alkylphenol-based anesthetic pharmacoproteome composed of 196 
propofol-binding proteins, or approximately 4% of the mouse synaptosomal proteome, 
was identified.  
3.2.1. Synthesis and characterization of AziPm-click(1c) 
To identify the alkylphenol binding proteins within the synaptic proteome, 2-
((prop-2-yn-1-yloxy)methyl)-5-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenol, or AziPm-
click (1c), a photoaffinity tandem bioorthogonal alkylphenol anesthetic ligand was 
developed. AziPm-click (1c) was designed to integrate two chemically active groups that 
allow for affinity-based protein profiling (ABPP): 1) a diazirine photoreactive group to 
covalently label protein-interaction sites and 2) an alkylnyl group for covalent attachment 
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of a reporter tag by 1,3-dipolarcycloaddition reaction (e.g. ‘Click Chemistry’) in order to 
capture and identify photoaffinity-labeled proteins within the synaptic proteome.  
Scheme 3.  
 
 
Synthesis of AziPm-click (1c), shown in Scheme 3, starts with the previously 
reported 4-bromo-2-(methoxymethoxy)-1-methylbenzene (2c) 204.  Conversion of 2c to 
the Grignard reagent using magnesium in THF followed by treatment with pyrolidine 
trifluoroacetamide produced trifluoromethylketone 3c. Conversion of 3c to the oxime 4c  
Table 6. Physicochemical properties of propofol and AziPm-click(1c) 
 
and oxime tosylate 5c followed standard procedures. Treatment of 5c with excess liquid 
ammonia produced diaziridine 6c which was oxidized to the diazirine 7c using 
pyridinium dichromate (PDC). Benzylic bromination using N-Bromosuccinimide (NBS) 
produced 8c, which was treated with the sodium salt of propargylic alcohol in 
Tetrahydrofuran (THF) to provide 9c. Removal of the methoxymethyl protecting group in 
the presence of the propargylic ether required carefully controlled conditions and was 
finally accomplished using sodium hydrogen sulfate impregnated silica gel in methylene 
chloride 205. 
	   MW, Da Density, g/mL cLogP 
AziPm-click (1c) 270 1.19 3.55 
propofol 178 0.96 3.79 
105 
 
 
The physicochemical characteristics of propofol and AziPm-click (1c) are summarized in 
Table 6 and the geometry-optimized structure is shown in Figure 26A.  
Table 7. Equilibrium binding parameters of propofol and AziPm-click(1c) to aF 
  a Stoichiometry of aF sites were modeled for one site therefore the Hill slope is fixed at 
1;  b KD Fluorescence data derived from Cheng–Prusoff equation 
 
The UV absorption spectrum of AziPm-click (1c) shows a well-defined peak 
between 330- 400 nm due to the diazirine group (methanol extinction coefficient (Σ365nm) 
of 580 /M).  Over the course of UV irradiation using a Rayonet RPR-3500 lamp within 
aqueous solution, the AziPm-click (1c) diazirine absorbance band decreased intensity 
indicating photoactivation (Figure 26B).  The time-dependent photoreactivity of AziPm-
click (1c) in aqueous solution was a single exponential decay with a half-life (t1/2) of 25 
min (95% CI; 20-33) within a 1 cm path-length cuvette and 6 cm from the lamp. To 
confirm retention of other major molecular recognition features, we compared 
equilibrium binding affinities of applied alkylphenol general anesthetics with the model 
protein aF by ITC and 1-AMA competition 187,206. The affinities of alkylphenols for aF 
have shown to be well correlated with GABAA receptor potentiation 87,88,186; results are 
summarized in Table 7. 
 Propofol AziPm-click (1c) 
 ITC  1-AMA 
displacement b 
ITC 1-AMA 
displacement b 
KD (95% CI; µM) 9 (7.1 - 11) 2.4 (1.3-4.4) 22 (20- 24) 4.0 (1.8 – 8.7) 
Hill slope  (Mean ± 
SEM) 
1a -1.1 ± 0.33 1a -0.97 ± 0.39 
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Figure 26. AziPm-click (1c) geometry and photoreactivity. A) Ball and stick structure of AziPm-
click (1c) in predicted lowest energy conformation (gray: carbon, red: oxygen, blue: nitrogen, 
green: fluorine). B) UV absorption spectra of AziPm-click (1) (175 µM) in double distilled water 
(black line) over the course of UV irradiation time points (gray and green lines). 
 
Propofol and AziPm-click (1c) demonstrated similar pharmacological endpoints 
within Xenopus laevis (X. laevis) tadpoles, inducing reversible hypnosis with no 
observable toxicity summarized in Table 8 and shown in Figure 27. To indicate 
photoaffinity labeling of pharmacologically relevant targets, we demonstrated that 
AziPm-click (1c) produced sustained anesthetic endpoints (immobility) in vivo after UV 
irradiation 93. X. laevis tadpoles were exposed to 12 µM AziPm-click (1c) or 3 µM 
propofol for 30 min. Tadpoles were then exposed to 10 min of low intensity UV 
irradiation or were maintained as a 10 min non-UV control. Similar to our previous 
reports for AziPm 93, only tadpoles exposed to AziPm-click (1c) and 10 min UV 
displayed prolonged immobility after drug washout (Figure 27). 
 
Figure 27. Anesthetic activity of AziPm-click(1c) A ) Dose-response curves for propofol (n= 210; 
black circle) and AziPm-click (1c) (n= 300; green diamond) for loss of spontaneous movement in 
tadpoles. Data was fitted to a sigmoidal dose response curve with variable Hill Slope and the EC50 
and Hill slope values are represented in Table 8. B ) Time course of recovery for Xenopus laevis 
tadpoles following propofol (n=30; black open circle) or AziPm-click (1c) (n=30; green open 
diamond) equilibration and 10 min no UV treatment control. E ) Time course of recovery for 
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tadpoles following propofol (n=30; black filled circle) or AziPm-click (1c) (n=30; green filled 
diamond) equilibration and 10 min of low intensity UV irradiation. 
 
Table 8. Tadpole studies with propofol and AziPm-click(1c) 
 
3.2.2. Affinity-based protein profiling (ABPP) of alkylphenol synaptic protein targets 
 
Figure 28. Fluorescent profiling of propofol proteome. A) Fluorescent image (FL) of SDS-PAGE 
gel of synaptosomes exposed to AziPm-click (1c) with or without UV irradiation and 
corresponding Coomassie blue (CB) stain of UV irradiated synaptosomes. B ) Protection from 
AziPm-click (1c) labeling of synaptosomes by propofol at 5x (75 µM), 10x (150 µM), 15x (225 
µM) and 25x (375 µM). C ) Chemical structure of ketamine. D ) Protection from AziPm-click 
(1c) labeling of synaptosomes by ketamine at 10x (150 µM), 20x (300 µM) and 30x (450 µM). 
All experiments were conducted in triplicate. 
 
To confirm the functionality of both the chemically active groups for downstream 
ABPP, AziPm-click (1c) was employed within mouse synaptosomes using an azide- 
PEG3-Alexa 488 fluorophore as a reporter tag. The fluorescent labeling of proteins was 
reliant on UV exposure (Figure 28A). Fluorescent labeling was decreased with increased 
concentrations of propofol indicating protection of alkylphenol-binding proteins within 
synaptosomes (Figure 28B). To control for potential ‘inner-filter’ of UV light, ketamine 
was employed as a protecting ligand (Figure 28C), which conferred no changes in 
fluorescence intensity seen in Figure 28D. 
 EC 50 (95% CI; µM) Hill slope (Mean ± SEM) 
AziPm-click (1c) 6.1 (5.1-7.4) 3.0 ± 0.54 
propofol 0.90 (0.84 -0.97) 3.4 ± 0.31 
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The ABPP workflow using AziPm-click (1c) with relative quantification, is 
summarized in Figure 29A. Azide-PEG3-biotin was employed as the reporter tag for 
streptavidin-affinity isolation of photoaffinity labeled protein targets. Tandem Mass Tag 
(TMT) isotopic labeling and three-stage mass spectrometry (MS3) 207 was coupled to 
ABPP for quantitative assessment of capture and propofol protection. The totals for 
identified proteins are summarized in Figure 29B. The AziPm-click (1c) proteome 
contained a discernible group of proteins that demonstrated a high degree of capture 
efficiency with a greater than 10 enrichment factor (Figure 29C). Of the higher capture 
group, the majority of proteins displayed propofol specificity with a greater than 50% 
protection, and a decrease of at least 5 in enrichment factor (Figure 29D, see appendix 
A.5.). 
It is unlikely that a given drug will only bind and act on a single protein target 
within a proteome. In particular, the small general anesthetic molecules have been shown 
to bind to many different proteins 208. While propofol is thought to have higher affinity 
for specific protein targets relative to volatile anesthetics, the projected affinities for  
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Figure 29.  Affinity-based propofol profiling of alkylphenol binding proteins in native 
synaptosomes. A ) Scheme for capture and analysis of AziPm-click (1c) labeling profiles in 
synaptosomes by biotin-streptavidin methods, tandem mass tag (TMT) labeling for relative 
quantification, strong cation exchange chromatography (SCX) and Nanoliquid chromatography - 
three-stage mass spectrometry (NanoLC-MS3) analysis. B ) Distribution of protein groups for the 
AziPm-click (1c)capture and approximant percentage of full synaptosomal proteome, with a 
summary of group’s threshold requirements. Proteomic experiments were conducted in 
quadruplicate; the log2 standard deviation between datasets was calculated as 0.28 for heavy over 
intermediate TMT labeled samples and 0.17 for heavy over light TMT labeled samples. C ) TMT 
ratio frequency distribution (Log10 scale) of UV versus no UV with high capture efficiency 
threshold. D ) Percent of high capture group proteins that demonstrated less then or greater then 
50% protection by propofol. 
 
major targets, such as the GABAA receptor, still remain in the low micromolar range 39. 
Therefore, it is not surprising that a number of targets (196) were captured due to the 
promiscuous binding associated with the general anesthetic. Whether the activity of every 
identified protein is altered upon alkylphenol binding is not clear and not likely. 
However, some captured targets have been reported as being influenced by propofol. 
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Examples include a likely major target synaptic GABAA receptor159, syntaxin-1A 109, N-
methyl-D-aspartate receptor (NMDA 1) 209, potassium/sodium hyperpolarization-
activated cyclic nucleotide-gated channel 1 (HCN 1) 210 as well as voltage-gated calcium 
channels 211 and potassium channels 129 all of which may contribute to desirable and/or 
undesirable pharmacological effects. 
3.2.3. Conclusions 
Propofol has been widely administered for over a quarter century in general 
anesthesia and for rapid sedation. Regardless, the drug’s mechanism of action remains 
elusive however mounting evidence has suggested that multiple pathways contribute to 
propofol’s pharmacological effects. Most of the proposed protein targets, such as ion 
channels and ligand-gated receptors138,212, are low abundance but functionally important 
proteins. To uncover these significant targets, we synthesized a bioorthoganol propofol a-
PAL, AziPm-click(1c). The introduction of an ortho-alkynyl group allows for the 
attachment of affinity tags for the designed capture of photomodified proteins by copper 
catalyzed 1,3-dipolar cycloaddition, or Click chemistry. AziPm-click(1c) maintains the 
physiochemical, biochemical and in vivo properties of propofol.  After the unbiased 
photoaffinity labeling of bound targets, the ortho-alkynyl click moiety successfully 
undergoes click chemistry reactions with azide-containing tags within mouse 
synaptosomes. Coupled with a quantitative mass spectrometry workflow, the study 
provided a strategy for labeling and capture of low abundance protein targets for 
propofol. Ultimately AziPm-click(1c) highlighted the expansive group of alkylphenol-
based anesthetic bound proteins within synapses and indicated the likely complex nature 
of propofol mechanisms of action. 
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3.2.4. Experimental methods 
Physicochemical properties. The UV spectrum and extinction coefficient of the AziPm-
click (1c) diazirine absorption were obtained from known concentrations in methanolic 
solutions and gathered from the Varian Cary 300 Bio UV-visible spectrophotometer. 
Photoactivation of the diazirine was measured by the disappearance of the diazirine UV 
absorption peaks when exposed to 350 nm light (Rayonet RPR-3500 lamp) ~ 6 cm from 
the light source. Maximum water solubility was approximated using the extinction 
coefficient. Calculated octanol/ water partition coefficients were generated using 
XLOGP3 software 22 with default settings. The geometry-optimized structures for 
AziPm-click (1c) was calculated at the B3LYP/6-311+G (2d,p) level of theory using t pH 
7.4) before decapitation. Brains were extracted and homogenized in ice cold isolation 
buffer (IB; 0.32 M sucrose/ 2.5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 1 mM ethylenediaminetetraacetic acid (EDTA) (pH 7.4)) (10% w/v%) in the 
presence of protease and phosphatase inhibitors.  The homogenate was centrifuged at 1, 
000 x g for 10 min at 4˚ C. The resulting supernatant was decanted and pellet was 
homogenized with equal volume IB and centrifuged at 1, 000 x g for 10 min at 4˚ C. Both 
supernatants were pooled were centrifuged at 1,000 x g for 10 min at 4˚ C. The 
supernatant was decanted and centrifuged at 12, 000 x g for 20 min at 4˚ C. The pellet 
was washed twice by resuspension of the pellet in 2X volumes of IB and centrifugation at 
12, 000 x g for 15 min at 4˚C. The resulting crude preparation of synaptosomes, now 
entirely free of the euthanizing isoflurane, was used in following experiments.  All 
following protein contents are measured using BCA assay (Thermo Scientific). Animal 
112 
 
care and experimental procedures involving mice were carried out according to a protocol 
approved by the IACUC of University of Pennsylvania. 
Synaptosomal photoaffinity labeling. Synaptosomes were resuspended to 1 mg 
protein/mL in HEPES buffer medium (in mM: 140 NaCl, 5 KCl, 5 NaHCO3, 1.2 
NaH2PO4, 1 MgCl2, 10 glucose, and 10 HEPES (pH 7.4)). Concentrations of AziPm-click 
(1c) with or without the presence of concentrations of competitive ligands (propofol or 
ketamine) in dimethyl sulfoxide (DMSO) vehicle (<0.3% v/v) were added and 
synaptosomes were gently vortexed for 10 s. The samples were allowed to equilibrate for 
5 min before being transferred to a parafilm-sealed 1 mm path-length quartz cuvette. The 
sample was then irradiated for 20 min at a peak band-width of 350 nm (Rayonet RPR-
3500 lamp) ~ 6 cm from the light source. Non-irradiated samples were left in the dark at 
ambient temperature (22-25˚C) for 20 min. All remaining procedures were conducted 
with restricted light exposure.  
Fluorophore conjugation for proteome detection. To 150 µg of photolabeled or control 
synaptosomes, 8 µL of 10% sodium dodecyl sulfate (SDS) in water and 2 µL of 1 mM 
dithiothreitol (DTT) in water were added. Samples were vortexed and heated at 65˚ C for 
10 min. After brief cooling final concentrations of 30 µM azide-PEG3-Fluor 488 (Click 
Chemistry Tools), 2 mM tris(3-hydroxypropyltriazolylmethyl)amine (THTPA) (Sigma), 
1 mM ascorbic acid (Sigma), and 1 mM CuSO4* 5H2O (Sigma) were added to each 
sample and vortexed vigorously. The samples were left in the dark for 1 hr. After, 4X 
volume of chilled methanol, 1.5X of chilled chloroform, and 3X of chilled ddH2O were 
added and vortexed vigorously. Samples were centrifuged at 1,300 x g for 30 min and 
both liquid layers were carefully removed. The protein pellet was washed with 500 µL of 
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1:1 (v:v) methanol: chloroform and centrifuged at 14,000 x g for 20 min at 4˚ C. Washed 
pellets were air dried for 10 min and resuspended in 25 µL of 1% SDS and 1% Triton-X 
in 50 mM TrisBase buffer. An equal volume of 2X SDS Laemmli buffer was added and 
25 µg of protein was loaded without boiling to 4-15% SDS-PAGE gel.  Proteins were 
directly visualized within the gel using fluorescence and then stained with Coomassie 
G250 stain. Fluorescent studies were normalized to Coomassie stain band intensity.  
Hypnotic activity and In vivo photolabeling in Xenopus laevis Tadpoles- Behavioral 
activity was initially determined in albino X. laevis tadpoles (stages 45-47) as previously 
described 93,187. All animal care and experimental procedures involving X. laevis tadpoles 
were carried out according to a protocol approved by the IACUC of the University of 
Pennsylvania  
Biotin conjugation- To 750 µg of photolabeled or control synaptosome sample, 40 µL of 
10% SDS and 2 µL of 5 mM DTT in water were added. Samples were then vortexed, 
heated for 10 min at 65˚C, and then briefly cooled.  Final concentrations of 150 µM 
azide-biotin (Click Chemistry Tools), 2 mM THPTA (Sigma), 1 mM ascorbic acid 
(Sigma), and 1 mM CuSO4* 5H2O (Sigma) were added to each sample and vortexed 
vigorously. The samples were left in the dark at ambient temperature (22-25˚ C) for 1 hr 
with mild agitation. Directly to each sample 4X volume chilled methanol, 1.5X chilled 
chloroform and 3X chilled ddH2O were added. Samples were vortexed vigorously and 
centrifuged at 1,400 x g for 30 min at 4˚C. Both liquid layers were carefully removed and 
the protein pellet was washed with 2 mL of 1:1 (v:v) chilled methanol: chloroform. 
Samples were centrifuged at 3,500 x g for 30 min at 4˚ C. Protein pellets were briefly air 
dried before further processing. 
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Sample processing for affinity-based protein profiling (ABPP) mass spectrometry 
studies- 750 µg of biotin conjugated protein sample was resuspended in 500 µL of 25 
mM NH4HCO3 and 6 M urea in water. Next, 150 µL 5% Trition-100X in water, 50 µL 
10% SDS in water and 1.5 µL 0.5 M DTT were added. The samples were heated for 15 
min at 65˚ C. After briefly cooling, 14 µL of 0.5 M iodoacetamide in water was added 
and the sample was left in the dark for 45 min. Insoluble debris was separated by 
centrifugation for 10 min at 14,000 x g. The supernatant was diluted to 4 mL with PBS 
and 2 mL of PBS containing 100 uL of 50% strepavidin-agarose resin (Thermo 
Scientific) was added. Biotinylated proteins within the sample were captured over resin 
overnight at 4˚ C with mild agitation.  The resin was first washed with 6 mL of 1% SDS 
in PBS, then 7 mL of 0.1 M urea in PBS followed by 10 mL PBS. The resin underwent a 
final wash with 0.9 mL 50 mM Tris-HCl and 1 mM CaCl2 in water (pH 8.0) and then 
resuspended in 200 uL of 50 mM Tris-HCl, 1 mM CaCl2 in water (pH 8.0) and 2 µg of 
porcine sequencing grade trypsin (Promega). Samples were digested overnight at 37˚ C. 
Samples were then centrifuged at 2,000 x g for 4 min and digest supernatant was 
decanted. Beads were washed in 100 µL PBS centrifuged at 5,200 x g for 5 min and the 
wash was combined with the digest supernatant.  To the combined sample, trifluoroacetic 
acid (TFA) was added to 0.4% (v/v) or until pH < 2. The sample was desalted with Oasis 
C18 10 mg columns (Waters) as previously described 213. The eluted sample was dried by 
speed vac and resuspended in 0.1 M HEPES buffer (pH 8.5). Samples were labeled with 
Tandem Mass Tag™ 6-plex (TMTsixplex™) (Thermo Scientific) with the UV(+) sample 
labeled with TMT6- 128 or 131 reagent, the propofol protection sample labeled with 
TMT6- 126 or 129 reagent and the UV (-) sample labeled with TMT6- 127 or 130 reagent 
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using product instructions. Appropriate corresponding TMTsixplex™-labeled samples 
were pooled and dried by speed vac. The combined samples were resuspended in 0.5% 
acetic acid in water, pH corrected with acetic acid until pH was < 2. 40 µg of protein was 
desalted with C18 stage tips prepared in house and dried by speed vac.  
Samples were resuspended in 10 mM KH2PO4 (pH 2.6) 30% ACN (v/v%) in 
water and fractionated by offline strong cation exchange (SCX) chromatography prior to 
mass spectrometry (MS) analysis similar to as previously reported 213. The full 
synaptosome proteome control was prepared similarly without TMTsixplex™ labeling.   
Mass spectrometry analysis- All TMT samples were analyzed with three-stage mass 
spectrometry (MS3) TMTsixplex™ quantification workflow previously described 207. 
Spectral analysis was conducted using Thermo Proteome Discoverer 2.0 (Thermo 
Scientific) and mouse non-redundant (gene-centric) FASTA database. Mascot searches 
allowed for variable oxidation of methionine (+15.9949 m/z) and static modifications of 
cysteine residues (+57.0215 m/z; iodoacetamide alkylation) and TMT6-plex tags on 
lysine residues and peptide N-termini (+ 229.162932 m/z). To establish the base 
synaptosomal proteome, searches allowed for variable oxidation of methionine (+15.9949 
m/z) and static modifications of cysteine residues (+57.0215 m/z; iodoacetamide 
alkylation). All studies maintained trypsin enzyme specificity filtered with no greater 
than 2 missed cleavages. The MS2 spectral assignment was restricted to a specified false 
positive rate of 1% and a minimum of 2 unique peptides were required for protein 
identifications.  Quantification was based on the theoretical m/z of the individual 
TMTsixplex™ reporter ions as previously reported 207. Enrichment factor was defined as 
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the mean (+)UV/(-)UV TMT ratio. Frequency distribution histograms of Log2 values 
were generated using GraphPad Prism 7.0.  
 3.3. Characterization of alkylphenol anesthetic selective GABAA receptor subunit 
binding in synaptosomes 
 Numerous drugs influence GABAA receptor activity, including propofol, which 
has been strongly implicated as a modulator of the GABAA receptor214. Relatively low 
concentrations of this alkylphenol significantly potentiate GABA-induced current, an 
action that hyperpolarizes the post-synaptic membrane and thereby likely contributes to 
hypnosis and possibly other anesthesia phenotypes 215,216. Furthermore multiple reports 
indicate that phasic inhibition is particularly sensitive to low concentrations of propofol, 
suggesting that synaptic GABAergic signaling is a critical pathway for the anesthetic’s 
pharmacological effects 217–219.  
Investigations have focused on the potential binding sites within heterologously 
expressed αβγ GABAA receptors. A wide range of mutagenesis studies have probed 
ligand-gated ion channel electrophysiology and have shown that mutation of various 
residues predicted to reside within subunit interfacial regions alter propofol modulation 
220–222,170. Particular point mutations within β subunits, such as N265, greatly decreased 
propofol positive modulation 216,223. Previous work using the [3H]AziPm demonstrated 
frequent labeling of interfacial residues within heterologously expressed Cys-loop 
superfamily of receptors, including α1β3γ2 GABAA receptors 76. These findings further 
suggest that subunit interfaces are potentially involved in propofol modulation. Structure-
activity relationships applying alkylphenol analogues and/or other chemical derivatives 
185,224, molecular dynamic (MD) simulations 225,226, as well as other investigations have 
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suggested complex physicochemical interactions between propofol and GABAA receptors 
227. Together, these studies have provided insight regarding the potential mechanism by 
which propofol perturbs GABAA receptor protein dynamics. However, in addition to the 
biased nature of using heterologously expressed receptors, it is recognized that each 
method has experimental limitations that result in the current uncertainty regarding 
alkylphenol interactions within the receptor.  
The objective of this investigation was to advance the current understanding of 
anesthetic interactions with heteromeric receptors by addressing the interaction(s) of 
alkylphenols with GABAA receptors within their native synaptic milieu. Five GABAA 
receptor subunits (α1,3 and β1-3) were identified as propofol-specific proteins (see appendix 
A.5.). All subunits showed a decrease of at least 10 in enrichment factor with propofol 
protection. This unbiased ABPP capture of the receptor from a complex biological 
milieu, derived from native tissue, is to our knowledge, the first such demonstration, and 
it further validates the receptor as a pharmacologically relevant target. To further 
corroborate the ABPP results and the apparent subunit-level selectivity binding to this 
single target other approaches were employed. Independent MD simulations using the 
Alchemical Free Energy Perturbation (AFEP) algorithm 228 were used to predict potential 
molecular recognition elements within α1β3γ2 GABAA receptor binding sites. The impact 
of the molecular recognition elements was examined within the synaptic GABAA 
receptors with photoaffinity protection experiments. Jointly, the studies led to the 
unbiased identification of GABAA receptor subunits in native synaptic membranes as 
alkylphenol binding proteins.  This investigation further suggested higher affinity for 
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β+/α- and α+/β- interfacial sites relative to γ- containing subunit interfaces with hydrogen 
bonding as the major recognition element for the alkylphenol/GABAA receptor complex.  
3.3.1. α1β2γ2L GABAA receptor modulation by AziPm-click(1c)  
 
Figure 30.  AziPm-click(1c) α1β2γ2L GABAA receptor activity. A) Representative traces of ligand 
activity on heterologously expressed α1β2γ2L GABAA receptors in Xenopus leavis oocytes. Traces 
are shown with the oocytes response to GABA EC10 and corresponding modulation propofol 
(3µM) or AziPm-click(1c) (20 µM). B) Concentration-response curves for propofol (black circle) 
and AziPm-click(1c) (green diamond) for the positive modulation of heterologously expressed 
GABAA receptor α1β2γ2L in Xenopus laevis oocytes. Each point represents the mean of 4 oocytes 
(n=4) +/- SEM and data was fitted to a sigmoidal dose response curve with variable Hill Slope. 
 
To associate AziPm-click (1c) binding to synaptic GABAA receptor functional 
activity, electrophysiological studies on heterologously expressed receptors were 
performed. AziPm-click (1c) was functionally active on α1β2γ2L GABAA receptors 
expressed in Xenopus oocytes. AziPm-click (1c) demonstrated similar positive 
modulation activity as propofol (Figure 30). The EC50 for propofol positive modulation 
(at a GABA EC10) in our system was 10 µM (95% CI; 3.3-17). AziPm-click (1c) 
required a higher concentration for a similar response with an EC50 of 49 µM (95% CI; 
38-61). These studies indicate, while with lower potency, that AziPm-click binding does 
transduce positive modulation similar to that of propofol, likely through the shared 
binding site. 
3.3.2. Alkylphenol anesthetic selective GABAA receptor subunit binding 
In order to understand the apparent subunit specificity noted in the above 
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experiments, MD simulations for alkylphenol anesthetic binding were generated with an 
α1β3γ2 GABAA model derived from an α1β1γ2 GABAA model used previously 168.  
Docking calculations to the entire pentamer identified at least one propofol pose in each 
subunit interface, β+/ α- (2 sites), α +/β-, α+/γ- and γ+/β-, as shown in Figure 31A. Other 
than the channel lumen, no alternate sites were consistently detected over multiple 
docking runs. Docking of AziPm-click(1c) to the same model yielded overlapping sites, 
demonstrating that AziPm-click(1c) is not sterically hindered from binding to the 
intersubunit sites, despite the larger molecular size. Furthermore, as shown in Figure 32, 
AziPm-click(1c) has sufficiently favorable interactions common to propofol that docking 
simulations yield similar orientations. 
 
Figure 31.  Selectivity of intersubunit propofol binding in an α1β3γ2 GABAA receptor as predicted 
by molecular dynamics simulations using the Alchemical Free Energy Perturbation algorithm.  A) 
Five propofol molecules (colored surfaces) docked in the GABAA receptor subunit interfaces 
(β+/α- (2 sites) in cyan; α+/β- in violet; α+/γ- in red; γ+/β- in orange). The transmembrane 
domain is viewed from the extracellular side along the pore axis, and colored by subunit type; α1 
in green, β3 in magenta, and γ2 in blue. B) Computational results for propofol pKD and its 
likelihood of hydrogen bonding to protein cavity residues (Phb) can be well fit by the line pKD = a 
(Phb) + b, where a = 3.4 +/- 0.8 and b = 3.4 +/- 0.1, and the 95% confidence band is shown in 
gray. C-E ) Interactions of propofol and water in the high-affinity and low-affinity interfacial 
sites. Hydrogen bonds (red dashed lines). C ) Propofol binding in α+/β- interface that contained 7 
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polar residue sidechains (left, side view; right, top view) forms a persistent hydrogen bonding 
with a backbone carbonyl group exposed by the M1 helical bulge (β-L223). D ) Bound propofol 
at the β+/α- interfacial site, which contained 7 polar residue sidechains, (side view) alternates 
between hydrogen bonds to β+M2:T262 and β+M2:N265. For compactness, the image shows a 
rare frame in which both hydrogen bonds coexist. E ) In the γ+/β- interface 8 polar residue 
sidechains were present (top view), these residues favor hydrogen bonding with a water cluster 
stablized by polar residues γ+T281 and γ+S301, which are homologous to hydrophobic residues 
in α and β subunits. 
 
A receptor/propofol complex was constructed with one propofol molecule in the 
highest scoring pose for each subunit interface (Figure 31A).  The complex was 
embedded in a fully hydrated phosphatidylcholine membrane and simulated for 270 ns 
using traditional equilibrium MD with atomic resolution.  In addition to allowing the 
propofol in the intersubunit space to equilibrate before the affinity calculations, we used 
this simulation to characterize and compare the microscopic interactions between 
propofol and the binding pocket across subunits. 
 
Figure 32. Intersubunit propofol and AziPm-click (1c) occupancy in an α1β3γ2 GABAA receptor as 
predicted by AutoDock Vina simulations. Helices of the four distinct subunit interface pairs (α1, 
green; β3 , magenta;  γ2 , blue) with the highest scored docking poses for propofol (orange) and 
AziPm-click (1c) (gray). 
 
 At the conclusion of the traditional MD simulation, standard binding affinities for 
propofol in each of the four distinct sites were calculated using separate 24 ns Alchemical 
Free Energy Perturbation (AFEP) simulations.  The AFEP method also involves running 
MD simulations, but is designed to facilitate simultaneous calculation of average 
quantities appearing in the Zwanzig equation 229, an exact expression for the free energy 
difference between two states (e.g. bound and unbound) that inherently accounts for all 
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entropic and enthalpic contributions.  The results from the AFEP simulations indicate 
three higher affinity sites at the α+/β- and two β+/α- interfaces, with KD values similar to 
propofol EC50.  KD values for the α+/γ- and +γ/β- interfaces, however, suggest markedly 
weaker propofol binding to those sites (Table 9). 
Table 9. Binding affinities of propofol bound to one of four GABAA receptor interfacial sites 
(shown in Figure 31, interfaces notated counter-clockwise), calculated using Alchemical Free 
Energy Perturbation algorithm.    
aKD range corresponding to an uncertainty in ΔG of δ = 1 kcal/mol.  Challenges inherent in 
determining constants required for correction to laboratory conditions contribute significantly to 
δ; errors in relative values of KD are substantially reduced compared to those for absolute KD.  
 
The particularly low affinity of propofol for the +γ/β- interfacial cavity, which has 
one more polar residue than the other interfacial cavities (Figure 33A), seemed 
potentially contradictory to an essential role for hydrogen bonding. As shown in Figure 
33B, however, the pKD values for different subunit interfaces were found to be strongly 
correlated (r2 = 0.94) with the probability (Phb) that the propofol hydroxyl would form at 
least one hydrogen bond with one of the cavity-lining residues. Propofol in either of the 
two sites with low KD values (α+/β- and β+/α-) had at least Phb > 0.8 ; for the two low-
affinity sites this probability was significantly reduced (Phb < 0.3).  Thus, although 
propofol affinity is correlated with propofol hydrogen bonding, propofol is less likely to 
form hydrogen bonds with the more hydrophilic +γ/β- interfacial cavity. This result was 
due to stable hydration of the +γ/β- cavity, due to interactions of water molecules with 
Interface KD (µM) KD  e-δ/RT - KD  eδ/RT (µM)a 
α+/β- 0.1 0.02-0.7 
β+/α- 2.0 0.4-10 
α+/γ- 30 5-200 
γ+/β- 200 40-1000 
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γSer-301 and γThr-281 (Figure 31E). The water molecules compete for hydrogen 
bonding partners and interact unfavorably with the propofol isopropyl groups. 
 Within the highest-affinity site at the α+/β- interface, propofol orients as a 
hydrogen donor to the carbonyl backbone of Leu-223 within the βM1 transmembrane 
helix (Figure 31C) where a bulge in backbone hydrogen bonding is observed in crystal 
structures for both the glutamate-gated chloride channel 230 and the GABAA receptor β3 
homopentamer 231. Similar behavior was observed in simulations of triiodothyronine 
bound to interfacial sites 232.  In the β+/α- interface, propofol alternates rapidly between 
serving as a hydrogen acceptor for βM2:Thr-262 and donor for βM2:Asn-265 (Figure 
31D).  The associated slight reduction in pKD is consistent with the slight reduction in Phb 
and the line of best fit.   
 
Figure 33.  Sequence variation in interfacial binding sites of an α1β3γ2 GABAA receptor 
heteropentamer.  A) Sequence alignment of + and – subunit interfaces that contribute to the 
formation of interfacial binding sites. Highlighted residues represent residue sidechains that 
directly contribute the formation of the binding cavity. Bold and (*) residues denote key sequence 
variations in the interfacial binding sites. B-C) Helices of the four distinct subunit interface pairs 
with α+/β- interface as the reference pair. In all panels, side-chains are colored by residue type: 
polar (green), hydrophobic (white), acidic (red), basic (blue).  B) Extended view and binding site 
cavity view of the α+/β- interface reference pair with all cavity contributing sidechain residues 
represented. C) Helices of the four distinct subunit interface pairs are colored according to 
sequence differences with the α+/β- interface as the reference subunit pair displaying identical 
(light blue), similar (white), change in residue type (orange).  Note that for a given interface, 
coloring of the + and – subunit backbone reflects sequence differences from α1 and β3 
respectively. Cavity residues are labeled according to a prime-numbering system in which 
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M2:16’ is equivalent to (I271, T266, T281) for α1, β3, and γ2 subunits respectively; M3:19’ is 
(Y294, F289, F304) and M3:22’ is (A291, M286, S301) with the same ordering. 
 
The AFEP calculations yield an intermediate affinity of propofol for the γ-/α+ 
interfacial site. Residues of the γ-  face, however, are nearly identical to those of the β- 
face, as shown in (Figure 33B-C), and sequence differences among site residues are 
unable to account for the moderate differences in hydrogen-bonding and affinity between 
γ-/α+ and the higher affinity β-/α+ site. Since hydrogen bonding of propofol to the M1 
backbone is frequently observed for β- but not γ-, it is possible that sensitivity of 
fluctuations in M1 secondary structure to non-cavity residues causes the observed weak 
sequence dependence. If so, the result suggests a further uncertainty in interpretations of 
mutagenesis experiments and the underlying assumption that identified residues are 
contact residues. 
 
Figure 34. Ligand protection of synaptic GABAA receptor capture. A ) Chemical structure of 2-
fluoro-1,3-diisopropylbenzene or fropofol(1b). B ) Representative western blots for GABAA 
receptor subunits of input (lanes 2-5) and the corresponding elution (lanes 7-10) for synaptosomal 
samples exposed to AziPm-click (1c) (10 µM) with or without UV irradiation and with or without 
co-exposure with propofol (100 µM) or fropofol(1b) (100 µM). Lane 1, 6 and 11 contain protein 
ladders. B ) Comparison of non-UV and UV capture with or without propofol or fropofol(1b) 
protection for each GABAA receptor subunit, values are represented as the mean of four 
experiments ± SEM of the fraction of the corresponding input sample. Data was analyzed by 2-
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way ANOVA with Tukey’s multiple comparison test comparing fraction captured between 
protection conditions for each subunit. Significant differences from UV irradiated elute without 
protection ligand are shown (***, p < 0.001) (**, p < 0.01) (*, p < 0.05).	  
 
To experimentally evaluate the role of the alkylphenol hydroxyl in selective 
binding to sites within synaptic GABAA receptor subunits, the fluorine substituted 
analogue fropofol(1b) (Figure 34A) was applied within protection experiments 233. 
Previously, fropofol(1b)  did not modulate or disrupt propofol potentiation of the 
GABAA receptor, and did not cause immobilization at even 100-fold higher 
concentrations than propofol.  On the other hand, fropofol(1b)  did display similar 
binding as propofol to protein sites that were not dependent on hydrogen bond 
interactions 233. Azide-PEG3-biotin was employed as the reporter tag for streptavidin-
affinity isolation of protein targets photoaffinity labeled by AziPm-click(1c) with or 
without protection ligands propofol or fropofol(1b). Protein levels of GABAA receptor 
subunits were determined by western blot before (or ‘input’) and after (or ‘elute’) 
streptavidin capture of biotinylated proteins. All GABAA receptor subunits were detected 
within synaptosomes prior to capture (Figure 34), consistent with synaptic localization of 
these subunits. After capture, only α and β subunits were detected. All GABAA receptor α 
and β subunits showed significant decreases in capture efficiency when propofol was 
present during UV irradiation. Unlike propofol, fropofol(1b) was unable to protect 
GABAA receptor α and β subunits from capture (Figure 34A-B). The lack of protection 
by fropofol(1b) corroborates MD simulations suggesting that complex hydrogen bond 
interactions between alkylphenol anesthetics and residues within α/β interface likely 
facilitates the selectivity for these sites.  
3.3.3. Conclusion 
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 Propofol is a positive modulator of the GABAA receptor, but the mechanistic 
details, including the relevant binding sites, remain disputed.  Previously a photoaffinity 
tandem bioorthogonal propofol a-PAL, AziPm-click(1c), was applied for the unbiased 
identification of propofol-binding proteins in their native state within mouse 
synaptosomes. Within the identitifed proteome was the selective identification of five α 
or β synaptic GABAA receptor subunits. Lack of γ2 subunit capture was not due to low 
abundance. Electrophysiology studies confirmed that AziPm-click(1c) retained 
GABAergic activity similar to propofol, therefore associating binding to functional 
activity. Molecular dynamics simulations revealed that the higher affinity interactions for 
propofol at α/β relative to γ-containing interfaces were likely due to differential 
hydrogen-bond probability. Application of a hydrogen-bond null propofol derivative 
fropofol(1b) supported these results. The investigation provided the first evidence for 
direct propofol interaction with specific GABAA receptor subunits within native tissue. 
3.3.4. Experimental methods  
Heterologous expression of GABAA receptor subunits and electrophysiological 
recordings- GABAA receptor expression in Xenpus laevis oocytes was completed as 
described previously 233. cDNAs for GABAA receptor α1, β2, and γ2L subunits were 
generously provided by Dr. Robert Pearce (University of Wisconsin). All animal care and 
experimental procedures involving X. laevis frogs were carried out according to a 
protocol approved by the IACUC of Thomas Jefferson University. GABAA receptor 
currents expressed in X. laevis oocytes were recorded as previously reported 233. Data 
acquisition and initial analysis were performed using pClamp 9.2/10.3 (Molecular 
Devices, Sunnyvale, CA). Macroscopic currents were low-pass filtered at 1 kHz and 
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digitized at 2 kHz. Data was fit to a sigmoidal dose-response curve with variable Hill 
Slope. 
Molecular dynamics simulations- A model of the α1β3γ2 GABAA receptor was built by 
mutating 31 residues in the β subunits from an α1β1γ2 GABAA Model 3 reported in Hénin 
et al., 2014 168.   The mutations were made using the MUTATOR plugin of VMD 175. 
AutoDock Vina 147 was used to generate initial coordinates for propofol; default 
parameters were used and the search space included the entire pentamer. AutoDock Vina 
returned at least one pose for each subunit interface; the ligand conformation with the 
best score was chosen for each site. The complex (GABAA receptor and 5 propofol 
molecules) was then placed in a 109 Å x 109 Å phosphatidylcholine (POPC) membrane 
aligned parallel to the xy plane using CHARMM-GUI Membrane Builder 234.  The 
system was solvated to a total height in z of 139 Å, followed by the addition of sodium 
and potassium ions that neutralized the system and brought the salt concentration to 0.15 
M.  The complete simulation system contained about 167000 atoms. 
The CHARMM36 forcefield was used for protein 235,236 and phospholipid 237 
parameters, with parameters for TIP3P waters 238 and ions 239 corresponding to those 
traditionally used with CHARMM-based force fields. Propofol parameters relied on atom 
types from CHARMM36; as described in LeBard et al., 2012 240, further parameterization 
and use of a CMAP potential was required to accurately enforce coupling between 
rotation of the hydroxyl and isopropyl groups due to steric clashes.   
Atomistic molecular dynamics simulations were run with NAMD v2.10 241. All 
simulations used periodic boundary conditions and particle mesh Ewald (PME) 
electrostatics. Interactions between non-bonded atoms were cutoff at 12 Å, and bonds 
127 
 
involving hydrogen were constrained using the SHAKE/RATTLE algorithm. A Langevin 
thermostat and barostat were used to maintain a temperature and pressure of 300 K and 1 
atm, respectively, and vanishing surface tension was imposed. The simulation timestep 
was 2 fs. Following the system generation, 30000 minimization steps and a 7 ns 
equilibration protocol that gradually softened restraints on the protein and ligand were 
run. Subsequently we ran a 200 ns production run with soft harmonic restraints on the Cα 
atoms (k = 0.5 kcal/mol/Å2).   The probability of hydrogen bonding was calculated using 
a VMD script that measured the fraction of frames in which propofol was hydrogen 
bonding to any residue in the site, detected using the VMD geometric criterion with a 
distance cutoff of 3.3 Å and an angle cutoff of 40 degrees.  The first 50 ns of the 
production run were not included in the analysis.  
Binding affinities were calculated using the Alchemical Free Energy Perturbation 
(AFEP) method, a theoretically exact method that involves gradually decoupling 
(reducing interaction strength) the ligand and the binding site throughout an MD 
simulation 242,243.  The decoupling free energy is then corrected by the ligand solvation 
free energy, as well as the entropic cost of transferring the ligand from the available 
volume per molecule in the standard state (1660 Å3) to the volume of the ligand binding 
site, yielding the standard Gibbs free energy of binding, ΔG0. The dissociation constant 
KD is calculated using the relationship KD=exp (-ΔG0/RT).  Implementation of the 
method was very closely based on the procedure used in LeBard et al., 2012 240 for 
propofol binding to intrasubunit sites TMD of GLIC.  Decoupling of propofol from each 
of four interfaces was carried out in four separate simulations, over 24 windows, with 1 
ns/window for a total of 24 ns per interfacial binding site.  
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The probability of propofol hydrogen bond formation (Phb) was estimated by 
calculating the frequency that a single hydrogen bond with the propofol hydroxyl was 
detected over the course of the equilibrium MD simulation.  Molecular images in Figure 
31 A and C-E and Figure 32 were generated using VMD 175, while data in Figure 31 B 
was plotted and fit using python scripts. 
Synaptosomal photoaffinity labeling- Synaptosomes were resuspended to 1 mg 
protein/mL in HEPES buffer medium (in mM: 140 NaCl, 5 KCl, 5 NaHCO3, 1.2 
NaH2PO4, 1 MgCl2, 10 glucose, and 10 HEPES (pH 7.4)). Concentrations of AziPm-click 
(1c) with or without the presence of concentrations of competitive ligands (propofol or 
fropofol(1b)) in dimethyl sulfoxide (DMSO) vehicle (<0.3% v/v) were added and 
synaptosomes were gently vortexed for 10 s. The samples were allowed to equilibrate for 
5 min before being transferred to a parafilm-sealed 1 mm path-length quartz cuvette. The 
sample was then irradiated for 20 min at a peak band-width of 350 nm (Rayonet RPR-
3500 lamp) ~ 6 cm from the light source. Non-irradiated samples were left in the dark at 
ambient temperature (22-25˚C) for 20 min. All remaining procedures were conducted 
with restricted light exposure.  
Biotin conjugation- To 750 µg of photolabeled or control synaptosome sample, 40 µL of 
10% SDS and 2 µL of 5 mM DTT in water were added. Samples were then vortexed, 
heated for 10 min at 65˚C, and then briefly cooled.  Final concentrations of 150 µM 
azide-biotin (Click Chemistry Tools), 2 mM THPTA (Sigma), 1 mM ascorbic acid 
(Sigma), and 1 mM CuSO4* 5H2O (Sigma) were added to each sample and vortexed 
vigorously. The samples were left in the dark at ambient temperature (22-25˚ C) for 1 hr 
with mild agitation. Directly to each sample 4X volume chilled methanol, 1.5X chilled 
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chloroform and 3X chilled ddH2O were added. Samples were vortexed vigorously and 
centrifuged at 1,400 x g for 30 min at 4˚C. Both liquid layers were carefully removed and 
the protein pellet was washed with 2 mL of 1:1 (v:v) chilled methanol: chloroform. 
Samples were centrifuged at 3,500 x g for 30 min at 4˚ C. Protein pellets were briefly air 
dried before further processing. 
Western blot for biotin conjugated protein targets- 750 µg of biotin conjugated protein 
sample was resuspended via sonication in 500 µL of 25 mM NH4HCO3 and 6 M urea in 
water. Following, 150 µL 5% Trition-100X in water, 50 µL 10% SDS in water and 1.5 
µL 0.5 M DTT was added. The samples were heated for 15 min at 65˚ C. Insoluble debris 
was separated by centrifugation for 10 min at 14,000 x g. The supernatant was diluted to 
1 mL with PBS and 50 µL was removed for the input sample. An additional 5 mL of PBS 
containing 100 uL of 50% strepavidin-agarose resin (Thermo Scientific) was added. 
Biotinylated proteins were captured over resin overnight at 4˚ C with mild agitation.  The 
resin was first washed with 6 mL of 1% SDS in PBS, then 7 mL of 0.1 M urea in PBS 
followed by 10 mL PBS. The resin underwent final wash with 0.9 mL PBS then was 
resuspended in 100 uL of 2x SDS Laemmli buffer containing 100 mM DTT. Samples 
were then incubated with agitation at 37˚ C for 30 min, centrifuged at 700 x g for 2 min 
and heated for 15 min at 90˚C. 50 µL of 2x SDS Laemmli buffer containing 100 mM 
DTT was joined to the input sample and heated for 5 min at 90˚C. Samples were 
centrifuged at 14, 000 x g for 10 min prior to electrophoresis using 4-15% SDS-PAGE 
gels with 10 µL of each sample was introduced into each well. Proteins were then 
transferred to PDVF membranes. The membranes were blocked for 1 hr with 2.5% BSA 
in Tris-buffered saline containing 0.1% Tween-20 (v/v%; TBST).  Membranes were 
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incubated with GABAA receptor subunit antibodies overnight at   4˚ C.  All antibodies for 
GABAA receptor subunits were purchased from Santa Cruz Biotechnology, Inc. and 
included rabbit or goat polyclonal ɑ1 ((A-20): sc-31405), ɑ3 ((J-23)sc122603), β1((N-
19)sc-7361), β2 ((C-20): sc-7362), and γ2 ((Q-18): sc- 101963),  antibodies and 
monoclonal β3 ((D-12): sc-376252)  antibody. For GABAA receptor subunit analysis 
membranes were washed three times with TBST prior to 2 hr incubation with appropriate 
HRP-conjugated secondary at room temperature. All membranes were then washed twice 
with TBST and once with Tris-buffered saline (TBS) before being developed with 
Amersham ECL select reagent and scanned. Only the net ratio of intensity (ROI) detected 
band(s) between the 75-50 kDa molecular weights were considered. The elution 
intensities were normalized to the corresponding input sample. Samples showing no 
detectable band elution were set to a net ROI of 0. Studies were conducted in 
quadruplicates and are represented as the fraction of the corresponding input. 
Statistics- GraphPad Prism 7.0, unless otherwise noted, was used for preparation and 
statistical data analysis. Details are given in the figure legends. 
 
CHAPTER 4: CONCLUSIONS 
Of all the achievements that have been made within medicine, the ability of 
general anesthetics to impede the perception of pain, induce immobility, and prevent 
recall of surgical procedures is one of the greatest. However, general anesthetics are not 
without their drawbacks. Furthering our knowledge regarding the mechanisms behind 
their pharmacological effects is critical to continuing the improvement of general 
anesthetic administration and design. The field of anesthesiology research is rapidly 
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evolving, incorporating and integrating methods from a full range of science disciplines 
including molecular and chemical biology. The body of work presented in this thesis 
utilizes these techniques to help advance our understanding of molecular mechanisms of 
propofol, sevoflurane, and isoflurane.  
 Sevoflurane is a volatile anesthetic that is most commonly used within pediatric 
care. As a comparatively new general anesthetic, much of this agent’s mechanism is 
unclear. The novel a-PAL derivative azisevoflurane(1a) demonstrated similar 
physicochemical, functional and biological endpoints of the parent anesthetic and thus 
shows promise as a tool to further understanding of molecular targets. Azisevoflurane(1a) 
was applied to investigate the mammalian Shaker Kv1.2 channel that is a unique target of 
sevoflurane. An allosteric binding site was identified within a critical location of the 
channel, the S4-S5 linker, which was supported by mutagenesis studies as a likely site 
that leads to sevoflurane’s voltage-dependent positive modulation of the channel. The 
study of sevoflurane’s action on the Kv1.2 channel also indicated a complex molecular 
mechanism through at least two binding sites, each with distinctive influence(s) on the 
channel’s activity.  
 The molecular mechanism of sevoflurane was further explored in a joint 
investigation with another commonly use volatile anesthetic isoflurane. Both volatile 
anesthetics have been shown to positively modulate synaptic αβγ GABAA receptors, 
however the binding sites that lead to this enhanced activity was previously unclear. 
Photoaffinity labeling studies using a-PAL derivatives, azisevoflurane(1a) and 
aziisoflurane for sevoflurane and isoflurane respectively, identified likely positive 
modulatory sites that overlap within the β+/α- TMD interface and are selective within the 
132 
 
α+/β- TMD interface. Potential TMD inter- and intrasubunit sites were also identified 
within γ-containing interfaces; however, how the occupancy of these cavities may alter 
function of the receptor is less clear.  
 In addition to the volatile anesthetics, the most commonly used intravenous 
anesthetic propofol was studied in this work. Reflecting the findings for sevoflurane and 
isoflurane, the molecular mechanism(s) of propofol were shown to be complex despite 
the comparatively simple chemical structure of the drug. The novel derivative 
fropofol(1b) demonstrated that the 1-hydroxyl within the propofol structure, and the 
hydrogen bonding interactions it allows, is critical for overt anesthesia endpoints. The 1-
hydroxyl was observed to be specifically significant for the propofol positive modulation 
of synaptic GABAA receptors. However the hydrogen bonding properties of propofol did 
not abolish all the physiological activity of the anesthetic, as fropofol(1b) did decrease 
muscle contractility in a fashion similar to propofol.  
 An area of contrast between propofol and the volatile anesthetics is their relative 
protein binding affinities with propofol displaying, in general, a higher affinity. Although 
the micromolar EC50 concentrations associated with propofol’s biological activity still 
indicates transient interactions with a large range of molecular targets. To determine the 
propofol-binding proteins a novel tandem anesthetic photoaffinity-click chemistry active 
ligand called AziPm-click(1c) was synthesized. Application of AziPm-click(1c) within a 
developed ABPP workflow allowed for the identification of the propofol-specific 
proteome within a synaptosomal system. Of the over 4,500 proteins identified within the 
synaptosomes, 196 were identified as being likely propofol-binding proteins. These 
findings expand the repertoire of potential targets for propofol and can be used for future 
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drug design. Furthermore, many of the identified proteins have been previously suggested 
as potentially functionally relevant targets in vitro, confirming these findings in a system 
derived from native tissue.  
 One protein target that was identified as propofol-specific within the synapse was 
the αβγ GABAA receptor. Only the α and β subunits of this receptor were identified as 
propofol-specific proteins, and the lack of γ subunit was not a result of low abundance 
within the synaptosomal system. The similar positive modulatory activity of AziPm-
click(1c) associated the selective binding of the α and β subunits to the enhancement of 
αβγ GABAA receptor activity characteristic of propofol. Independent MD simulations 
indicated higher affinity within β+/α- and α+/β- TMD interfaces compared to γ-
containing interfaces and that hydrogen bonding is likely the key feature that contributes 
to the selective binding of subunits. The application of fropofol(1b) in protection studies 
further associated this functional significance and confirmed MD predictions of proposed 
GABAA receptor sites within the synaptosomal system.  
 The above investigations displayed intricate anesthetic-protein interactions and 
likely only scratch the surface of the molecular mechanisms behind general anesthesia. 
With their higher EC50 concentrations it is anticipated that anesthetics have multiple 
target proteins that cumulatively result in anesthesia endpoints and/or adverse side effects 
118 (Figure 35A). This hypothesis is further supported by the studies presented within this 
work. Anesthetic binding within particular target proteins likely play a larger role in 
causing overt anesthesia endpoints, one example being the GABAA receptor. 
Interestingly, within this single protein target multiple potential general anesthetic  
binding sites appear to exist. Some of these sites within the same receptor overlap despite 
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Figure 35. Schematic of the major conclusions presented in this work.  A) General anesthetics 
bind to a complex range of shared and unique macromolecular targets that cumulatively result to 
distinct general anesthesia states.  B) Multiple binding sites might exist within a single protein 
target that overlap across chemotypes or be unique to an anesthetic. The various potential binding 
sites have differing influences on the protein activity. 
 
 significantly different chemical structures, while others appear to be selective even 
within the same anesthetic chemotype (Figure 35B). Evidence also suggested at least two 
sevoflurane binding sites within Kv1.2 channels. Studies indicated that binding within 
these sites might contribute to different molecular mechanisms that collectively result in 
the changes in channel’s activity. Ultimately, the work provided within this thesis adds to 
the abundant opportunities that lay within anesthesiology research to further our 
knowledge of molecular biology and medicine.  
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APPENDIX 
A.1.Equations  
Equation 1.  
T1/2 = 0.3/ (ΨI0ε) 
T1/2 : half-life of photoactivation 
I0 : intensity of the lamp 
ε : molar extinction coefficient 
Ψ : quantum yield of photoactivation   
 
Equation 2.  𝐺 = 𝐺𝑚𝑎𝑥1+ 𝑒 !!!!!! ! 
G ; peak chord conductance 
Gmax ; maximum conductance 
k ; slope factor 
Vc ; command voltage 
Vs ; activation midpoint voltage of a single subunit 
V1/2 ; midpoint voltage of the peak conductance curve 
 
Equation 3. 𝑉1/2 = 1.665  𝑘 + 𝑉s 
 
V1/2 ; midpoint voltage of the peak conductance curve 
k ; slope factor 
Vs ; activation midpoint voltage of a single subunit 
 
Equation 4. 
z=RT/Fk=25.5/k 
z ; equivalent gating charge 
R ;  gas constant 
T ; absolute temperature  
F ; Faraday constant 
k ; slope factor 
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A.2. Detailed synthetic methods  
A.2.1. 3-(Difluoro((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)methyl)-3H-diazirine; 
Azisevoflurane(1a) 
Preparation of Ethyl 2-((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)acetate (2a). A 2 L 
rbf with large magnetic stir bar was filled with 76.45 g (0.455 mol) of 
hexafluoroisopropanol, 72.38 g (0.433 mol) of ethyl bromoacetate, 800 mL of acetone 
and 160.0 g (1.16 mol) of anhydrous K2CO3. The flask was fitted with a condenser, and 
the reaction was stirred vigorously under reflux for 2 h. The mixture was cooled, and 200 
mL methylene chloride was added. The mixture was vacuum-filtered through a fritted 
funnel and the resulting liquid was concentrated in vacuo. The product was purified by 
distillation at atmospheric pressure to yield 87.52 g (80%) of a clear, colorless liquid 2a, 
bp 156-160 ºC. 1H NMR (500 MHz, CDCl3): δ 4.46 (sep, 1 H, JH-F = 5.8 Hz), 4.38 (s, 2 
H), 4.22 (q, 2 H, JH-H = 7.2 Hz), 1.27 (t, 3 H, JH-H = 7.2 Hz). 13C NMR (500 MHz, 
CDCl3): δ 167.88 (s), 121.31 (q, JC-F = 285 Hz), 75.26 (sep, JC-F = 33 Hz), 68.90 (s), 
61.48 (s). 19F NMR (360 MHz, CDCl3): δ -73.73 (d, 6 F, JH-F = 5.5 Hz). HRMS m/z calcd 
for C7H8F6O3 (M + Na)+ 277.0275; found 277.0271. 
Preparation of 2-((1,1,1,3,3,3-Hexafluoropropan-2-yl)oxy)acetic acid (3a). To a 500 
mL rbf was added 79.54 g (0.313 mol) of 2a and 18.79 g (0.470 mol) of NaOH dissolved 
in 80 mL of H2O. The biphasic reaction mixture was stirred vigorously overnight. 
Concentrated HCl (86.0 mL) was then added. The resulting mixture was extracted with 
methylene chloride (3 x 200 mL) and the organic layer was dried over Na2SO4. The 
solvent was evaporated and the product was dried in vacuo to yield 69.54 g (98%) of a 
white solid 3a, mp 52-54 °C. 1H NMR (500 MHz, CDCl3): δ 9.00 (br s, 1 H), 4.49 (s, 2 
H), 4.38 (sep, 1 H, JH-F = 5.7 Hz). 13C NMR (500 MHz, CDCl3): δ 173.29 (s), 121.15 (q, 
JC-F = 285 Hz), 75.64 (sep, JC-F = 33 Hz), 68.60 (s). 19F NMR (360 MHz, CDCl3): δ -
73.40 (d, 6 F, JH-F = 5.8 Hz). HRMS m/z calcd for C7H8F6O3 (M)+ 226.0065; found 
226.0065. 
Preparation of 2-((1,1,1,3,3,3-Hexafluoropropan-2-yl)oxy)acetyl chloride (4a). A 1 L 
rbf with stir bar was filled with 69.54 g (0.307 mol) of 3a and 500 mL of CH2Cl2 and the 
mixture was stirred until a clear solution. Then 0.25 mL of DMF was added with stirring. 
In a separate flask 35.1 mL (46.86 g; 0.369 mol) of oxalyl chloride was dissolved in 60 
mL CH2Cl2. The oxalyl chloride solution was added dropwise over the course of 15 
minutes into the solution of 3a. The mixture was stirred for 1 h at room temperature, and 
then was heated under reflux for 2 h. Distillation at atmospheric pressure yielded 61.74 g 
(82%) of a clear, colorless liquid 4a, bp 128-132 °C. 1H NMR (500 MHz, CDCl3): δ 4.74 
(s, 2 H), 4.30 (sep, 1 H, JH-F = 5.6 Hz). 13C NMR (500 MHz, CDCl3): δ 169.32 (s), 120.89 
(q, JC-F = 285 Hz), 75.79 (sep, JC-F = 33 Hz), 75.65 (s). 19F NMR (360 MHz, CDCl3): δ -
71.23 (d, 6 F, JH-F = 5.3 Hz). HRMS m/z calcd for C7H8F6O3 (M - F)- 224.9742; found 
224.9744. 
Preparation of Methyl 2,2-dichloro-2-((1,1,1,3,3,3-hexafluoropropan-2-
yl)oxy)acetate (5a). To an annular Pyrex photochemical flask was added 35.2 g (0.144 
mol) of 4a and 2 mL of carbon tetrachloride. Chlorine gas was bubbled through the 
solution under irradiation by UV light (450W Hanovia Lamp) for 5.5 h. The solution was 
cooled and air was bubbled through the solution to expel excess chlorine. Methanol (7.0 
mL, 5.5 g; 0.17 mol) was added to the crude product and the solution was stirred for 1 h. 
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Concentration in vacuo followed by vacuum distillation (60 torr) yielded 28.82 g (65 % 
over two steps) of a clear, colorless liquid 5a, bp60 91-97 °C. 1H NMR (500 MHz, 
CDCl3): δ 5.14 (sep, 1 H, JH-F =5.4 Hz), 3.98 (s, 3 H). 13C NMR (500 MHz, CDCl3): δ 
161.48 (s), 120.05 (q, JC-F = 285 Hz), 104.08 (s), 72.53 (sep, JC-F = 35 Hz), 55.22 (s). 19F 
NMR (360 MHz, CDCl3): δ -73.62 (d, 6 F, JH-F = 5.4 Hz). HRMS m/z calcd for C7H8F6O3 
(M - Cl)+ 272.9753; found 272.9760. 
Preparation of Methyl 2,2-difluoro-2-((1,1,1,3,3,3-hexafluoropropan-2-
yl)oxy)acetate (6a). To a 50 mL rbf with stir bar was added 9.50 g (30.7 mmol) of 5a, 
5.50 g (30.9 mmol) of SbF3 and 0.35 mL of SbCl5 . The suspension was heated with 
stirring to 80 °C in an oil bath 1 h. Distillation of the mixture at atmospheric pressure 
yielded 7.24 g (85%) of a clear, colorless liquid 6a, bp 119-124 °C. 1H NMR (500 MHz, 
CDCl3): δ 4.95 (sep, 1 H, JH-F = 5.6 Hz), 3.96 (s, 3 H). 13C NMR (500 MHz, CDCl3): 
158.40 (t, JC-F = 39 Hz), 119.85 (q, JC-F = 283 Hz), 113.34 (t, JC-F = 279 Hz), 69.42 (m), 
54.31 (s). 19F NMR (360 MHz, CDCl3): δ -73.69 (q, 6 F, JH-F = JF-F = 4.5 Hz), -79.07 
(sept, 2 F, JF-F = 4.5 Hz). HRMS m/z calcd for C7H8F6O3 (M + H)+ 277.0111; found 
277.0110. 
Preparation of N-(tert-Butyl)-2,2-difluoro-2-((1,1,1,3,3,3-hexafluoropropan-2-
yl)oxy)ethan-1-imine (7a). Under an inert atmostphere, a 100 mL rbf with stir bar was 
filled with 6.75 g (24.4 mmol) of ester 6a and 50 mL of ether. The mixture was cooled to 
-80 °C in a dry ice/acetone bath and 32 mL (32 mmol; 1 M in hexane) DIBAL-H solution 
was added dropwise, over the course of 15 minutes. The mixture was stirred at -80 °C for 
2 h and was then poured into a cold solution of 5 mL concentrated H2SO4 in 275 mL 
water and stirred vigorously for several minutes. After all of the solid had dissolved, the 
solution was extracted with ether (3 x 100 mL) and the combined ether extracts were 
concentrated using a rotary evaporator at room temperature. The resulting oil was 
dissolved in 50 mL benzene and 5.36 g (73.3 mmol) of tert-butylamine was added. The 
solution was heated to reflux with a Dean-Stark water separator for 4 h after which 
another 5.36 g (73.3 mmol) tert-butylamine was added. The solution was then heated to 
reflux with a Dean-Stark water separator overnight. Concentration of the solution 
followed by dynamic transfer under high vacuum to a U-trap cooled in liquid nitrogen 
yielded 3.21 g (44% over two steps) of a clear, colorless liquid 7a, which was sufficiently 
pure for conversion to diaziridine. 1H NMR (500 MHz, CDCl3): δ 7.50 (t, 1 H, JH-F = 4.9 
Hz), 5.00 (sept, 1 H, JH-F = 5.6 Hz), 1.26 (s, 9 H). 13C NMR (500 MHz, CDCl3): 145.32 
(t, JC-F = 33 Hz), 120.16 (q, JC-F = 285 Hz), 117.62 (t, JC-F = 270 Hz), 68.99 (m), 58.91 (s) 
28.68 (s). 19F NMR (360 MHz, CDCl3): δ -73.46 (q, 6 F, JH-F = JF-F = 4.9 Hz), -77.04 (oct, 
2 F, JH-F = JF-F = 4.7 Hz). HRMS m/z calcd for C9H11F8NO (M + H)+ 302.0798; found 
302.0791. 
Preparation of 1-(tert-Butyl)-3-(difluoro((1,1,1,3,3,3-hexafluoropropan-2 
yl)oxy)methyl)diaziridine (8a). To a 25 mL rbf with stir bar was added 1.85 g (6.14 
mmol) of imine 7a dissolved in 3 mL absolute ethanol, and the solution was cooled in an 
ice bath. A mixture of 0.83 g (7.33 mmol) of hydroxylamine-O-sulfonic acid (HOSA) in 
4.2 mL absolute ethanol was cooled in an ice bath, and 0.64 g (6.32 mmol) of 
triethylamine was added slowly, over 5 minutes, with good stirring. The clear, colorless 
HOSA solution was added dropwise to the solution of 7a, and the resulting solution was 
stirred at 0 °C for 20 minutes. The ice bath was removed, and the mixture was stirred at 
room temperature for 1 h during which a white precipitate formed. Concentration using a 
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rotary evaporator resulted in a white semisolid that was subsequently triturated with ether 
(3 x 20 mL). Evaporation of the ether yielded 0.86 g (44 %) of a clear, colorless liquid 
8a, which was sufficiently pure for conversion to diazirine. 1H NMR (500 MHz, CDCl3): 
δ 4.90 (sept, 1 H, JH-F = 5.6 Hz), 3.21 (d, 1 H), 2.16 (s, 1 H), 1.03 (s, 9 H). 13C NMR (500 
MHz, CDCl3): δ 121.02 (t, JC-F = 271 Hz), 120.02 (q, JC-F = 283 Hz), 69.00 (m), 55.84 (s), 
50.85 (t, JC-F = 36 Hz), 25.21 (s). 19F NMR (360 MHz, CDCl3): δ -73.71 (oct, 2 F, JH-F = 
JF-F = 5.2 Hz), -82.51 (q, 6 F, JH-F = JF-F = 4.7 Hz). HRMS m/z calcd for C7H8F6O3 (M + 
H)+ 317.0900; found 317.0901. 
Preparation of 3-(Difluoro((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)methyl)-3H-
diazirine (1a). To a 10 mL conical flask with stir bar was added 0.6 g (1.90 mmol) of 8a 
dissolved in 1 mL of 1,2-dichloroethane. The solution was cooled to 0 °C in an ice bath 
and 0.36 g (2.00 mmol) NBS was added in one portion. The resulting suspension was 
stirred at 0 °C for 10 minutes and then at room temperature for 1 h. The volatiles were 
transferred to a U-trap cooled in liquid nitrogen under vacuum. Purification of the 
solution by preparative gas chromatography was accomplished using a 10 ft x 0.25 in. 
column packed with 10% SF-96 on Chromasorb W. GC collection conditions were as 
follows: injector 40 °C; column 30 °C; detector 60 °C; helium flow rate = 120 mL/min. 
The order of elution was 1, tert-butylbromide, and dichloroethane. Product 1a was 
collected in a U-trap cooled in liquid nitrogen. 1H NMR (500 MHz, CDCl3): δ 4.83 (sept, 
1 H, JH-F = 5.7 Hz), 1.71 (t, 1 H, JH-F  = 4.6 Hz). 13C NMR (500 MHz, CDCl3): δ 120.94 
(q, JC-F = 283 Hz), 118.98 (t, JC-F = 268 Hz), 69.32 (m), 20.66 (t, JC-F = 42 Hz). 19F NMR 
(500 MHz, CDCl3): δ -73.62 (q, 6 F, JH-F = JF-F = 5.0 Hz), -74.06 (oct, 2 F, JH-F = JF-F = 
4.7 Hz). 
A. 2.2. 2-fluoro-1,3-diisopropylbenzene; Fropofol (1b) 
A 250 mL round bottom flask (rbf) with stir bar was filled with 2.0 g (11.3 mmol) of 
>99% pure 2,6-diisopropylaniline, water (39 mL), and 48% HBF4 (5.7 g; 31.1 mmol). 
This clear, homogeneous solution was cooled to 0°C in an ice-water bath. A solution of 
NaNO2 (0.78 g; 11.3 mmol) in water (1.7 mL) was added dropwise over the course of 
5min, while keeping the temperature of the stirred solution below 3°C. After stirring for a 
few additional minutes, the resulting yellow crystals were suction filtered on a fritted 
glass funnel and then transferred to a 250mL rbf, which was evacuated under aspirator 
pressure overnight. The next day, the resulting brown liquid residue was extracted with 
hexanes (3 x 25 mL) and the combined organic layers were washed with 1 N KOH 
solution (4 x 35 mL), followed by water (3 x 15 mL). The organic layer was dried over 
magnesium sulfate and concentrated in vacuo to yield 1.53 g of a yellow oil. The product 
was purified by passing it through a plug of silica gel (33 cc) using hexane. Evaporation 
of the solvent followed by bulb-to-bulb transfer of the residue under dynamic vacuum 
gave 1.15 g (57%) of fropofol as a clear, colorless liquid. 1H NMR (500 MHz, CDCl3): δ 
7.14-7.23 (3H, m), 3.41 (2H, sep, J = 7 Hz), 1.40 (12H, d, J = 7 Hz). 13C NMR (125 
MHz, CDCl3): δ 158.5 (d, JC-F = 243 Hz), 135.1 (d, JC-F = 15 Hz), 124.4 (d, JC-F = 6.3 Hz), 
123.8 (d, JC-F = 3.8 Hz), 27.2 (d, J = 3.8 Hz), 22.8 ppm. 19F NMR (360 MHz, CDCl3): δ  -
126.14 ppm (t, J = 3.6 Hz). HRMS m/z calculated for C12H17F (M)+ 180.1314; found 
180.1311. 
A. 2.3. 2-((prop-2-yn-1-yloxy)methyl)-5-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenol; 
AziPm-click (1c) 
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2,2,2-Trifluoro-1-(3-(methoxymethoxy)-4-methylphenyl)ethan-1-one (3c):  Under an 
argon atmosphere, a solution of 2 (5.0 g; 21.6 mmol) in dry THF (23 mL) and 
magnesium metal (0.57 g; 23.5 mmol) were added to a 50 mL rbf equipped with a 
condenser and stir bar. The flask was heated slowly to initiate the reaction, and then was 
allowed to react without external heating. Once the exothermic reaction was finished, the 
contents were heated to reflux for 20 minutes to ensure complete consumption of 2c. The 
flask was cooled in an ice-salt bath for 25 minutes, causing a white precipitate to form. 
The condenser was replaced with an addition funnel containing 2,2,2-trifluoro-1-
pyrollidin-1-ylethanone (2.9 g; 17.4 mmol) in dry THF (4.3 mL) and the amide solution 
was added dropwise over 30 minutes at 0 °C while stirring. After the addition, the 
mixture was stirred in the ice bath for 1 hour. The reaction was then quenched with 
saturated aqueous NH4Cl solution (6 mL), and the mixture was vacuum-filtered. The 
resulting liquid was dried over MgSO4, and the solvent was removed under reduced 
pressure to give 5.4 g of a yellow liquid. Distillation under high vacuum yielded 3.2 g 
(72%) of 3 as a yellow liquid, bp 59°C (35 mTorr). 1H NMR (500 MHz, CDCl3): δ 7.74 
(1 H, s), 7.61 (1 H, d, J = 8 Hz), 7.29 (1 H, d, J = 8 Hz), 5.27 (2 H, s), 3.50 (3 H, s), 2.34 
(3 H, s). 13C NMR (125 MHz, CDCl3): δ 179.89 (q, JC-F= 34 Hz), 155.80, 136.95, 131.15, 
128.90, 123.81, 116.79 (q, JC-F= 290 Hz), 114.14, 94.43, 56.10, 16.71 ppm.  19F NMR 
(340 MHz, CDCl3) : δ  -71.2 ppm. HRMS m/z calcd for C11H12F3O3 (M + H+) 249.0738; 
found 249.0742. 
2,2,2-Trifluoro-1-(3-(methoxymethoxy)-4-methylphenyl)ethan-1-one oxime (4c):  To 
a 25 mL rbf with stir bar was added 3 (1.0 g; 4 mmol), hydroxylamine hydrochloride 
(0.35 g; 4 mmol), and pyridine (10 mL). The flask was heated in an oil bath at 60 °C for 4 
hours. The mixture was evaporated to remove volatiles and the residue was partitioned 
between methylene chloride (25 mL) and water (25 mL), and the separated organic layer 
was washed with additional water (20 mL). The organic solution was dried (Na2SO4) and 
was evaporated in vacuo to give 1.0 g of yellow oil. Crystallization from hexanes 
produced 600 mg (58%) of 4c as colorless needles, mp. 101-102 °C. 1H NMR (500 MHz, 
CDCl3): δ 9.19 (1 H, s), 7.26 (2 H, d, J = 8 Hz), 7.09 (1 H, d, J = 8 Hz), 5.25 (2 H, s), 
3.52 (3 H, s), 2.31 (3 H, s). 13C NMR (125 MHz, CDCl3): δ 155.28, 147.44 (q, JC-F= 33 
Hz), 130.90, 130.62, 124.41, 121.80, 120.64 (q, JC-F= 274 Hz), 114.18, 94.61, 56.18, 
16.37 ppm. 19F NMR (340MHz, CDCl3): δ - 66.6 ppm. HRMS m/z calcd for 
C11H11F3NO3 (M-H)- 262.0691; found 262.0690. 
2,2,2-Trifluoro-1-(3-(methoxymethoxy)-4-methylphenyl)ethan-1-one O-tosyl oxime 
(5c):  In a 25 mL rbf with stir bar, 4c (280 mg; 1.06 mmol) was dissolved in methylene 
chloride (7.3 mL). While stirring, 4-(N,N-dimethylamino)pyridine (6.2 mg; 0.05 mmol), 
p-toluenesulfonyl chloride (0.21 g; 1.16 mmol), and triethylamine (0.15 g; 208 µL; 1.5 
mmol) were added to the flask. The mixture was stirred for 24 hours under nitrogen 
atmosphere at room temperature. Water (20 mL) and methylene chloride (20 mL) were 
then added to the reaction mixture, and the separated organic phase was washed with 
additional water (20 mL). The mixture was concentrated in vacuo to give 440 mg of a 
pale yellow crystalline solid. The crude product was purified by column chromatography 
with silica gel using 8% EtOAc/hexanes to give 360 mg (81%) of 7c as a clear crystalline 
solid, mp 65-66 °C. 1H NMR (500 MHz, CDCl3): δ 7.89 (2 H, d, J = 8.5 Hz), 7.38 (2 H, 
d, J = 8.5 Hz), 7.23 (1 H, d, J = 8 Hz), 7.11 (1 H, s), 6.96 (1 H, d, J = 8 Hz), 5.20 (2 H, s), 
3.50 (3 H, s), 2.49 (3 H, s), 2.28 (3 H, s). 13C NMR (125 MHz, CDCl3): δ 155.46, 153.9 
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(q, JC-F = 38 Hz), 146.06, 131.90, 131.34, 131.04, 129.88, 129.26, 122.88, 121.65, 
120.78, 118.57, 116.58 (q, JC-F = 56.6 Hz), 113.82, 94.66, 56.12, 21.77, 16.56 ppm. 19F 
NMR (340 MHz, CDCl3): δ - 66.6 ppm. HRMS calcd for C18H19F3NO5S (M+H)+ 
418.0936; found 418.0928. 
3-(3-(Methoxymethoxy)-4-methylphenyl)-3-(trifluoromethyl)diaziridine (6c):   To a 
solution of 5 (340 mg; 0.82 mmol) in diethyl ether (2 mL) in a 50 mL rbf equipped with 
stir bar and dry ice gas condenser was added excess liquid ammonia at -78 °C. The 
mixture was stirred overnight and allowed to warm to room temperature. The remaining 
residue was partitioned between diethyl ether (35 mL) and water (40 mL). The organic 
layer was washed with additional water (20 mL). The ether solution was dried over 
Na2SO4, and the solvent was removed to give 215 mg (100%) of 6 as a white solid, mp 
79-80 °C. 1H NMR (500 MHz, CDCl3): δ 7.29 (1 H, s), 7.20-7.15 (2 H, m), 5.23 (1 H, d, 
J = 7 Hz), 5.20 (1 H, d, J = 7 Hz), 3.50 (3 H, s), 2.79 (1 H, d, J = 9 Hz), 2.26 (3 H, s), 
2.24 (1 H, d, J = 9 Hz). 13C NMR (125 MHz, CDCl3): δ 155.50, 130.99, 130.38, 129.78, 
123.56 (q, JC-F= 278 Hz), 121.21, 113.35, 94.56, 57.93 (q, JC-F= 35 Hz), 56.13, 16.19 
ppm. 19F NMR (340 MHz, CDCl3): δ -75.5 ppm. HRMS m/z calcd for C11H14F3N2O2 
(M+H)+ 263.1007; found 263.1010. 
3-(3-(Methoxymethoxy)-4-methylphenyl)-3-(trifluoromethyl)-3H-diazirine (7c):  To 
a 50 mL rbf with stir bar was added 6 (1.0 g; 3.82 mmol), PDC (2.0 g; 5.32 mmol), and 
methylene chloride (10 mL). The mixture was stirred overnight at room temperature. The 
solution was diluted with hexanes (10 mL) and flushed through a short plug of silica gel 
with more hexanes. Evaporation of volatiles left 0.89 g (89%) of 7 as a clear light yellow 
liquid. 1H NMR (500 MHz, CDCl3): δ 7.17 (1 H, d, J = 8.5 Hz), 6.85 (1 H, s), 6.80 (1 H, 
d, J = 8.5 Hz), 5.19 (2 H, s), 3.50 (3 H, s), 2.25 (3 H, s). 13C NMR (125 MHz, CDCl3): δ 
155.69, 131.13, 129.59, 127.74, 122.20 (q, JC-F= 274 Hz), 119.85, 111.83, 94.56, 56.08, 
28.45 (q, JC-F= 40 Hz), 16.09 ppm. 19F NMR (340 MHz, CDCl3): δ -65.3 ppm. HRMS m/z 
calcd for C11H10F3N2O2 (M-H)- 259.0694; found 259.0695. 
3-(4-(Bromomethyl)-3-(methoxymethoxy)phenyl)-3-(trifluoromethyl)-3H-diazirine 
(8c):   In a 10 mL rbf with stir bar, 7 (0.47 g; 1.8 mmol), NBS (0.32 g; 1.8 mmol), and 
CCl4 (3.5 mL) were combined. The flask was equipped with a condenser and a nitrogen 
balloon and placed in an oil bath preheated to 90 °C. Incandescent light was shone 
directly on the flask. When the reaction was complete as monitored by TLC, the product 
was dissolved in hexanes (5 mL) and flushed through a pipette containing Celite (2 cc). 
The resulting mixture was evaporated in vacuo to give 0.63 g of a yellow liquid. The 
product was then flushed through a plug of silica gel (15 cc) with hexanes, and the 
solvent was evaporated to yield 0.5 g (83%) of 8c as a colorless liquid. 1H NMR (500 
MHz, CDCl3): δ 7.37 (1 H, d, J = 8 Hz), 6.88-6.84 (2 H, m), 5.27 (2 H, s), 4.53 (2 H, s), 
3.52 (3 H, s). 13C NMR (125 MHz, CDCl3): δ 155.25, 151.46, 131.22, 131.14, 131.05, 
128.65, 121.99 (q, JC-F= 275 Hz), 120.00, 112.28, 94.74, 94.59, 56.59, 56.44, 56.10, 
33.98, 28.42 (q, JC-F= 40 Hz), 27.48, 16.11 ppm. 19F NMR (340 MHz, CDCl3): δ -65.1 
ppm. HRMS m/z calcd for C11H9BrF3N2O2 (M-H)+ 336.9799; found 336.9799. 
3-(3-(Methoxymethoxy)-4-((prop-2-yn-1-yloxy)methyl)phenyl)-3-(trifluoromethyl)-
3H-diazirine (9c):  To a 10 mL rbf with stir bar was added 60% dispersion of sodium 
hydride in mineral oil (0.06 g; 1.50 mmol) under nitrogen. The oil was removed by 
washing with hexanes (5 mL). Dry THF (2 mL) was then added, forming a cloudy white 
suspension. The mixture was cooled in an ice-water bath to 0 °C. To this mixture was 
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added propargyl alcohol (0.08g; 79µL; 1.37 mmol) via syringe which caused bubbling. 
After the bubbling stopped, a solution of 8c (0.31 g; 0.91 mmol) dissolved in THF (1 mL) 
was added. The reaction was stirred at room temperature overnight. The mixture was 
dissolved in water (15 mL) and was extracted with diethyl ether (3 x 15 mL). The 
combined organic layers were washed with water (3 x 15 mL), and then dried over 
Na2SO4. The mixture was evaporated in vacuo to give 0.22 g (77%) of a yellow oil. The 
product was purified by column chromatography using silica gel and 5% ethyl 
acetate/hexanes, giving 0.13 g (45%) of 9c as a colorless oil, Rf = 0.33 (5% 
EtOAc/hexanes). 1H NMR (500 MHz, CDCl3): δ 7.43 (1 H, d, J = 8.5 Hz), 6.89 (1 H, d, J 
= 8.5 Hz), 6.88 (1H, s), 5.20 (2 H, s), 4.66 (2 H, s), 4.22 (2 H, d, J = 2.5 Hz), 3.48 (3 H, 
s), 2.46 (1 H, t, J = 2.5 Hz). 13C NMR (125 MHz, CDCl3): δ 154.96, 129.73, 129.35, 
128.73, 122.09 (q, JC-F= 275 Hz), 119.99, 111.94, 79.58, 74.66, 66.06, 57.74, 56.27, 
28.45 (q, JC-F= 40 Hz) ppm. 19F NMR (340 MHz, CDCl3): δ -65.3 ppm. HRMS m/z calcd 
for C14H12F3N2O3 (M-H)- 313.0800; found 313.0812. 
2-((Prop-2-yn-1-yloxy)methyl)-5-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenol 
(AziPm-click 1c).  In a 10 mL rbf with stir bar, 9 (65 mg; 0.21 mmol) was dissolved in 
methylene chloride (2.3 mL) at room temperature. While stirring, activated (hot) 
NaHSO4•SiO2 (43 mg) was added. After 4 hours the reaction was complete, as shown by 
TLC, and the mixture was dissolved in methylene chloride (2 mL) and run through a 
pipette containing silica gel (2 cc). The resulting solution was evaporated in vacuo and 
then evaporated under high vacuum to give 37.3 mg of a clear oil. The product was 
purified by column chromatography with silica gel using 15% EtOAc/hexanes to give 
28.5 mg (52%) of 12, a colorless oil. Rf = 0.3 (15% EtOAc/hexanes). 1H NMR (500 
MHz, CDCl3): δ 7.17 (1 H, s), 7.09 (1 H, d, J = 8 Hz), 6.73 (1 H, s), 6.66 (1 H, d, J = 8 
Hz), 4.80 (2 H, s), 4.25 (2 H, d, J = 2 Hz), 2.54 (1 H, t, J = 2 Hz). 13C NMR (125 MHz, 
CDCl3): δ 156.50, 131.12, 129.22, 123.33, 122.21 (1, JC-F= 274 Hz), 118.18, 115.04, 
78.19, 76.39, 70.30, 57.94, 28.44 (q, JC-F= 40 Hz) ppm. 19F NMR (340 MHz, CDCl3): δ -
65.3 ppm. HRMS m/z calcd for C12H9F3N2O2 (M)+ 270.0616; found 270.0618. 
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A.3. Mass spectrometry protein coverage 
Protein coverage maps and sequences are provided with detected peptide residues 
highlighted in green or denoted in bold and underlined. 
 
A.3.1.  aF coverage photoaffinity labeled by azisevoflurane(1a) 
Horse spleen apo-ferritin light chain 
 
MSSQIRQNYS   TEVEAAVNRL   VNLYLRASYT   YLSLGFYFDR   
DDVALEGVCH   FFRELAEEKR   EGAERLLKMQ   NQRGGRALFQ   
DLQKPSQDEW   GTTLDAMKAA   IVLEKSLNQA   LLDLHALGSA   
QADPHLCDFL   ESHFLDEEVK   LIKKMGDHLT   NIQRLVGSQA   
GLGEYLFERL   TLKHD 
 
A.3.2. Kv1.2 coverage photoaffinity labeled by azisevoflurane(1a) 
Rat Kv1.2 with appended Arg-Gly-Ser-His10 tag 
 
MTVATGDPVD   EAAALPGHPQ   DTYDPEADHE   CCERVVINIS   
GLRFETQLKT   LAQFPETLLG   DPKKRMRYFD   PLRNEYFFDR   
NRPSFDAILY   YYQSGGRLRR   PVNVPLDIFS   EEIRFYELGE   
EAMEMFREDE   GYIKEEERPL   PENEFQRQVW   LLFEYPESSG   
PARIIAIVSV   MVILISIVSF   CLETLPIFRD   ENEDMHGGGV   
TFHTYSNSTI   GYQQSTSFTD   PFFIVETLCI   IWFSFEFLVR   
FFACPSKAGF   FTNIMNIIDI   VAIIPYFITL   GTELAEKPED   
AQQGQQAMSL   AILRVIRLVR   VFRIFKLSRH   SKGLQILGQT   
LKASMRELGL   LIFFLFIGVI   LFSSAVYFAE   ADERDSQFPS   
IPDAFWWAVV   SMTTVGYGDM   VPTTIGGKIV   GSLCAIAGVL   
TIALPVPVIV   SNFNYFYHRE   TEGEEQAQYL   QVTSCPKIPS   
SPDLKKSRSA   STISKSDYME   IQEGVNNSNE   DFREENLKTA   
NCTLANTNYV   NITKMLTDVS   GLEVLFQGPN   GARGSHHHHH    
HHHHH 
 
A.3.3. FLAG-α1β3γ2L-L3-1D4 GABAA receptor coverage photoaffinity labeled by 
azisevoflurane(1a) 
FLAG-α1 GABAA receptor subunit 
	  
MKKSPGLSDY LWAWTLFLST LTGRSYGDYK DDDDKQPSLQ DELKDNTTVF 
TRILDRLLDG YDNRLRPGLG ERVTEVKTDI FVTSFGPVSD HDMEYTIDVF 
FRQSWKDERL KFKGPMTVLR LNNLMASKIW TPDTFFHNGK KSVAHNMTMP 
NKLLRITEDG TLLYTMRLTV RAECPMHLED FPMDAHACPL KFGSYAYTRA 
EVVYEWTREP ARSVVVAEDG SRLNQYDLLG QTVDSGIVQS STGEYVVMTT 
464451401351301251201151101511
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HFHLKRKIGY FVIQTYLPCI MTVILSQVSF WLNRESVPAR TVFGVTTVLT 
MTTLSISARN SLPKVAYATA MDWFIAVCYA FVFSALIEFA TVNYFTKRGY 
AWDGKSVVPE KPKKVKDPLI KKNNTYAPTA TSYTPNLARG DPGLATIAKS 
ATIEPKEVKP ETKPPEPKKT FNSVSKIDRL SRIAFPLLFG IFNLVYWATY 
LNREPQLKAP TPHQ 
 
β3 GABAA receptor subunit 
 
MCSGLLELLL PIWLSWTLGT RGSEPRSVND PGNMSFVKET VDKLLKGYDI 
RLRPDFGGPP VCVGMNIDIA SIDMVSEVNM DYTLTMYFQQ YWRDKRLAYS 
GIPLNLTLDN RVADQLWVPD TYFLNDKKSF VHGVTVKNRM IRLHPDGTVL 
YGLRITTTAA CMMDLRRYPL DEQNCTLEIE SYGYTTDDIE FYWRGGDKAV 
TGVERIELPQ FSIVEHRLVS RNVVFATGAY PRLSLSFRLK RNIGYFILQT 
YMPSILITIL SWVSFWINYD ASAARVALGI TTVLTMTTIN THLRETLPKI 
PYVKAIDMYL MGCFVFVFLA LLEYAFVNYI FFGRGPQRQK KLAEKTAKAK 
NDRSKSESNR VDAHGNILLT SLEVHNEMNE VSGGIGDTRN SAISFDNSGI 
QYRKQSMPRE GHGRFLGDRS LPHKKTHLRR RSSQLKIKIP DLTDVNAIDR 
WSRIVFPFTF SLFNLVYWLY YVN                                                                                     
 
γ2L-L3-1D4 GABAA receptor subunit 
 
MSSPNIWSTG SSVYSTPVFS QKMTVWILLL LSLYPGFTSQ KSDDDYEDYA 
SNKTWVLTPK VPEGDVTVIL NNLLEGYDNK LRPDIGVKPT LIHTDMYVNS 
IGPVNAINME YTIDIFFAQT WYDRRLKFNS TIKVLRLNSN MVGKIWIPDT 
FFRNSKKADA HWITTPNRML RIWNDGRVLY TLRLTIDAEC QLQLHNFPMD 
EHSCPLEFSS YGYPREEIVY QWKRSSVEVG DTRSWRLYQF SFVGLRNTTE 
VVKTTSGDYV VMSVYFDLSR RMGYFTIQTY IPCTLIVVLS WVSFWINKDA 
VPARTSLGIT TVLTMTTLST IARKSLPKVS YVTAMDLFVS VCFIFVFSAL 
VEYGTLHYFV SNRKPSKDKD KKKKNPLLRM FSFKAPTIDI RPRSATIQMN 
NATHLQERDE EYGYECLDGK DCASFFCCFE DCRTGAWRHG RIHIRIAKMD 
SYARIFFPTA FCLFNLVYWV SYLYLGGSGG SGGSGKTETS QVAPA 
 
A.3.4. α1β3γ2L GABAA receptor coverage photoaffinity labeled by aziisoflurane 
FLAG-α1 GABAA receptor subunit 
 
MKKSPGLSDY LWAWTLFLST LTGRSYGDYK DDDDKQPSLQ DELKDNTTVF 
TRILDRLLDG YDNRLRPGLG ERVTEVKTDI FVTSFGPVSD HDMEYTIDVF 
FRQSWKDERL KFKGPMTVLR LNNLMASKIW TPDTFFHNGK KSVAHNMTMP 
NKLLRITEDG TLLYTMRLTV RAECPMHLED FPMDAHACPL KFGSYAYTRA 
473451401351301251201151101511
495451401351301251201151101511
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EVVYEWTREP ARSVVVAEDG SRLNQYDLLG QTVDSGIVQS STGEYVVMTT 
HFHLKRKIGY FVIQTYLPCI MTVILSQVSF WLNRESVPAR TVFGVTTVLT 
MTTLSISARN SLPKVAYATA MDWFIAVCYA FVFSALIEFA TVNYFTKRGY 
AWDGKSVVPE KPKKVKDPLI KKNNTYAPTA TSYTPNLARG DPGLATIAKS 
ATIEPKEVKP ETKPPEPKKT FNSVSKIDRL SRIAFPLLFG IFNLVYWATY 
LNREPQLKAP TPHQ 
 
β3 GABAA receptor subunit 
 
MCSGLLELLL PIWLSWTLGT RGSEPRSVND PGNMSFVKET VDKLLKGYDI 
RLRPDFGGPP VCVGMNIDIA SIDMVSEVNM DYTLTMYFQQ YWRDKRLAYS 
GIPLNLTLDN RVADQLWVPD TYFLNDKKSF VHGVTVKNRM IRLHPDGTVL 
YGLRITTTAA CMMDLRRYPL DEQNCTLEIE SYGYTTDDIE FYWRGGDKAV 
TGVERIELPQ FSIVEHRLVS RNVVFATGAY PRLSLSFRLK RNIGYFILQT 
YMPSILITIL SWVSFWINYD ASAARVALGI TTVLTMTTIN THLRETLPKI 
PYVKAIDMYL MGCFVFVFLA LLEYAFVNYI FFGRGPQRQK KLAEKTAKAK 
NDRSKSESNR VDAHGNILLT SLEVHNEMNE VSGGIGDTRN SAISFDNSGI 
QYRKQSMPRE GHGRFLGDRS LPHKKTHLRR RSSQLKIKIP DLTDVNAIDR 
WSRIVFPFTF SLFNLVYWLY YVN 
 
γ2L-L3-1D4 GABAA receptor subunit 
 
MSSPNIWSTG SSVYSTPVFS QKMTVWILLL LSLYPGFTSQ KSDDDYEDYA 
SNKTWVLTPK VPEGDVTVIL NNLLEGYDNK LRPDIGVKPT LIHTDMYVNS 
IGPVNAINME YTIDIFFAQT WYDRRLKFNS TIKVLRLNSN MVGKIWIPDT 
FFRNSKKADA HWITTPNRML RIWNDGRVLY TLRLTIDAEC QLQLHNFPMD 
EHSCPLEFSS YGYPREEIVY QWKRSSVEVG DTRSWRLYQF SFVGLRNTTE 
VVKTTSGDYV VMSVYFDLSR RMGYFTIQTY IPCTLIVVLS WVSFWINKDA 
VPARTSLGIT TVLTMTTLST IARKSLPKVS YVTAMDLFVS VCFIFVFSAL 
VEYGTLHYFV SNRKPSKDKD KKKKNPLLRM FSFKAPTIDI RPRSATIQMN 
NATHLQERDE EYGYECLDGK DCASFFCCFE DCRTGAWRHG RIHIRIAKMD 
SYARIFFPTA FCLFNLVYWV SYLYLGGSGG SGGSGKTETS QVAPA 
 
A.3.5. α1β3 GABAA receptor coverage photoaffinity labeled by azisevoflurane(1a) 
FLAG-α1 GABAA receptor subunit 
 
MKKSPGLSDY LWAWTLFLST LTGRSYGDYK DDDDKQPSLQ DELKDNTTVF 
TRILDRLLDG YDNRLRPGLG ERVTEVKTDI FVTSFGPVSD HDMEYTIDVF 
FRQSWKDERL KFKGPMTVLR LNNLMASKIW TPDTFFHNGK KSVAHNMTMP 
464451401351301251201151101511
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NKLLRITEDG TLLYTMRLTV RAECPMHLED FPMDAHACPL KFGSYAYTRA 
EVVYEWTREP ARSVVVAEDG SRLNQYDLLG QTVDSGIVQS STGEYVVMTT 
HFHLKRKIGY FVIQTYLPCI MTVILSQVSF WLNRESVPAR TVFGVTTVLT 
MTTLSISARN SLPKVAYATA MDWFIAVCYA FVFSALIEFA TVNYFTKRGY 
AWDGKSVVPE KPKKVKDPLI KKNNTYAPTA TSYTPNLARG DPGLATIAKS 
ATIEPKEVKP ETKPPEPKKT FNSVSKIDRL SRIAFPLLFG IFNLVYWATY 
LNREPQLKAP TPHQ 
 
β3 GABAA receptor subunit 
 
MCSGLLELLL PIWLSWTLGT RGSEPRSVND PGNMSFVKET VDKLLKGYDI 
RLRPDFGGPP VCVGMNIDIA SIDMVSEVNM DYTLTMYFQQ YWRDKRLAYS 
GIPLNLTLDN RVADQLWVPD TYFLNDKKSF VHGVTVKNRM IRLHPDGTVL 
YGLRITTTAA CMMDLRRYPL DEQNCTLEIE SYGYTTDDIE FYWRGGDKAV 
TGVERIELPQ FSIVEHRLVS RNVVFATGAY PRLSLSFRLK RNIGYFILQT 
YMPSILITIL SWVSFWINYD ASAARVALGI TTVLTMTTIN THLRETLPKI 
PYVKAIDMYL MGCFVFVFLA LLEYAFVNYI FFGRGPQRQK KLAEKTAKAK 
NDRSKSESNR VDAHGNILLT SLEVHNEMNE VSGGIGDTRN SAISFDNSGI 
QYRKQSMPRE GHGRFLGDRS LPHKKTHLRR RSSQLKIKIP DLTDVNAIDR 
WSRIVFPFTF SLFNLVYWLY YVN      
 
A.3.6. α1β3 GABAA receptor coverage photoaffinity labeled by aziisoflurane 
FLAG-α1 GABAA receptor subunit 
 
MKKSPGLSDY LWAWTLFLST LTGRSYGDYK DDDDKQPSLQ DELKDNTTVF 
TRILDRLLDG YDNRLRPGLG ERVTEVKTDI FVTSFGPVSD HDMEYTIDVF 
FRQSWKDERL KFKGPMTVLR LNNLMASKIW TPDTFFHNGK KSVAHNMTMP 
NKLLRITEDG TLLYTMRLTV RAECPMHLED FPMDAHACPL KFGSYAYTRA 
EVVYEWTREP ARSVVVAEDG SRLNQYDLLG QTVDSGIVQS STGEYVVMTT 
HFHLKRKIGY FVIQTYLPCI MTVILSQVSF WLNRESVPAR TVFGVTTVLT 
MTTLSISARN SLPKVAYATA MDWFIAVCYA FVFSALIEFA TVNYFTKRGY 
AWDGKSVVPE KPKKVKDPLI KKNNTYAPTA TSYTPNLARG DPGLATIAKS 
ATIEPKEVKP ETKPPEPKKT FNSVSKIDRL SRIAFPLLFG IFNLVYWATY 
LNREPQLKAP TPHQ 
 
β3 GABAA receptor subunit 
 
MCSGLLELLL PIWLSWTLGT RGSEPRSVND PGNMSFVKET VDKLLKGYDI 
RLRPDFGGPP VCVGMNIDIA SIDMVSEVNM DYTLTMYFQQ YWRDKRLAYS 
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GIPLNLTLDN RVADQLWVPD TYFLNDKKSF VHGVTVKNRM IRLHPDGTVL 
YGLRITTTAA CMMDLRRYPL DEQNCTLEIE SYGYTTDDIE FYWRGGDKAV 
TGVERIELPQ FSIVEHRLVS RNVVFATGAY PRLSLSFRLK RNIGYFILQT 
YMPSILITIL SWVSFWINYD ASAARVALGI TTVLTMTTIN THLRETLPKI 
PYVKAIDMYL MGCFVFVFLA LLEYAFVNYI FFGRGPQRQK KLAEKTAKAK 
NDRSKSESNR VDAHGNILLT SLEVHNEMNE VSGGIGDTRN SAISFDNSGI 
QYRKQSMPRE GHGRFLGDRS LPHKKTHLRR RSSQLKIKIP DLTDVNAIDR 
WSRIVFPFTF SLFNLVYWLY YVN  
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A.4. Mass spectra 
For all spectra, hypothetical fragment ions are listed in the tables, and their predicted 
positions are indicated on the spectra. Fragment ions that were identified on the spectra 
are colored in the ion tables. Respective residue modifications are noted within ion tables. 
Photoaffinity labeled residues are denoted bold and with an (*) and labeled within ion 
tables for azisevoflurane(1a) (AziSev) and aziisoflurane (AziIso) 
 
A.4.1. Apo-ferritin (aF) peptides photoaffinity labeled by azisevoflurane(1a) 
76-ALFQDL*QKPSQDEWGTTLDAMK-97 
 
#1 a⁷  a²⁷  a³⁷  b⁷  b²⁷  b³⁷  Seq. y⁷  y²⁷  y³⁷  #2 
1 44.049 22.528 15.355 72.044 36.526 24.686 A       22 
2 157.134 79.070 53.049 185.128 93.068 62.381 L 2681.184 1341.096 894.400 21 
3 304.202 152.605 102.072 332.197 166.602 111.404 F 2568.100 1284.554 856.705 20 
4 432.261 216.634 144.758 460.255 230.631 154.090 Q 2421.031 1211.019 807.682 19 
5 547.288 274.147 183.101 575.282 288.145 192.432 D 2292.973 1146.990 764.996 18 
6 890.369 445.688 297.461 918.364 459.686 306.793 L-AziSev 2177.946 1089.477 726.654 17 
7 1018.428 509.718 340.148 1046.423 523.715 349.479 Q 1834.864 917.936 612.293 16 
8 1146.523 573.765 382.846 1174.518 587.763 392.177 K 1706.806 853.906 569.607 15 
9 1243.576 622.291 415.197 1271.571 636.289 424.528 P 1578.711 789.859 526.908 14 
10 1330.608 665.807 444.207 1358.603 679.805 453.539 S 1481.658 741.333 494.557 13 
11 1458.666 729.837 486.894 1486.661 743.834 496.225 Q 1394.626 697.817 465.547 12 
12 1573.693 787.350 525.236 1601.688 801.348 534.568 D 1266.567 633.787 422.861 11 
13 1702.736 851.872 568.250 1730.731 865.869 577.582 E 1151.540 576.274 384.518 10 
14 1888.815 944.911 630.277 1916.810 958.909 639.608 W 1022.498 511.752 341.504 9 
15 1945.837 973.422 649.284 1973.832 987.419 658.615 G 836.418 418.713 279.478 8 
16 2046.884 1023.946 682.966 2074.879 1037.943 692.298 T 779.397 390.202 260.470 7 
17 2147.932 1074.470 716.649 2175.927 1088.467 725.980 T 678.349 339.678 226.788 6 
18 2261.016 1131.012 754.344 2289.011 1145.009 763.675 L 577.301 289.154 193.105 5 
19 2376.043 1188.525 792.686 2404.038 1202.523 802.017 D 464.217 232.612 155.411 4 
20 2447.080 1224.044 816.365 2475.075 1238.041 825.697 A 349.190 175.099 117.068 3 
21 2578.121 1289.564 860.045 2606.116 1303.561 869.377 M 278.153 139.580 93.389 2 
22             K 147.113 74.060 49.709 1 
 
76-ALFQDLQ*KPSQDEWGTTLDAMK-97 
148 
 
 
 
53-ELAEEKR*EGAER-64 
 
7 a⁷  a²⁷  b⁷  b²⁷  Seq. y⁷  y²⁷  #2 
1 102.055 51.531 130.050 65.529 E     12 
2 215.139 108.073 243.134 122.071 L 1517.663 759.335 11 
3 286.176 143.592 314.171 157.589 A 1404.579 702.793 10 
4 415.219 208.113 443.214 222.110 E 1333.542 667.275 9 
#1 a⁷  a²⁷  a³⁷  b⁷  b²⁷  b³⁷  Seq. y⁷  y²⁷  y³⁷  #2 
1 44.049 22.528 15.355 72.044 36.526 24.686 A       22 
2 157.134 79.070 53.049 185.128 93.068 62.381 L 2697.179 1349.093 899.731 21 
3 304.202 152.605 102.072 332.197 166.602 111.404 F 2584.095 1292.551 862.036 20 
4 432.261 216.634 144.758 460.255 230.631 154.090 Q 2437.026 1219.017 813.014 19 
5 547.288 274.147 183.101 575.282 288.145 192.432 D 2308.968 1154.988 770.327 18 
6 660.372 330.689 220.795 688.366 344.687 230.127 L 2193.941 1097.474 731.985 17 
7 1018.428 509.718 340.148 1046.423 523.715 349.479 Q-AziSev 2080.857 1040.932 694.290 16 
8 1146.523 573.765 382.846 1174.518 587.763 392.177 K 1722.800 861.904 574.938 15 
9 1243.576 622.291 415.197 1271.571 636.289 424.528 P 1594.705 797.856 532.240 14 
10 1330.608 665.807 444.207 1358.603 679.805 453.539 S 1497.653 749.330 499.889 13 
11 1458.666 729.837 486.894 1486.661 743.834 496.225 Q 1410.621 705.814 470.878 12 
12 1573.693 787.350 525.236 1601.688 801.348 534.568 D 1282.562 641.785 428.192 11 
13 1702.736 851.872 568.250 1730.731 865.869 577.582 E 1167.535 584.271 389.850 10 
14 1888.815 944.911 630.277 1916.810 958.909 639.608 W 1038.493 519.750 346.836 9 
15 1945.837 973.422 649.284 1973.832 987.419 658.615 G 852.413 426.710 284.809 8 
16 2046.884 1023.946 682.966 2074.879 1037.943 692.298 T 795.392 398.200 265.802 7 
17 2147.932 1074.470 716.649 2175.927 1088.467 725.980 T 694.344 347.676 232.120 6 
18 2261.016 1131.012 754.344 2289.011 1145.009 763.675 L 593.296 297.152 198.437 5 
19 2376.043 1188.525 792.686 2404.038 1202.523 802.017 D 480.212 240.610 160.742 4 
20 2447.080 1224.044 816.365 2475.075 1238.041 825.697 A 365.185 183.096 122.400 3 
21 2594.116 1297.561 865.377 2622.110 1311.559 874.708 M-Oxidation 294.148 147.578 98.721 2 
22             K 147.113 74.060 49.709 1 
149 
 
5 544.261 272.634 572.256 286.632 E 1204.499 602.753 8 
6 672.356 336.682 700.351 350.679 K 1075.457 538.232 7 
7 1058.455 529.731 1086.450 543.729 R-AziSev 947.362 474.184 6 
8 1187.498 594.253 1215.493 608.250 E 561.263 281.135 5 
9 1244.519 622.763 1272.514 636.761 G 432.220 216.614 4 
10 1315.556 658.282 1343.551 672.279 A 375.199 188.103 3 
11 1444.599 722.803 1472.594 736.801 E 304.162 152.584 2 
12         R 175.119 88.063 1 
 
19-lVNLYLR*-25 
 
#1 a⁷  a²⁷  b⁷  b²⁷  Seq. y⁷  y²⁷  #2 
1 86.096 43.552 114.091 57.549 L     7 
2 185.165 93.086 213.160 107.084 V 1007.460 504.233 6 
3 299.208 150.108 327.203 164.105 N 908.391 454.699 5 
4 412.292 206.650 440.287 220.647 L 794.348 397.678 4 
5 575.355 288.181 603.350 302.179 Y 681.264 341.136 3 
6 688.439 344.723 716.434 358.721 L 518.201 259.604 2 
7         R-AziSev 405.117 203.062 1 
 
A.4.2. Kv1.2 peptide photoaffinity labeled by azisevoflurane(1a) 
313-GLQIL*GQTLK-322 
Spectra (See Figure 8) 
#1 a⁷  a²⁷  b⁷  b²⁷  Seq. y⁷  y²⁷  #2 
1 30.034 15.521 58.029 29.518 G     10 
2 143.118 72.063 171.113 86.060 L 1243.633 622.320 9 
3 271.176 136.092 299.171 150.089 Q 1130.549 565.778 8 
4 384.261 192.634 412.255 206.631 I 1002.491 501.749 7 
5 727.342 364.175 755.337 378.172 L-AziSev 889.406 445.207 6 
6 784.364 392.686 812.359 406.683 G 546.325 273.666 5 
7 912.422 456.715 940.417 470.712 Q 489.303 245.155 4 
8 1013.470 507.239 1041.465 521.236 T 361.245 181.126 3 
9 1126.554 563.781 1154.549 577.778 L 260.197 130.602 2 
10         K 147.113 74.060 1 
 
A.4.3. α1β3γ2L GABAA receptor peptides photoaffinity labeled by azisevoflurane(1a) 
FLAG-α1 GABAA receptor subunit 
276-S*QVSFWLNRESVPARTVFGVTTVL-299 
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#
1   a⁺   a²⁺   a³⁺   b⁺   b²⁺   b³⁺   Seq.   y⁺   y²⁺   y³⁺  
#
2  
1 290.0421
8 
145.5247
3 
97.3522
5 
318.0371
0 
159.5221
9 
106.683
88 
S-AziSev       2
4 
2 419.0847
8 
210.0460
3 
140.366
44 
447.0796
9 
224.0434
8 
149.698
08 
Q-
Deamidate
d 
2608.377
08 
1304.692
18 
870.130
55 
2
3 
3 518.1532
0 
259.5802
4 
173.389
25 
546.1481
1 
273.5776
9 
182.720
89 
V 2479.334
49 
1240.170
88 
827.116
35 
2
2 
4 605.1852
3 
303.0962
5 
202.399
93 
633.1801
4 
317.0937
1 
211.731
57 
S 2380.266
07 
1190.636
67 
794.093
54 
2
1 
5 752.2536
5 
376.6304
6 
251.422
73 
780.2485
6 
390.6279
2 
260.754
37 
F 2293.234
04 
1147.120
66 
765.082
86 
2
0 
6 938.3329
7 
469.6701
2 
313.449
17 
966.3278
8 
483.6675
8 
322.780
81 
W 2146.165
62 
1073.586
45 
716.060
06 
1
9 
7 1051.417
04 
526.2121
6 
351.143
86 
1079.411
95 
540.2096
1 
360.475
50 
L 1960.086
30 
980.5467
9 
654.033
62 
1
8 
8 1166.443
98 
583.7256
3 
389.486
18 
1194.438
90 
597.7230
9 
398.817
82 
N-
Deamidate
d 
1847.002
23 
924.0047
5 
616.338
93 
1
7 
9 1322.545
10 
661.7761
9 
441.519
89 
1350.540
02 
675.7736
5 
450.851
52 
R 1731.975
28 
866.4912
8 
577.996
61 
1
6 
1
0 
1451.587
70 
726.2974
9 
484.534
09 
1479.582
62 
740.2949
5 
493.865
72 
E 1575.874
16 
788.4407
2 
525.962
90 
1
5 
1
1 
1538.619
73 
769.8135
1 
513.544
76 
1566.614
65 
783.8109
6 
522.876
40 
S 1446.831
56 
723.9194
2 
482.948
70 
1
4 
1
2 
1637.688
15 
819.3477
2 
546.567
57 
1665.683
07 
833.3451
7 
555.899
21 
V 1359.799
53 
680.4034
0 
453.938
03 
1
3 
1
3 
1734.740
92 
867.8741
0 
578.918
49 
1762.735
84 
881.8715
6 
588.250
13 
P 1260.731
11 
630.8691
9 
420.915
22 
1
2 
1
4 
1805.778
04 
903.3926
6 
602.597
53 
1833.772
96 
917.3901
2 
611.929
17 
A 1163.678
34 
582.3428
1 
388.564
30 
1
1 
1
5 
1961.879
16 
981.4432
2 
654.631
24 
1989.874
08 
995.4406
8 
663.962
88 
R 1092.641
22 
546.8242
5 
364.885
26 
1
0 
1
6 
2062.926
84 
1031.967
06 
688.313
80 
2090.921
76 
1045.964
52 
697.645
44 
T 936.5401
0 
468.7736
9 
312.851
55 
9 
1
7 
2161.995
26 
1081.501
27 
721.336
61 
2189.990
18 
1095.498
73 
730.668
24 
V 835.4924
2 
418.2498
5 
279.168
99 
8 
1
8 
2309.063
68 
1155.035
48 
770.359
41 
2337.058
60 
1169.032
94 
779.691
05 
F 736.4240
0 
368.7156
4 
246.146
18 
7 
1
9 
2366.085
15 
1183.546
22 
789.366
57 
2394.080
07 
1197.543
67 
798.698
21 
G 589.3555
8 
295.1814
3 
197.123
38 
6 
2
0 
2465.153
57 
1233.080
43 
822.389
38 
2493.148
49 
1247.077
88 
831.721
01 
V 532.3341
1 
266.6706
9 
178.116
22 
5 
2
1 
2566.201
25 
1283.604
27 
856.071
94 
2594.196
17 
1297.601
72 
865.403
57 
T 433.2656
9 
217.1364
8 
145.093
41 
4 
2
2 
2667.248
93 
1334.128
11 
889.754
50 
2695.243
85 
1348.125
56 
899.086
13 
T 332.2180
1 
166.6126
4 
111.410
85 
3 
2
3 
2766.317
35 
1383.662
32 
922.777
30 
2794.312
27 
1397.659
77 
932.108
94 
V 231.1703
3 
116.0888
0 
77.7282
9 
2 
2
4 
            L 132.1019
1 
66.55459 44.7054
9 
1 
 
290-R*TVFGV*TTVLTMTTLSISARNSLPKV-315 
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#
1  
a⁺   a²⁺   a³⁺   b⁺   b²⁺   b³⁺   Seq.   y⁺   y²⁺   y³⁺   #
2  
1 359.1112
7 
180.0592
7 
120.3752
8 
387.1061
9 
194.0567
3 
129.7069
1 
R-AziSev       2
6 
2 460.1589
5 
230.5831
1 
154.0578
4 
488.1538
7 
244.5805
7 
163.3894
7 
T 2867.451
08 
1434.229
18 
956.488
54 
2
5 
3 559.2273
7 
280.1173
2 
187.0806
4 
587.2222
9 
294.1147
8 
196.4122
8 
V 2766.403
40 
1383.705
34 
922.805
98 
2
4 
4 706.2957
9 
353.6515
3 
236.1034
5 
734.2907
1 
367.6489
9 
245.4350
9 
F 2667.334
98 
1334.171
13 
889.783
18 
2
3 
5 763.3172
6 
382.1622
7 
255.1106
1 
791.3121
8 
396.1597
3 
264.4422
4 
G 2520.266
56 
1260.636
92 
840.760
37 
2
2 
6 1092.383
47 
546.6953
7 
364.7993
4 
1120.378
39 
560.6928
3 
374.1309
8 
V-AziSev 2463.245
09 
1232.126
18 
821.753
21 
2
1 
7 1193.431
15 
597.2192
1 
398.4819
0 
1221.426
07 
611.2166
7 
407.8135
4 
T 2134.178
88 
1067.593
08 
712.064
48 
2
0 
8 1294.478
83 
647.7430
5 
432.1644
6 
1322.473
75 
661.7405
1 
441.4961
0 
T 2033.131
20 
1017.069
24 
678.381
92 
1
9 
9 1393.547
25 
697.2772
6 
465.1872
7 
1421.542
17 
711.2747
2 
474.5189
1 
V 1932.083
52 
966.5454
0 
644.699
36 
1
8 
1
0 
1506.631
32 
753.8193
0 
502.8819
6 
1534.626
24 
767.8167
6 
512.2136
0 
L 1833.015
10 
917.0111
9 
611.676
55 
1
7 
1
1 
1607.679
00 
804.3431
4 
536.5645
2 
1635.673
92 
818.3406
0 
545.8961
6 
T 1719.931
03 
860.4691
5 
573.981
86 
1
6 
1
2 
1738.719
50 
869.8633
9 
580.2446
9 
1766.714
42 
883.8608
5 
589.5763
2 
M 1618.883
35 
809.9453
1 
540.299
30 
1
5 
1
3 
1839.767
18 
920.3872
3 
613.9272
5 
1867.762
10 
934.3846
9 
623.2588
8 
T 1487.842
85 
744.4250
6 
496.619
13 
1
4 
1
4 
1940.814
86 
970.9110
7 
647.6098
1 
1968.809
78 
984.9085
3 
656.9414
4 
T 1386.795
17 
693.9012
2 
462.936
57 
1
3 
1
5 
2053.898
93 
1027.453
10 
685.3045
0 
2081.893
85 
1041.450
56 
694.6361
3 
L 1285.747
49 
643.3773
8 
429.254
01 
1
2 
1
6 
2140.930
96 
1070.969
12 
714.3151
7 
2168.925
88 
1084.966
58 
723.6468
1 
S 1172.663
42 
586.8353
5 
391.559
32 
1
1 
1
7 
2254.015
03 
1127.511
15 
752.0098
6 
2282.009
95 
1141.508
61 
761.3415
0 
I 1085.631
39 
543.3193
3 
362.548
65 
1
0 
1
8 
2341.047
06 
1171.027
17 
781.0205
4 
2369.041
98 
1185.024
63 
790.3521
8 
S 972.5473
2 
486.7773
0 
324.853
96 
9 
1
9 
2412.084
18 
1206.545
73 
804.6995
8 
2440.079
10 
1220.543
19 
814.0312
2 
A 885.5152
9 
443.2612
8 
295.843
28 
8 
2
0 
2568.185
30 
1284.596
29 
856.7332
9 
2596.180
22 
1298.593
75 
866.0649
2 
R 814.4781
7 
407.7427
2 
272.164
24 
7 
2
1 
2683.212
25 
1342.109
76 
895.0756
0 
2711.207
16 
1356.107
22 
904.4072
4 
N-
Deamidate
d 
658.3770
5 
329.6921
6 
220.130
53 
6 
2
2 
2770.244
28 
1385.625
78 
924.0862
8 
2798.239
19 
1399.623
23 
933.4179
2 
S 543.3501
0 
272.1786
9 
181.788
22 
5 
2
3 
2883.328
35 
1442.167
81 
961.7809
7 
2911.323
26 
1456.165
27 
971.1126
1 
L 456.3180
7 
228.6626
7 
152.777
54 
4 
2
4 
2980.381
12 
1490.694
20 
994.1318
9 
3008.376
03 
1504.691
65 
1003.463
53 
P 343.2340
0 
172.1206
4 
115.082
85 
3 
2
5 
3108.476
09 
1554.741
68 
1036.830
21 
3136.471
00 
1568.739
14 
1046.161
85 
K 246.1812
3 
123.5942
5 
82.7319
3 
2 
2
6 
            V 118.0862
6 
59.54677 40.0336
0 
1 
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292-VFGVT*TVLTMTTLSISARN-310 
 
#
1  
a⁺   a²⁺   a³⁺   b⁺   b²⁺   b³⁺   Seq.   y⁺   y²⁺   y³⁺  
#
2  
1 72.08078 36.54403 24.6984
5 
100.0757
0 
50.54149 34.0300
8 
V       1
9 
2 219.1492
0 
110.0782
4 
73.7212
5 
247.1441
2 
124.0757
0 
83.0528
9 
F 2158.997
63 
1080.002
45 
720.337
40 
1
8 
3 276.1706
7 
138.5889
7 
92.7284
1 
304.1655
9 
152.5864
3 
102.060
05 
G 2011.929
21 
1006.468
24 
671.314
59 
1
7 
4 375.2390
9 
188.1231
8 
125.751
22 
403.2340
1 
202.1206
4 
135.082
85 
V 1954.907
74 
977.9575
1 
652.307
43 
1
6 
5 706.2845
6 
353.6459
2 
236.099
71 
734.2794
8 
367.6433
8 
245.431
34 
T-AziSev 1855.839
32 
928.4233
0 
619.284
63 
1
5 
6 807.3322
4 
404.1697
6 
269.782
27 
835.3271
6 
418.1672
2 
279.113
90 
T 1524.793
85 
762.9005
6 
508.936
14 
1
4 
7 906.4006
6 
453.7039
7 
302.805
07 
934.3955
8 
467.7014
3 
312.136
71 
V 1423.746
17 
712.3767
2 
475.253
58 
1
3 
8 1019.484
73 
510.2460
0 
340.499
76 
1047.479
65 
524.2434
6 
349.831
40 
L 1324.677
75 
662.8425
1 
442.230
77 
1
2 
9 1120.532
41 
560.7698
4 
374.182
32 
1148.527
33 
574.7673
0 
383.513
96 
T 1211.593
68 
606.3004
8 
404.536
08 
1
1 
1
0 
1267.567
83 
634.2875
5 
423.194
13 
1295.562
74 
648.2850
1 
432.525
76 
M-
Oxidation 
1110.546
00 
555.7766
4 
370.853
52 
1
0 
1
1 
1368.615
51 
684.8113
9 
456.876
69 
1396.610
42 
698.8088
5 
466.208
32 
T 963.5105
9 
482.2589
3 
321.841
71 
9 
1
2 
1469.663
19 
735.3352
3 
490.559
25 
1497.658
10 
749.3326
9 
499.890
88 
T 862.4629
1 
431.7350
9 
288.159
15 
8 
1
3 
1582.747
26 
791.8772
7 
528.253
94 
1610.742
17 
805.8747
2 
537.585
57 
L 761.4152
3 
381.2112
5 
254.476
59 
7 
1
4 
1669.779
29 
835.3932
8 
557.264
61 
1697.774
20 
849.3907
4 
566.596
25 
S 648.3311
6 
324.6692
2 
216.781
90 
6 
1
5 
1782.863
36 
891.9353
2 
594.959
30 
1810.858
27 
905.9327
7 
604.290
94 
I 561.2991
3 
281.1532
0 
187.771
23 
5 
1
6 
1869.895
39 
935.4513
3 
623.969
98 
1897.890
30 
949.4487
9 
633.301
62 
S 448.2150
6 
224.6111
7 
150.076
54 
4 
1
7 
1940.932
51 
970.9698
9 
647.649
02 
1968.927
42 
984.9673
5 
656.980
66 
A 361.1830
3 
181.0951
5 
121.065
86 
3 
1
8 
2097.033
63 
1049.020
45 
699.682
73 
2125.028
54 
1063.017
91 
709.014
36 
R 290.1459
1 
145.5765
9 
97.3868
2 
2 
1
9 
            N-
Deamidate
d 
134.0447
9 
67.52603 45.3531
1 
1 
 
294-GVTTVLT*MTTLSISARN-310 
153 
 
 
#
1  
a⁺   a²⁺   a³⁺   a⁴⁺   b⁺   b²⁺   b³⁺   b⁴⁺   Seq.   y⁺   y²⁺   y³⁺   y⁴⁺  
#
2  
1 30.033
83 
15.52
055 
10.68
280 
8.263
92 
58.028
75 
29.51
801 
20.01
443 
15.26
264 
G         1
7 
2 129.10
225 
65.05
476 
43.70
560 
33.03
102 
157.09
717 
79.05
222 
53.03
724 
40.02
975 
V 1938.9
1283 
969.9
6005 
646.9
7579 
485.4
8366 
1
6 
3 230.14
993 
115.5
7860 
77.38
816 
58.29
294 
258.14
485 
129.5
7606 
86.71
980 
65.29
167 
T 1839.8
4441 
920.4
2584 
613.9
5299 
460.7
1656 
1
5 
4 331.19
761 
166.1
0244 
111.0
7072 
83.55
486 
359.19
253 
180.0
9990 
120.4
0236 
90.55
359 
T 1738.7
9673 
869.9
0200 
580.2
7043 
435.4
5464 
1
4 
5 430.26
603 
215.6
3665 
144.0
9353 
108.3
2197 
458.26
095 
229.6
3411 
153.4
2517 
115.3
2069 
V 1637.7
4905 
819.3
7816 
546.5
8787 
410.1
9272 
1
3 
6 543.35
010 
272.1
7869 
181.7
8822 
136.5
9298 
571.34
502 
286.1
7615 
191.1
1986 
143.5
9171 
L 1538.6
8063 
769.8
4395 
513.5
6506 
385.4
2561 
1
2 
7 874.39
557 
437.7
0142 
292.1
3671 
219.3
5435 
902.39
049 
451.6
9888 
301.4
6835 
226.3
5308 
T-
AziSev 
1425.5
9656 
713.3
0192 
475.8
7037 
357.1
5460 
1
1 
8 1005.4
3607 
503.2
2167 
335.8
1688 
252.1
1448 
1033.4
3099 
517.2
1913 
345.1
4851 
259.1
1320 
M 1094.5
5109 
547.7
7918 
365.5
2188 
274.3
9323 
1
0 
9 1106.4
8375 
553.7
4551 
369.4
9944 
277.3
7640 
1134.4
7867 
567.7
4297 
378.8
3107 
284.3
7512 
T 963.51
059 
482.2
5893 
321.8
4171 
241.6
3310 
9 
1
0 
1207.5
3143 
604.2
6935 
403.1
8200 
302.6
3832 
1235.5
2635 
618.2
6681 
412.5
1363 
309.6
3704 
T 862.46
291 
431.7
3509 
288.1
5915 
216.3
7118 
8 
1
1 
1320.6
1550 
660.8
1139 
440.8
7669 
330.9
0933 
1348.6
1042 
674.8
0885 
450.2
0832 
337.9
0806 
L 761.41
523 
381.2
1125 
254.4
7659 
191.1
0926 
7 
1
2 
1407.6
4753 
704.3
2740 
469.8
8736 
352.6
6734 
1435.6
4245 
718.3
2486 
479.2
1900 
359.6
6607 
S 648.33
116 
324.6
6922 
216.7
8190 
162.8
3825 
6 
1
3 
1520.7
3160 
760.8
6944 
507.5
8205 
380.9
3836 
1548.7
2652 
774.8
6690 
516.9
1369 
387.9
3709 
I 561.29
913 
281.1
5320 
187.7
7123 
141.0
8024 
5 
1
4 
1607.7
6363 
804.3
8545 
536.5
9273 
402.6
9637 
1635.7
5855 
818.3
8291 
545.9
2437 
409.6
9509 
S 448.21
506 
224.6
1117 
150.0
7654 
112.8
0922 
4 
1
5 
1678.8
0075 
839.9
0401 
560.2
7177 
420.4
5565 
1706.7
9567 
853.9
0147 
569.6
0341 
427.4
5437 
A 361.18
303 
181.0
9515 
121.0
6586 
91.05
121 
3 
1
6 
1834.9
0187 
917.9
5457 
612.3
0548 
459.4
8093 
1862.8
9679 
931.9
5203 
621.6
3711 
466.4
7965 
R 290.14
591 
145.5
7659 
97.38
682 
73.29
193 
2 
1
7 
                N-
Deamid
ated 
134.04
479 
67.52
603 
45.35
311 
34.26
665 
1 
 
β3 GABAA receptor subunit 
273-A*ARVALGITTVL-284 
154 
 
 
#
1   a⁺   a²⁺   a³⁺   b⁺   b²⁺   b³⁺   Seq.   y⁺   y²⁺   y³⁺  
#
2  
1 274.0472
7 
137.527
27 
92.0206
1 
302.0421
9 
151.524
73 
101.352
25 
A-
AziSev 
      1
2 
2 345.0843
9 
173.045
83 
115.699
65 
373.0793
1 
187.043
29 
125.031
29 
A 1113.699
08 
557.353
18 
371.904
54 
1
1 
3 501.1855
1 
251.096
39 
167.733
36 
529.1804
3 
265.093
85 
177.064
99 
R 1042.661
96 
521.834
62 
348.225
50 
1
0 
4 600.2539
3 
300.630
60 
200.756
16 
628.2488
5 
314.628
06 
210.087
80 
V 886.5608
4 
443.784
06 
296.191
80 
9 
5 671.2910
5 
336.149
16 
224.435
20 
699.2859
7 
350.146
62 
233.766
84 
A 787.4924
2 
394.249
85 
263.168
99 
8 
6 784.3751
2 
392.691
20 
262.129
89 
812.3700
4 
406.688
66 
271.461
53 
L 716.4553
0 
358.731
29 
239.489
95 
7 
7 841.3965
9 
421.201
93 
281.137
05 
869.3915
1 
435.199
39 
290.468
69 
G 603.3712
3 
302.189
25 
201.795
26 
6 
8 954.4806
6 
477.743
97 
318.831
74 
982.4755
8 
491.741
43 
328.163
38 
I 546.3497
6 
273.678
52 
182.788
10 
5 
9 1055.528
34 
528.267
81 
352.514
30 
1083.523
26 
542.265
27 
361.845
94 
T 433.2656
9 
217.136
48 
145.093
41 
4 
1
0 
1156.576
02 
578.791
65 
386.196
86 
1184.570
94 
592.789
11 
395.528
50 
T 332.2180
1 
166.612
64 
111.410
85 
3 
1
1 
1255.644
44 
628.325
86 
419.219
67 
1283.639
36 
642.323
32 
428.551
30 
V 231.1703
3 
116.088
80 
77.7282
9 
2 
1
2 
            L 132.1019
1 
66.5545
9 
44.7054
9 
1 
 
γ2L-L3-1D4 GABAA receptor subunit 
304-RTSL*GITTVLT-314 
 
#1   a⁺   a²⁺   b⁺   b²⁺   Seq.   y⁺   y²⁺   #2  
1 129.11348 65.06038 157.10840 79.05784 R     11 
155 
 
2 230.16116 115.58422 258.15608 129.58168 T 1235.58048 618.29388 10 
3 317.19319 159.10023 345.18811 173.09769 S 1134.53280 567.77004 9 
4 660.27505 330.64116 688.26997 344.63862 L-AziSev 1047.50077 524.25402 8 
5 717.29652 359.15190 745.29144 373.14936 G 704.41891 352.71309 7 
6 830.38059 415.69393 858.37551 429.69139 I 647.39744 324.20236 6 
7 931.42827 466.21777 959.42319 480.21523 T 534.31337 267.66032 5 
8 1032.47595 516.74161 1060.47087 530.73907 T 433.26569 217.13648 4 
9 1131.54437 566.27582 1159.53929 580.27328 V 332.21801 166.61264 3 
10 1244.62844 622.81786 1272.62336 636.81532 L 233.14959 117.07843 2 
11         T 120.06552 60.53640 1 
 
294-WINKDAVPARTSLG*ITTV-312 
 
#1   a⁺   a²⁺   b⁺   b²⁺   Seq.   y⁺   y²⁺   #2  
1 159.09168 80.04948 187.08660 94.04694 W     18 
2 272.17575 136.59151 300.17067 150.58897 I 1986.97822 993.99275 17 
3 387.20270 194.10499 415.19761 208.10244 N-Deamidated 1873.89415 937.45071 16 
4 515.29767 258.15247 543.29258 272.14993 K 1758.86720 879.93724 15 
5 630.32462 315.66595 658.31953 329.66340 D 1630.77223 815.88975 14 
6 701.36174 351.18451 729.35665 365.18196 A 1515.74528 758.37628 13 
7 800.43016 400.71872 828.42507 414.71617 V 1444.70816 722.85772 12 
8 897.48293 449.24510 925.47784 463.24256 P 1345.63974 673.32351 11 
9 968.52005 484.76366 996.51496 498.76112 A 1248.58697 624.79712 10 
10 1124.62117 562.81422 1152.61608 576.81168 R 1177.54985 589.27856 9 
11 1225.66885 613.33806 1253.66376 627.33552 T 1021.44873 511.22800 8 
12 1312.70088 656.85408 1340.69579 670.85153 S 920.40105 460.70416 7 
13 1425.78495 713.39611 1453.77986 727.39357 L 833.36902 417.18815 6 
14 1712.80421 856.90574 1740.79912 870.90320 G-AziSev 720.28495 360.64611 5 
15 1825.88828 913.44778 1853.88319 927.44523 I 433.26569 217.13648 4 
16 1926.93596 963.97162 1954.93087 977.96907 T 320.18162 160.59445 3 
17 2027.98364 1014.49546 2055.97855 1028.49291 T 219.13394 110.07061 2 
18         V 118.08626 59.54677 1 
 
 
A.4.4. α1β3γ2L GABAA receptor peptides photoaffinity labeled by aziisoflurane 
FLAG-α1 GABAA receptor subunit 
156 
 
282-LNRE*SVPA-289 
 
#1   a⁺   a²⁺   b⁺   b²⁺   Seq.   y⁺   y²⁺   #2  
1 86.09643 43.55185 114.09135 57.54931 L     8 
2 201.12338 101.06533 229.11829 115.06278 N-Deamidated 969.35028 485.17878 7 
3 357.22450 179.11589 385.21941 193.11334 R 854.32334 427.66531 6 
4 682.23853 341.62290 710.23345 355.62036 E-AziIso 698.22222 349.61475 5 
5 769.27056 385.13892 797.26548 399.13638 S 373.20818 187.10773 4 
6 868.33898 434.67313 896.33390 448.67059 V 286.17615 143.59171 3 
7 965.39175 483.19951 993.38667 497.19697 P 187.10773 94.05750 2 
8         A 90.05496 45.53112 1 
 
303-TLSISARNSLP*KV-315 
 
#1   a⁺   a²⁺   b⁺   b²⁺   Seq.   y⁺   y²⁺   #2  
1 74.06004 37.53366 102.05496 51.53112 T     13 
2 187.14411 94.07569 215.13903 108.07315 L 1481.71892 741.36310 12 
3 274.17614 137.59171 302.17106 151.58917 S 1368.63485 684.82106 11 
4 387.26021 194.13374 415.25513 208.13120 I 1281.60282 641.30505 10 
5 474.29224 237.64976 502.28716 251.64722 S 1168.51875 584.76301 9 
6 545.32936 273.16832 573.32428 287.16578 A 1081.48672 541.24700 8 
7 701.43048 351.21888 729.42540 365.21634 R 1010.44960 505.72844 7 
8 816.45743 408.73235 844.45234 422.72981 N-Deamidated 854.34848 427.67788 6 
9 903.48946 452.24837 931.48437 466.24582 S 739.32154 370.16441 5 
157 
 
10 1016.57353 508.79040 1044.56844 522.78786 L 652.28951 326.64839 4 
11 1309.59773 655.30250 1337.59265 669.29996 P-AziIso 539.20544 270.10636 3 
12 1437.69270 719.34999 1465.68762 733.34745 K 246.18123 123.59425 2 
13         V 118.08626 59.54677 1 
 
302-TTLSISARNS*LPKVAYATAMD-222 
 
#
1   a⁺   a²⁺   a³⁺   b⁺   b²⁺   b³⁺   Seq.   y⁺   y²⁺   y³⁺  
#
2  
1 74.06004 37.53366 25.3582
0 
102.0549
6 
51.53112 34.6898
4 
T       2
1 
2 175.1077
2 
88.05750 59.0407
6 
203.1026
4 
102.0549
6 
68.3724
0 
T 2322.051
33 
1161.529
30 
774.688
63 
2
0 
3 288.1917
9 
144.5995
3 
96.7354
5 
316.1867
1 
158.5969
9 
106.067
09 
L 2221.003
65 
1111.005
46 
741.006
07 
1
9 
4 375.2238
2 
188.1155
5 
125.746
13 
403.2187
4 
202.1130
1 
135.077
76 
S 2107.919
58 
1054.463
43 
703.311
38 
1
8 
5 488.3078
9 
244.6575
8 
163.440
82 
516.3028
1 
258.6550
4 
172.772
45 
I 2020.887
55 
1010.947
41 
674.300
70 
1
7 
6 575.3399
2 
288.1736
0 
192.451
49 
603.3348
4 
302.1710
6 
201.783
13 
S 1907.803
48 
954.4053
8 
636.606
01 
1
6 
7 646.3770
4 
323.6921
6 
216.130
53 
674.3719
6 
337.6896
2 
225.462
17 
A 1820.771
45 
910.8893
6 
607.595
33 
1
5 
8 802.4781
6 
401.7427
2 
268.164
24 
830.4730
8 
415.7401
8 
277.495
88 
R 1749.734
33 
875.3708
0 
583.916
29 
1
4 
9 917.5051
1 
459.2561
9 
306.506
55 
945.5000
2 
473.2536
5 
315.838
19 
N-
Deamidate
d 
1593.633
21 
797.3202
4 
531.882
59 
1
3 
1
0 
1200.508
57 
600.7579
2 
400.841
04 
1228.503
49 
614.7553
8 
410.172
68 
S-AziIso 1478.606
26 
739.8067
7 
493.540
27 
1
2 
1
1 
1313.592
64 
657.2999
6 
438.535
73 
1341.587
56 
671.2974
2 
447.867
37 
L 1195.602
80 
598.3050
4 
399.205
78 
1
1 
1
2 
1410.645
41 
705.8263
4 
470.886
66 
1438.640
33 
719.8238
0 
480.218
29 
P 1082.518
73 
541.7630
0 
361.511
09 
1
0 
1
3 
1538.740
38 
769.8738
3 
513.584
98 
1566.735
30 
783.8712
9 
522.916
62 
K 985.4659
6 
493.2366
2 
329.160
17 
9 
1
4 
1637.808
80 
819.4080
4 
546.607
79 
1665.803
72 
833.4055
0 
555.939
42 
V 857.3709
9 
429.1891
3 
286.461
85 
8 
1
5 
1708.845
92 
854.9266
0 
570.286
83 
1736.840
84 
868.9240
6 
579.618
46 
A 758.3025
7 
379.6549
2 
253.439
04 
7 
1
6 
1871.909
24 
936.4582
6 
624.641
27 
1899.904
16 
950.4557
2 
633.972
90 
Y 687.2654
5 
344.1363
6 
229.760
00 
6 
1
7 
1942.946
36 
971.9768
2 
648.320
31 
1970.941
28 
985.9742
8 
657.651
94 
A 524.2021
3 
262.6047
0 
175.405
56 
5 
1
8 
2043.994
04 
1022.500
66 
682.002
87 
2071.988
96 
1036.498
12 
691.334
50 
T 453.1650
1 
227.0861
4 
151.726
52 
4 
1
9 
2115.031
16 
1058.019
22 
705.681
91 
2143.026
08 
1072.016
68 
715.013
54 
A 352.1173
3 
176.5623
0 
118.043
96 
3 
2
0 
2262.066
58 
1131.536
93 
754.693
71 
2290.061
49 
1145.534
38 
764.025
35 
M-
Oxidation 
281.0802
1 
141.0437
4 
94.3649
2 
2 
2
1 
            D 134.0447
9 
67.52603 45.3531
1 
1 
 
158 
 
β3 GABAA receptor subunit 
241-RNIGYFILQ*-249 
 
#1   a⁺   a²⁺   b⁺   b²⁺   Seq.   y⁺   y²⁺   #2  
1 129.11348 65.06038 157.10840 79.05784 R     9 
2 244.14043 122.57385 272.13534 136.57131 N-Deamidated 1164.48022 582.74375 8 
3 357.22450 179.11589 385.21941 193.11334 I 1049.45328 525.23028 7 
4 414.24597 207.62662 442.24088 221.62408 G 936.36921 468.68824 6 
5 577.30929 289.15828 605.30420 303.15574 Y 879.34774 440.17751 5 
6 724.37771 362.69249 752.37262 376.68995 F 716.28442 358.64585 4 
7 837.46178 419.23453 865.45669 433.23198 I 569.21600 285.11164 3 
8 950.54585 475.77656 978.54076 489.77402 L 456.13193 228.56960 2 
9         Q-AziIso 343.04786 172.02757 1 
 
247-I*LQTY*MPSILITI-259 
 
#1   a⁺   a²⁺   b⁺   b²⁺   Seq.   y⁺   y²⁺   #2  
1 282.06787 141.53757 310.06278 155.53503 I-AziIs     13 
2 395.15194 198.07961 423.14685 212.07706 L 1588.75219 794.87973 12 
3 523.21052 262.10890 551.20543 276.10635 Q 1475.66812 738.33770 11 
4 624.25820 312.63274 652.25311 326.63019 T 1347.60954 674.30841 10 
5 983.29295 492.15011 1011.28786 506.14757 Y-AziIso 1246.56186 623.78457 9 
6 1114.33345 557.67036 1142.32836 571.66782 M 887.52710 444.26719 8 
7 1211.38622 606.19675 1239.38113 620.19421 P 756.48660 378.74694 7 
159 
 
8 1298.41825 649.71276 1326.41316 663.71022 S 659.43383 330.22055 6 
9 1411.50232 706.25480 1439.49723 720.25226 I 572.40180 286.70454 5 
10 1524.58639 762.79683 1552.58130 776.79429 L 459.31773 230.16250 4 
11 1637.67046 819.33887 1665.66537 833.33633 I 346.23366 173.62047 3 
12 1738.71814 869.86271 1766.71305 883.86017 T 233.14959 117.07843 2 
13         I 132.10191 66.55459 1 
 
274-ARVALGI*TTVLTMTTI*NT-300 
 
#
1  
a⁺   a²⁺   a³⁺   a⁴⁺   b⁺   b²⁺   b³⁺   b⁴⁺   Seq.   y⁺   y²⁺   y³⁺   y⁴⁺  
#
2  
1 44.049
48 
22.528
38 
15.35
468 
11.76
783 
72.044
40 
36.525
84 
24.68
632 
18.76
656 
A         1
8 
2 200.15
060 
100.57
894 
67.38
839 
50.79
311 
228.14
552 
114.57
640 
76.72
002 
57.79
184 
R 2213.9
4198 
1107.4
7463 
738.6
5218 
554.2
4095 
1
7 
3 299.21
902 
150.11
315 
100.4
1119 
75.56
021 
327.21
394 
164.11
061 
109.7
4283 
82.55
894 
V 2057.8
4086 
1029.4
2407 
686.6
1847 
515.2
1567 
1
6 
4 370.25
614 
185.63
171 
124.0
9023 
93.31
949 
398.25
106 
199.62
917 
133.4
2187 
100.3
1822 
A 1958.7
7244 
979.88
986 
653.5
9566 
490.4
4857 
1
5 
5 483.34
021 
242.17
374 
161.7
8492 
121.5
9051 
511.33
513 
256.17
120 
171.1
1656 
128.5
8924 
L 1887.7
3532 
944.37
130 
629.9
1662 
472.6
8929 
1
4 
6 540.36
168 
270.68
448 
180.7
9208 
135.8
4588 
568.35
660 
284.68
194 
190.1
2372 
142.8
4461 
G 1774.6
5125 
887.82
926 
592.2
2193 
444.4
1827 
1
3 
7 849.41
719 
425.21
223 
283.8
1058 
213.1
0975 
877.41
210 
439.20
969 
293.1
4222 
220.1
0848 
I-AziIso 1717.6
2978 
859.31
853 
573.2
1478 
430.1
6290 
1
2 
8 950.46
487 
475.73
607 
317.4
9314 
238.3
7167 
978.45
978 
489.73
353 
326.8
2478 
245.3
7040 
T 1408.5
7428 
704.79
078 
470.1
9628 
352.8
9903 
1
1 
9 1051.5
1255 
526.25
991 
351.1
7570 
263.6
3359 
1079.5
0746 
540.25
737 
360.5
0734 
270.6
3232 
T 1307.5
2660 
654.26
694 
436.5
1372 
327.6
3711 
1
0 
1
0 
1150.5
8097 
575.79
412 
384.1
9851 
288.4
0070 
1178.5
7588 
589.79
158 
393.5
3014 
295.3
9943 
V 1206.4
7892 
603.74
310 
402.8
3116 
302.3
7519 
9 
1
1 
1263.6
6504 
632.33
616 
421.8
9320 
316.6
7172 
1291.6
5995 
646.33
361 
431.2
2483 
323.6
7045 
L 1107.4
1050 
554.20
889 
369.8
0835 
277.6
0808 
8 
1
2 
1364.7
1272 
682.86
000 
455.5
7576 
341.9
3364 
1392.7
0763 
696.85
745 
464.9
0739 
348.9
3237 
T 994.32
643 
497.66
685 
332.1
1366 
249.3
3706 
7 
1
3 
1511.7
4813 
756.37
770 
504.5
8756 
378.6
9249 
1539.7
4305 
770.37
516 
513.9
1920 
385.6
9122 
M-
Oxidatio
n 
893.27
875 
447.14
301 
298.4
3110 
224.0
7514 
6 
1
4 
1612.7
9581 
806.90
154 
538.2
7012 
403.9
5441 
1640.7
9073 
820.89
900 
547.6
0176 
410.9
5314 
T 746.24
333 
373.62
530 
249.4
1929 
187.3
1629 
5 
1
5 
1713.8
4349 
857.42
538 
571.9
5268 
429.2
1633 
1741.8
3841 
871.42
284 
581.2
8432 
436.2
1506 
T 645.19
565 
323.10
146 
215.7
3673 
162.0
5437 
4 
1
6 
2022.8
9900 
1011.9
5314 
674.9
7118 
506.4
8021 
2050.8
9391 
1025.9
5059 
684.3
0282 
513.4
7893 
I-AziIso 544.14
797 
272.57
762 
182.0
5417 
136.7
9245 
3 
1
7 
2137.9
2594 
1069.4
6661 
713.3
1350 
535.2
3694 
2165.9
2086 
1083.4
6407 
722.6
4514 
542.2
3567 
N-
Deamid
ated 
235.09
247 
118.04
987 
79.03
567 
59.52
857 
2 
1
8 
                T 120.06
552 
60.536
40 
40.69
336 
30.77
184 
1 
 
γ2L-L3-1D4 GABAA receptor subunit 
160 
 
 
 
#
1   a⁺   a²⁺   a³⁺   b⁺   b²⁺   b³⁺   Seq.   y⁺   y²⁺   y³⁺  
#
2  
1 129.113
48 
65.0603
8 
43.7093
5 
157.108
40 
79.0578
4 
53.0409
8 
R       2
0 
2 276.148
90 
138.578
09 
92.7211
5 
304.143
81 
152.575
54 
102.052
79 
M-Oxidation 2431.11
548 
1216.06
138 
811.043
35 
1
9 
3 333.170
37 
167.088
82 
111.728
31 
361.165
28 
181.086
28 
121.059
94 
G 2284.08
007 
1142.54
367 
762.031
54 
1
8 
4 496.233
69 
248.620
48 
166.082
75 
524.228
60 
262.617
94 
175.414
38 
Y 2227.05
860 
1114.03
294 
743.024
38 
1
7 
5 643.302
11 
322.154
69 
215.105
55 
671.297
02 
336.152
15 
224.437
19 
F 2063.99
528 
1032.50
128 
688.669
94 
1
6 
6 744.349
79 
372.678
53 
248.788
11 
772.344
70 
386.675
99 
258.119
75 
T 1916.92
686 
958.967
07 
639.647
14 
1
5 
7 857.433
86 
429.220
57 
286.482
80 
885.428
77 
443.218
02 
295.814
44 
I 1815.87
918 
908.443
23 
605.964
58 
1
4 
8 985.492
44 
493.249
86 
329.169
00 
1013.48
735 
507.247
31 
338.500
63 
Q 1702.79
511 
851.901
19 
568.269
89 
1
3 
9 1086.54
012 
543.773
70 
362.851
56 
1114.53
503 
557.771
15 
372.183
19 
T 1574.73
653 
787.871
90 
525.583
69 
1
2 
1
0 
1445.57
487 
723.291
07 
482.529
81 
1473.56
979 
737.288
53 
491.861
45 
Y-AziIso 1473.68
885 
737.348
06 
491.901
13 
1
1 
1
1 
1558.65
894 
779.833
11 
520.224
50 
1586.65
386 
793.830
57 
529.556
14 
I 1114.65
410 
557.830
69 
372.222
88 
1
0 
1
2 
1655.71
171 
828.359
49 
552.575
42 
1683.70
663 
842.356
95 
561.907
06 
P 1001.57
003 
501.288
65 
334.528
19 
9 
1
3 
1815.74
237 
908.374
82 
605.918
97 
1843.73
728 
922.372
28 
615.250
61 
C-
Carbamidomet
hyl 
904.517
26 
452.762
27 
302.177
27 
8 
1
4 
1916.79
005 
958.898
66 
639.601
53 
1944.78
496 
972.896
12 
648.933
17 
T 744.486
60 
372.746
94 
248.833
72 
7 
1
5 
2029.87
412 
1015.44
070 
677.296
22 
2057.86
903 
1029.43
815 
686.627
86 
L 643.438
92 
322.223
10 
215.151
16 
6 
1
6 
2142.95
819 
1071.98
273 
714.990
91 
2170.95
310 
1085.98
019 
724.322
55 
I 530.354
85 
265.681
06 
177.456
47 
5 
1
7 
2242.02
661 
1121.51
694 
748.013
72 
2270.02
152 
1135.51
440 
757.345
36 
V 417.270
78 
209.139
03 
139.761
78 
4 
1
8 
2341.09
503 
1171.05
115 
781.036
53 
2369.08
994 
1185.04
861 
790.368
16 
V 318.202
36 
159.604
82 
106.738
97 
3 
1
9 
2454.17
910 
1227.59
319 
818.731
22 
2482.17
401 
1241.59
064 
828.062
85 
L 219.133
94 
110.070
61 
73.7161
6 
2 
2
0 
            S 106.049
87 
53.5285
7 
36.0214
7 
1 
 
A.4.5. α1β3 GABAA receptor peptides photoaffinity labeled by azisevoflurane(1a) 
FLAG-α1 GABAA receptor subunit 
227-SKIWTPDTFFHNG*KKSVAHN-446 
161 
 
 
#
1  
a⁺   a²⁺   a³⁺   b⁺   b²⁺   b³⁺   Seq.   y⁺   y²⁺   y³⁺   #
2  
1 60.04439 30.52583 20.6863
2 
88.03931 44.52329 30.0179
5 
S       2
1 
2 188.1393
6 
94.57332 63.3846
4 
216.1342
8 
108.5707
8 
72.7162
8 
K 2604.173
99 
1302.590
63 
868.729
51 
2
0 
3 301.2234
3 
151.1153
5 
101.079
33 
329.2183
5 
165.1128
1 
110.410
97 
I 2476.079
02 
1238.543
15 
826.031
19 
1
9 
4 487.3027
5 
244.1550
1 
163.105
77 
515.2976
7 
258.1524
7 
172.437
41 
W 2362.994
95 
1182.001
11 
788.336
50 
1
8 
5 588.3504
3 
294.6788
5 
196.788
33 
616.3453
5 
308.6763
1 
206.119
97 
T 2176.915
63 
1088.961
45 
726.310
06 
1
7 
6 685.4032
0 
343.2052
4 
229.139
25 
713.3981
2 
357.2027
0 
238.470
89 
P 2075.867
95 
1038.437
61 
692.627
50 
1
6 
7 800.4301
5 
400.7187
1 
267.481
57 
828.4250
7 
414.7161
7 
276.813
21 
D 1978.815
18 
989.9112
3 
660.276
58 
1
5 
8 901.4778
3 
451.2425
5 
301.164
13 
929.4727
5 
465.2400
1 
310.495
77 
T 1863.788
23 
932.3977
5 
621.934
26 
1
4 
9 1048.546
25 
524.7767
6 
350.186
94 
1076.541
17 
538.7742
2 
359.518
57 
F 1762.740
55 
881.8739
1 
588.251
70 
1
3 
1
0 
1195.614
67 
598.3109
7 
399.209
74 
1223.609
59 
612.3084
3 
408.541
38 
F 1615.672
13 
808.3397
0 
539.228
89 
1
2 
1
1 
1332.673
58 
666.8404
3 
444.896
05 
1360.668
50 
680.8378
9 
454.227
68 
H 1468.603
71 
734.8054
9 
490.206
09 
1
1 
1
2 
1446.716
51 
723.8618
9 
482.910
36 
1474.711
43 
737.8593
5 
492.241
99 
N 1331.544
80 
666.2760
4 
444.519
78 
1
0 
1
3 
1733.735
77 
867.3715
2 
578.583
44 
1761.730
69 
881.3689
8 
587.915
08 
G-AziSev 1217.501
87 
609.2545
7 
406.505
47 
9 
1
4 
1861.830
74 
931.4190
1 
621.281
77 
1889.825
66 
945.4164
7 
630.613
40 
K 930.4826
1 
465.7449
4 
310.832
39 
8 
1
5 
1989.925
71 
995.4664
9 
663.980
09 
2017.920
63 
1009.463
95 
673.311
73 
K 802.3876
4 
401.6974
6 
268.134
06 
7 
1
6 
2076.957
74 
1038.982
51 
692.990
77 
2104.952
66 
1052.979
97 
702.322
40 
S 674.2926
7 
337.6499
7 
225.435
74 
6 
1
7 
2176.026
16 
1088.516
72 
726.013
57 
2204.021
08 
1102.514
18 
735.345
21 
V 587.2606
4 
294.1339
6 
196.425
06 
5 
1
8 
2247.063
28 
1124.035
28 
749.692
61 
2275.058
20 
1138.032
74 
759.024
25 
A 488.1922
2 
244.5997
5 
163.402
26 
4 
1
9 
2384.122
19 
1192.564
73 
795.378
92 
2412.117
11 
1206.562
19 
804.710
55 
H 417.1551
0 
209.0811
9 
139.723
22 
3 
2
0 
2498.165
12 
1249.586
20 
833.393
23 
2526.160
04 
1263.583
66 
842.724
86 
N 280.0961
9 
140.5517
3 
94.0369
1 
2 
2
1 
            M-
Oxidation 
166.0532
6 
83.53027 56.0226
0 
1 
 
286-SVP*ARTVFGVTTVLTMTTLS-305 
162 
 
 
#
1  
a⁺   a²⁺   a³⁺   b⁺   b²⁺   b³⁺   Seq.   y⁺   y²⁺   y³⁺   #
2  
1 60.04439 30.52583 20.6863
2 
88.03931 44.52329 30.0179
5 
S       2
0 
2 159.1128
1 
80.06004 53.7091
2 
187.1077
3 
94.05750 63.0407
6 
V 2224.096
96 
1112.552
12 
742.037
17 
1
9 
3 486.1633
7 
243.5853
2 
162.725
98 
514.1582
9 
257.5827
8 
172.057
61 
P-
AziSev 
2125.028
54 
1063.017
91 
709.014
36 
1
8 
4 557.2004
9 
279.1038
8 
186.405
02 
585.1954
1 
293.1013
4 
195.736
65 
A 1797.977
98 
899.4926
3 
599.997
51 
1
7 
5 713.3016
1 
357.1544
4 
238.438
72 
741.2965
3 
371.1519
0 
247.770
36 
R 1726.940
86 
863.9740
7 
576.318
47 
1
6 
6 814.3492
9 
407.6782
8 
272.121
28 
842.3442
1 
421.6757
4 
281.452
92 
T 1570.839
74 
785.9235
1 
524.284
76 
1
5 
7 913.4177
1 
457.2124
9 
305.144
09 
941.4126
3 
471.2099
5 
314.475
73 
V 1469.792
06 
735.3996
7 
490.602
20 
1
4 
8 1060.486
13 
530.7467
0 
354.166
90 
1088.481
05 
544.7441
6 
363.498
53 
F 1370.723
64 
685.8654
6 
457.579
40 
1
3 
9 1117.507
60 
559.2574
4 
373.174
05 
1145.502
52 
573.2549
0 
382.505
69 
G 1223.655
22 
612.3312
5 
408.556
59 
1
2 
1
0 
1216.576
02 
608.7916
5 
406.196
86 
1244.570
94 
622.7891
1 
415.528
50 
V 1166.633
75 
583.8205
1 
389.549
43 
1
1 
1
1 
1317.623
70 
659.3154
9 
439.879
42 
1345.618
62 
673.3129
5 
449.211
06 
T 1067.565
33 
534.2863
0 
356.526
63 
1
0 
1
2 
1418.671
38 
709.8393
3 
473.561
98 
1446.666
30 
723.8367
9 
482.893
62 
T 966.5176
5 
483.7624
6 
322.844
07 
9 
1
3 
1517.739
80 
759.3735
4 
506.584
79 
1545.734
72 
773.3710
0 
515.916
42 
V 865.4699
7 
433.2386
2 
289.161
51 
8 
1
4 
1630.823
87 
815.9155
7 
544.279
48 
1658.818
79 
829.9130
3 
553.611
11 
L 766.4015
5 
383.7044
1 
256.138
70 
7 
1
5 
1731.871
55 
866.4394
1 
577.962
04 
1759.866
47 
880.4368
7 
587.293
67 
T 653.3174
8 
327.1623
8 
218.444
01 
6 
1
6 
1862.912
05 
931.9596
6 
621.642
20 
1890.906
97 
945.9571
2 
630.973
84 
M 552.2698
0 
276.6385
4 
184.761
45 
5 
1
7 
1963.959
73 
982.4835
0 
655.324
76 
1991.954
65 
996.4809
6 
664.656
40 
T 421.2293
0 
211.1182
9 
141.081
28 
4 
1
8 
2065.007
41 
1033.007
34 
689.007
32 
2093.002
33 
1047.004
80 
698.338
96 
T 320.1816
2 
160.5944
5 
107.398
72 
3 
1
9 
2178.091
48 
1089.549
38 
726.702
01 
2206.086
40 
1103.546
84 
736.033
65 
L 219.1339
4 
110.0706
1 
73.7161
6 
2 
2
0 
            S 106.0498
7 
53.52857 36.0214
7 
1 
 
268-PC*IMTVILSQVS-279 
163 
 
 
#1   a⁺   a²⁺   b⁺   b²⁺   Seq.   y⁺   y²⁺   #2  
1 70.06513 35.53620 98.06005 49.53366 P     12 
2 403.07211 202.03969 431.06703 216.03715 C-AziSev 1423.62469 712.31598 11 
3 516.15618 258.58173 544.15110 272.57919 I 1090.61771 545.81249 10 
4 647.19668 324.10198 675.19160 338.09944 M 977.53364 489.27046 9 
5 748.24436 374.62582 776.23928 388.62328 T 846.49314 423.75021 8 
6 847.31278 424.16003 875.30770 438.15749 V 745.44546 373.22637 7 
7 960.39685 480.70206 988.39177 494.69952 I 646.37704 323.69216 6 
8 1073.48092 537.24410 1101.47584 551.24156 L 533.29297 267.15012 5 
9 1160.51295 580.76011 1188.50787 594.75757 S 420.20890 210.60809 4 
10 1288.57153 644.78940 1316.56645 658.78686 Q 333.17687 167.09207 3 
11 1387.63995 694.32361 1415.63487 708.32107 V 205.11829 103.06278 2 
12         S 106.04987 53.52857 1 
 
291-TV*FGVTTVLTMTTL-304 
 
#1   a⁺   a²⁺   b⁺   b²⁺   Seq.   y⁺   y²⁺   #2  
1 74.06004 37.53366 102.05496 51.53112 T     14 
2 403.12625 202.06676 431.12117 216.06422 V-AziSev 1628.75274 814.88001 13 
3 550.19467 275.60097 578.18959 289.59843 F 1299.68653 650.34690 12 
4 607.21614 304.11171 635.21106 318.10917 G 1152.61811 576.81269 11 
5 706.28456 353.64592 734.27948 367.64338 V 1095.59664 548.30196 10 
6 807.33224 404.16976 835.32716 418.16722 T 996.52822 498.76775 9 
164 
 
7 908.37992 454.69360 936.37484 468.69106 T 895.48054 448.24391 8 
8 1007.44834 504.22781 1035.44326 518.22527 V 794.43286 397.72007 7 
9 1120.53241 560.76984 1148.52733 574.76730 L 695.36444 348.18586 6 
10 1221.58009 611.29368 1249.57501 625.29114 T 582.28037 291.64382 5 
11 1368.61551 684.81139 1396.61042 698.80885 M-Oxidation 481.23269 241.11998 4 
12 1469.66319 735.33523 1497.65810 749.33269 T 334.19727 167.60227 3 
13 1570.71087 785.85907 1598.70578 799.85653 T 233.14959 117.07843 2 
14         L 132.10191 66.55459 1 
 
β3 GABAA receptor subunit 
197-DKAVTGVE*RIELP*QF-211 
 
#1   a⁺   a²⁺   b⁺   b²⁺   Seq.   y⁺   y²⁺   #2  
1 88.03931 44.52329 116.03423 58.52075 D     15 
2 216.13428 108.57078 244.12920 122.56824 K 2046.88573 1023.94650 14 
3 287.17140 144.08934 315.16632 158.08680 A 1918.79076 959.89902 13 
4 386.23982 193.62355 414.23474 207.62101 V 1847.75364 924.38046 12 
5 487.28750 244.14739 515.28242 258.14485 T 1748.68522 874.84625 11 
6 544.30897 272.65812 572.30389 286.65558 G 1647.63754 824.32241 10 
7 643.37739 322.19233 671.37231 336.18979 V 1590.61607 795.81167 9 
8 1002.41778 501.71253 1030.41270 515.70999 E-AziSev 1491.54765 746.27746 8 
9 1158.51890 579.76309 1186.51382 593.76055 R 1132.50726 566.75727 7 
10 1271.60297 636.30512 1299.59789 650.30258 I 976.40614 488.70671 6 
11 1400.64557 700.82642 1428.64049 714.82388 E 863.32207 432.16467 5 
12 1513.72964 757.36846 1541.72456 771.36592 L 734.27947 367.64337 4 
13 1840.78020 920.89374 1868.77512 934.89120 P-AziSev 621.19540 311.10134 3 
14 1968.83878 984.92303 1996.83370 998.92049 Q 294.14484 147.57606 2 
15         F 166.08626 83.54677 1 
 
266-W*INYDASAARVALGITTVLTMTTI-289 
165 
 
 
#
1   a⁺   a²⁺   a³⁺   a⁴⁺   b⁺   b²⁺   b³⁺   b⁴⁺   Seq.   y⁺   y²⁺   y³⁺   y⁴⁺  
#
2  
1 389.08
947 
195.04
837 
130.3
6801 
98.02
783 
417.08
439 
209.04
583 
139.6
9965 
105.0
2655 
W-
AziSev 
        2
4 
2 502.17
354 
251.59
041 
168.0
6270 
126.2
9884 
530.16
846 
265.58
787 
177.3
9434 
133.2
9757 
I 2411.2
8515 
1206.1
4621 
804.4
3323 
603.5
7674 
2
3 
3 616.21
647 
308.61
187 
206.0
7701 
154.8
0958 
644.21
139 
322.60
933 
215.4
0865 
161.8
0830 
N 2298.2
0108 
1149.6
0418 
766.7
3854 
575.3
0573 
2
2 
4 779.27
979 
390.14
353 
260.4
3145 
195.5
7541 
807.27
471 
404.14
099 
269.7
6309 
202.5
7413 
Y 2184.1
5815 
1092.5
8271 
728.7
2423 
546.7
9499 
2
1 
5 894.30
674 
447.65
701 
298.7
7377 
224.3
3214 
922.30
166 
461.65
447 
308.1
0540 
231.3
3087 
D 2021.0
9483 
1011.0
5105 
674.3
6979 
506.0
2916 
2
0 
6 965.34
386 
483.17
557 
322.4
5281 
242.0
9142 
993.33
878 
497.17
303 
331.7
8444 
249.0
9015 
A 1906.0
6788 
953.53
758 
636.0
2748 
477.2
7243 
1
9 
7 1052.3
7589 
526.69
158 
351.4
6348 
263.8
4943 
1080.3
7081 
540.68
904 
360.7
9512 
270.8
4816 
S 1835.0
3076 
918.01
902 
612.3
4844 
459.5
1315 
1
8 
8 1123.4
1301 
562.21
014 
375.1
4252 
281.6
0871 
1151.4
0793 
576.20
760 
384.4
7416 
288.6
0744 
A 1747.9
9873 
874.50
300 
583.3
3776 
437.7
5514 
1
7 
9 1194.4
5013 
597.72
870 
398.8
2156 
299.3
6799 
1222.4
4505 
611.72
616 
408.1
5320 
306.3
6672 
A 1676.9
6161 
838.98
444 
559.6
5872 
419.9
9586 
1
6 
1
0 
1350.5
5125 
675.77
926 
450.8
5527 
338.3
9327 
1378.5
4617 
689.77
672 
460.1
8691 
345.3
9200 
R 1605.9
2449 
803.46
588 
535.9
7968 
402.2
3658 
1
5 
1
1 
1449.6
1967 
725.31
347 
483.8
7808 
363.1
6038 
1477.6
1459 
739.31
093 
493.2
0971 
370.1
5910 
V 1449.8
2337 
725.41
532 
483.9
4597 
363.2
1130 
1
4 
1
2 
1520.6
5679 
760.83
203 
507.5
5712 
380.9
1966 
1548.6
5171 
774.82
949 
516.8
8875 
387.9
1838 
A 1350.7
5495 
675.88
111 
450.9
2317 
338.4
4419 
1
3 
1
3 
1633.7
4086 
817.37
407 
545.2
5181 
409.1
9067 
1661.7
3578 
831.37
153 
554.5
8344 
416.1
8940 
L 1279.7
1783 
640.36
255 
427.2
4413 
320.6
8491 
1
2 
1
4 
1690.7
6233 
845.88
480 
564.2
5896 
423.4
4604 
1718.7
5725 
859.88
226 
573.5
9060 
430.4
4477 
G 1166.6
3376 
583.82
052 
389.5
4944 
292.4
1390 
1
1 
1
5 
1803.8
4640 
902.42
684 
601.9
5365 
451.7
1706 
1831.8
4132 
916.42
430 
611.2
8529 
458.7
1579 
I 1109.6
1229 
555.30
978 
370.5
4228 
278.1
5853 
1
0 
1
6 
1904.8
9408 
952.95
068 
635.6
3621 
476.9
7898 
1932.8
8900 
966.94
814 
644.9
6785 
483.9
7771 
T 996.52
822 
498.76
775 
332.8
4759 
249.8
8751 
9 
1
7 
2005.9
4176 
1003.4
7452 
669.3
1877 
502.2
4090 
2033.9
3668 
1017.4
7198 
678.6
5041 
509.2
3963 
T 895.48
054 
448.24
391 
299.1
6503 
224.6
2559 
8 
1
8 
2105.0
1018 
1053.0
0873 
702.3
4158 
527.0
0800 
2133.0
0510 
1067.0
0619 
711.6
7322 
534.0
0673 
V 794.43
286 
397.72
007 
265.4
8247 
199.3
6367 
7 
1
9 
2218.0
9425 
1109.5
5076 
740.0
3627 
555.2
7902 
2246.0
8917 
1123.5
4822 
749.3
6791 
562.2
7775 
L 695.36
444 
348.18
586 
232.4
5966 
174.5
9657 
6 
2
0 
2319.1
4193 
1160.0
7460 
773.7
1883 
580.5
4094 
2347.1
3685 
1174.0
7206 
783.0
5047 
587.5
3967 
T 582.28
037 
291.64
382 
194.7
6497 
146.3
2555 
5 
2
1 
2466.1
7735 
1233.5
9231 
822.7
3063 
617.2
9979 
2494.1
7226 
1247.5
8977 
832.0
6227 
624.2
9852 
M-
Oxidati
on 
481.23
269 
241.11
998 
161.0
8241 
121.0
6363 
4 
2
2 
2567.2
2503 
1284.1
1615 
856.4
1319 
642.5
6171 
2595.2
1994 
1298.1
1361 
865.7
4483 
649.5
6044 
T 334.19
727 
167.60
227 
112.0
7061 
84.30
478 
3 
2
3 
2668.2
7271 
1334.6
3999 
890.0
9575 
667.8
2363 
2696.2
6762 
1348.6
3745 
899.4
2739 
674.8
2236 
T 233.14
959 
117.07
843 
78.38
805 
59.04
286 
2 
2
4 
                I 132.10
191 
66.554
59 
44.70
549 
33.78
094 
1 
 
274-A*RVALGITTVLTMTTINTHLRE-265 
166 
 
 
#
1   a⁺   a²⁺   a³⁺   a⁴⁺   b⁺   b²⁺   b³⁺   b⁴⁺   Seq.   y⁺   y²⁺   y³⁺   y⁴⁺  
#
2  
1 274.04
727 
137.52
727 
92.02
061 
69.26
728 
302.04
219 
151.52
473 
101.3
5225 
76.26
600 
A-
AziSev 
        2
2 
2 430.14
839 
215.57
783 
144.0
5432 
108.2
9256 
458.14
331 
229.57
529 
153.3
8595 
115.2
9128 
R 2357.2
8581 
1179.1
4654 
786.4
3346 
590.0
7691 
2
1 
3 529.21
681 
265.11
204 
177.0
7712 
133.0
5966 
557.21
173 
279.10
950 
186.4
0876 
140.0
5839 
V 2201.1
8469 
1101.0
9598 
734.3
9975 
551.0
5163 
2
0 
4 600.25
393 
300.63
060 
200.7
5616 
150.8
1894 
628.24
885 
314.62
806 
210.0
8780 
157.8
1767 
A 2102.1
1627 
1051.5
6177 
701.3
7694 
526.2
8453 
1
9 
5 713.33
800 
357.17
264 
238.4
5085 
179.0
8996 
741.33
292 
371.17
010 
247.7
8249 
186.0
8869 
L 2031.0
7915 
1016.0
4321 
677.6
9790 
508.5
2525 
1
8 
6 770.35
947 
385.68
337 
257.4
5801 
193.3
4533 
798.35
439 
399.68
083 
266.7
8965 
200.3
4405 
G 1917.9
9508 
959.50
118 
640.0
0321 
480.2
5423 
1
7 
7 883.44
354 
442.22
541 
295.1
5270 
221.6
1634 
911.43
846 
456.22
287 
304.4
8434 
228.6
1507 
I 1860.9
7361 
930.99
044 
620.9
9606 
465.9
9886 
1
6 
8 984.49
122 
492.74
925 
328.8
3526 
246.8
7826 
1012.4
8614 
506.74
671 
338.1
6690 
253.8
7699 
T 1747.8
8954 
874.44
841 
583.3
0137 
437.7
2784 
1
5 
9 1085.5
3890 
543.27
309 
362.5
1782 
272.1
4018 
1113.5
3382 
557.27
055 
371.8
4946 
279.1
3891 
T 1646.8
4186 
823.92
457 
549.6
1881 
412.4
6592 
1
4 
1
0 
1184.6
0732 
592.80
730 
395.5
4063 
296.9
0729 
1212.6
0224 
606.80
476 
404.8
7226 
303.9
0602 
V 1545.7
9418 
773.40
073 
515.9
3625 
387.2
0400 
1
3 
1
1 
1297.6
9139 
649.34
933 
433.2
3532 
325.1
7831 
1325.6
8631 
663.34
679 
442.5
6695 
332.1
7703 
L 1446.7
2576 
723.86
652 
482.9
1344 
362.4
3690 
1
2 
1
2 
1398.7
3907 
699.87
317 
466.9
1788 
350.4
4023 
1426.7
3399 
713.87
063 
476.2
4951 
357.4
3895 
T 1333.6
4169 
667.32
448 
445.2
1875 
334.1
6588 
1
1 
1
3 
1545.7
7449 
773.39
088 
515.9
2968 
387.1
9908 
1573.7
6940 
787.38
834 
525.2
6132 
394.1
9781 
M-
Oxidatio
n 
1232.5
9401 
616.80
064 
411.5
3619 
308.9
0396 
1
0 
1
4 
1646.8
2217 
823.91
472 
549.6
1224 
412.4
6100 
1674.8
1708 
837.91
218 
558.9
4388 
419.4
5973 
T 1085.5
5860 
543.28
294 
362.5
2438 
272.1
4511 
9 
1
5 
1747.8
6985 
874.43
856 
583.2
9480 
437.7
2292 
1775.8
6476 
888.43
602 
592.6
2644 
444.7
2165 
T 984.51
092 
492.75
910 
328.8
4182 
246.8
8319 
8 
1
6 
1860.9
5392 
930.98
060 
620.9
8949 
465.9
9394 
1888.9
4883 
944.97
805 
630.3
2113 
472.9
9267 
I 883.46
324 
442.23
526 
295.1
5926 
221.6
2127 
7 
1
7 
1975.9
8086 
988.49
407 
659.3
3181 
494.7
5067 
2003.9
7578 
1002.4
9153 
668.6
6344 
501.7
4940 
N-
Deamid
ated 
770.37
917 
385.69
322 
257.4
6457 
193.3
5025 
6 
1
8 
2077.0
2854 
1039.0
1791 
693.0
1437 
520.0
1259 
2105.0
2346 
1053.0
1537 
702.3
4600 
527.0
1132 
T 655.35
222 
328.17
975 
219.1
2226 
164.5
9351 
5 
1
9 
2214.0
8745 
1107.5
4736 
738.7
0067 
554.2
7732 
2242.0
8237 
1121.5
4482 
748.0
3231 
561.2
7605 
H 554.30
454 
277.65
591 
185.4
3970 
139.3
3159 
4 
2
0 
2327.1
7152 
1164.0
8940 
776.3
9536 
582.5
4834 
2355.1
6644 
1178.0
8686 
785.7
2700 
589.5
4707 
L 417.24
563 
209.12
645 
139.7
5339 
105.0
6687 
3 
2
1 
2483.2
7264 
1242.1
3996 
828.4
2907 
621.5
7362 
2511.2
6756 
1256.1
3742 
837.7
6070 
628.5
7235 
R 304.16
156 
152.58
442 
102.0
5870 
76.79
585 
2 
2
2 
                E 148.06
044 
74.533
86 
50.02
500 
37.77
057 
1 
 
275-VALGIT*TVLTM-286 
167 
 
 
#1   a⁺   a²⁺   b⁺   b²⁺   Seq.   y⁺   y²⁺   #2  
1 72.08078 36.54403 100.07570 50.54149 V     11 
2 143.11790 72.06259 171.11282 86.06005 A 1265.57331 633.29029 10 
3 256.20197 128.60462 284.19689 142.60208 L 1194.53619 597.77173 9 
4 313.22344 157.11536 341.21836 171.11282 G 1081.45212 541.22970 8 
5 426.30751 213.65739 454.30243 227.65485 I 1024.43065 512.71896 7 
6 757.35298 379.18013 785.34790 393.17759 T-AziSev 911.34658 456.17693 6 
7 858.40066 429.70397 886.39558 443.70143 T 580.30111 290.65419 5 
8 957.46908 479.23818 985.46400 493.23564 V 479.25343 240.13035 4 
9 1070.55315 535.78021 1098.54807 549.77767 L 380.18501 190.59614 3 
10 1171.60083 586.30405 1199.59575 600.30151 T 267.10094 134.05411 2 
11         M-Oxidation 166.05326 83.53027 1 
 
337-IKIPDL*TDVN-446 
 
#1   a⁺   a²⁺   b⁺   b²⁺   Seq.   y⁺   y²⁺   #2  
1 86.09643 43.55185 114.09135 57.54931 I     10 
2 214.19140 107.59934 242.18632 121.59680 K 1244.54444 622.77586 9 
3 327.27547 164.14137 355.27039 178.13883 I 1116.44947 558.72837 8 
4 424.32824 212.66776 452.32316 226.66522 P 1003.36540 502.18634 7 
5 539.35519 270.18123 567.35011 284.17869 D 906.31263 453.65995 6 
6 882.43705 441.72216 910.43197 455.71962 L-AziSev 791.28568 396.14648 5 
7 983.48473 492.24600 1011.47965 506.24346 T 448.20382 224.60555 4 
168 
 
8 1098.51168 549.75948 1126.50660 563.75694 D 347.15614 174.08171 3 
9 1197.58010 599.29369 1225.57502 613.29115 V 232.12919 116.56823 2 
10         N 133.06077 67.03402 1 
 
A.4.6. α1β3 GABAA receptor peptides photoaffinity labeled by aziisoflurane 
FLAG-α1 GABAA receptor subunit 
135-FFHN*GKKSVAHNMTMPNKLL-154 
 
#
1  
a⁺   a²⁺   a³⁺   a⁴⁺   b⁺   b²⁺   b³⁺   b⁴⁺   Seq.   y⁺   y²⁺   y³⁺   y⁴⁺  
#
2  
1 120.08
078 
60.544
03 
40.69
845 
30.77
565 
148.07
570 
74.541
49 
50.03
008 
37.77
438 
F         2
0 
2 267.14
920 
134.07
824 
89.72
125 
67.54
276 
295.14
412 
148.07
570 
99.05
289 
74.54
149 
F 2379.0
9276 
1190.0
5002 
793.7
0244 
595.5
2865 
1
9 
3 404.20
811 
202.60
769 
135.4
0756 
101.8
0749 
432.20
303 
216.60
515 
144.7
3919 
108.8
0621 
H 2232.0
2434 
1116.5
1581 
744.6
7963 
558.7
6154 
1
8 
4 714.22
248 
357.61
488 
238.7
4568 
179.3
1108 
742.21
739 
371.61
233 
248.0
7731 
186.3
0981 
N-
AziIso 
2094.9
6543 
1047.9
8635 
698.9
9333 
524.4
9682 
1
7 
5 771.24
395 
386.12
561 
257.7
5283 
193.5
6644 
799.23
886 
400.12
307 
267.0
8447 
200.5
6517 
G 1784.9
5107 
892.97
917 
595.6
5521 
446.9
9322 
1
6 
6 899.33
892 
450.17
310 
300.4
5116 
225.5
9019 
927.33
383 
464.17
055 
309.7
8279 
232.5
8892 
K 1727.9
2960 
864.46
844 
576.6
4805 
432.7
3786 
1
5 
7 1027.4
3389 
514.22
058 
343.1
4948 
257.6
1393 
1055.4
2880 
528.21
804 
352.4
8112 
264.6
1266 
K 1599.8
3463 
800.42
095 
533.9
4973 
400.7
1411 
1
4 
8 1114.4
6592 
557.73
660 
372.1
6016 
279.3
7194 
1142.4
6083 
571.73
405 
381.4
9179 
286.3
7067 
S 1471.7
3966 
736.37
347 
491.2
5140 
368.6
9037 
1
3 
9 1213.5
3434 
607.27
081 
405.1
8296 
304.1
3904 
1241.5
2925 
621.26
826 
414.5
1460 
311.1
3777 
V 1384.7
0763 
692.85
745 
462.2
4073 
346.9
3236 
1
2 
1
0 
1284.5
7146 
642.78
937 
428.8
6200 
321.8
9832 
1312.5
6637 
656.78
682 
438.1
9364 
328.8
9705 
A 1285.6
3921 
643.32
324 
429.2
1792 
322.1
6526 
1
1 
1
1 
1421.6
3037 
711.31
882 
474.5
4831 
356.1
6305 
1449.6
2528 
725.31
628 
483.8
7994 
363.1
6178 
H 1214.6
0209 
607.80
468 
405.5
3888 
304.4
0598 
1
0 
1
2 
1535.6
7330 
768.34
029 
512.5
6262 
384.6
7378 
1563.6
6821 
782.33
774 
521.8
9425 
391.6
7251 
N 1077.5
4318 
539.27
523 
359.8
5258 
270.1
4125 
9 
1
3 
1666.7
1380 
833.86
054 
556.2
4278 
417.4
3391 
1694.7
0871 
847.85
799 
565.5
7442 
424.4
3264 
M 963.50
025 
482.25
376 
321.8
3827 
241.6
3052 
8 
1
4 
1767.7
6148 
884.38
438 
589.9
2534 
442.6
9583 
1795.7
5639 
898.38
183 
599.2
5698 
449.6
9456 
T 832.45
975 
416.73
351 
278.1
5810 
208.8
7039 
7 
1
5 
1914.7
9689 
957.90
208 
638.9
3715 
479.4
5468 
1942.7
9181 
971.89
954 
648.2
6879 
486.4
5341 
M-
Oxidati
on 
731.41
207 
366.20
967 
244.4
7554 
183.6
0847 
6 
1
6 
2011.8
4966 
1006.4
2847 
671.2
8807 
503.7
1787 
2039.8
4458 
1020.4
2593 
680.6
1971 
510.7
1660 
P 584.37
665 
292.69
196 
195.4
6373 
146.8
4962 
5 
1
7 
2125.8
9259 
1063.4
4993 
709.3
0238 
532.2
2861 
2153.8
8751 
1077.4
4739 
718.6
3402 
539.2
2733 
N 487.32
388 
244.16
558 
163.1
1281 
122.5
8643 
4 
1
8 
2253.9
8756 
1127.4
9742 
752.0
0070 
564.2
5235 
2281.9
8248 
1141.4
9488 
761.3
3234 
571.2
5108 
K 373.28
095 
187.14
411 
125.0
9850 
94.07
570 
3 
1
9 
2367.0
7163 
1184.0
3945 
789.6
9539 
592.5
2337 
2395.0
6655 
1198.0
3691 
799.0
2703 
599.5
2209 
L 245.18
598 
123.09
663 
82.40
018 
62.05
195 
2 
2
0 
                L 132.10
191 
66.554
59 
44.70
549 
33.78
094 
1 
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268-PCIMTVI*LSQVSFWLNRESVPART-301 
 
#
1  
a⁺   a²⁺   a³⁺   a⁴⁺   b⁺   b²⁺   b³⁺   b⁴⁺   Seq.   y⁺   y²⁺   y³⁺   y⁴⁺   #
2  
1 70.06
513 
35.53
620 
24.02
656 
18.27
174 
98.06
005 
49.53
366 
33.35
820 
25.27
047 
P         2
4 
2 230.0
9579 
115.5
5153 
77.37
011 
58.27
940 
258.0
9070 
129.5
4899 
86.70
175 
65.27
813 
C-
Carbamido
methyl 
2921.
34035 
1461.
17381 
974.4
5163 
731.0
9054 
2
3 
3 343.1
7986 
172.0
9357 
115.0
6480 
86.55
042 
371.1
7477 
186.0
9102 
124.3
9644 
93.54
915 
I 2761.
30969 
1381.
15848 
921.1
0808 
691.0
8288 
2
2 
4 490.2
1527 
245.6
1127 
164.0
7661 
123.3
0928 
518.2
1019 
259.6
0873 
173.4
0825 
130.3
0800 
M-
Oxidation 
2648.
22562 
1324.
61645 
883.4
1339 
662.8
1186 
2
1 
5 591.2
6295 
296.1
3511 
197.7
5917 
148.5
7120 
619.2
5787 
310.1
3257 
207.0
9081 
155.5
6992 
T 2501.
19021 
1251.
09874 
834.4
0159 
626.0
5301 
2
0 
6 690.3
3137 
345.6
6932 
230.7
8197 
173.3
3830 
718.3
2629 
359.6
6678 
240.1
1361 
180.3
3703 
V 2400.
14253 
1200.
57490 
800.7
1903 
600.7
9109 
1
9 
7 999.3
8688 
500.1
9708 
333.8
0048 
250.6
0218 
1027.
38179 
514.1
9453 
343.1
3211 
257.6
0090 
I-AziIso 2301.
07411 
1151.
04069 
767.6
9622 
576.0
2398 
1
8 
8 1112.
47095 
556.7
3911 
371.4
9517 
278.8
7319 
1140.
46586 
570.7
3657 
380.8
2680 
285.8
7192 
L 1992.
01860 
996.5
1294 
664.6
7772 
498.7
6011 
1
7 
9 1199.
50298 
600.2
5513 
400.5
0584 
300.6
3120 
1227.
49789 
614.2
5258 
409.8
3748 
307.6
2993 
S 1878.
93453 
939.9
7090 
626.9
8303 
470.4
8909 
1
6 
1
0 
1328.
54557 
664.7
7642 
443.5
2004 
332.8
9185 
1356.
54049 
678.7
7388 
452.8
5168 
339.8
9058 
Q-
Deamidate
d 
1791.
90250 
896.4
5489 
597.9
7235 
448.7
3108 
1
5 
1
1 
1427.
61399 
714.3
1063 
476.5
4285 
357.6
5896 
1455.
60891 
728.3
0809 
485.8
7449 
364.6
5768 
V 1662.
85991 
831.9
3359 
554.9
5815 
416.4
7043 
1
4 
1
2 
1514.
64602 
757.8
2665 
505.5
5352 
379.4
1696 
1542.
64094 
771.8
2411 
514.8
8516 
386.4
1569 
S 1563.
79149 
782.3
9938 
521.9
3535 
391.7
0333 
1
3 
1
3 
1661.
71444 
831.3
6086 
554.5
7633 
416.1
8407 
1689.
70936 
845.3
5832 
563.9
0797 
423.1
8280 
F 1476.
75946 
738.8
8337 
492.9
2467 
369.9
4532 
1
2 
1
4 
1847.
79376 
924.4
0052 
616.6
0277 
462.7
0390 
1875.
78868 
938.3
9798 
625.9
3441 
469.7
0263 
W 1329.
69104 
665.3
4916 
443.9
0186 
333.1
7822 
1
1 
1
5 
1960.
87783 
980.9
4255 
654.2
9746 
490.9
7492 
1988.
87275 
994.9
4001 
663.6
2910 
497.9
7364 
L 1143.
61172 
572.3
0950 
381.8
7542 
286.6
5839 
1
0 
1
6 
2075.
90478 
1038.
45603 
692.6
3978 
519.7
3165 
2103.
89969 
1052.
45348 
701.9
7141 
526.7
3038 
N-
Deamidate
d 
1030.
52765 
515.7
6746 
344.1
8073 
258.3
8737 
9 
1
7 
2232.
00590 
1116.
50659 
744.6
7348 
558.7
5693 
2260.
00081 
1130.
50404 
754.0
0512 
565.7
5566 
R 915.5
0070 
458.2
5399 
305.8
3842 
229.6
3063 
8 
1
8 
2361.
04850 
1181.
02789 
787.6
8768 
591.0
1758 
2389.
04341 
1195.
02534 
797.0
1932 
598.0
1631 
E 759.3
9958 
380.2
0343 
253.8
0471 
190.6
0535 
7 
1
9 
2448.
08053 
1224.
54390 
816.6
9836 
612.7
7559 
2476.
07544 
1238.
54136 
826.0
3000 
619.7
7432 
S 630.3
5698 
315.6
8213 
210.7
9051 
158.3
4470 
6 
2
0 
2547.
14895 
1274.
07811 
849.7
2117 
637.5
4269 
2575.
14386 
1288.
07557 
859.0
5280 
644.5
4142 
V 543.3
2495 
272.1
6611 
181.7
7983 
136.5
8670 
5 
2
1 
2644.
20172 
1322.
60450 
882.0
7209 
661.8
0589 
2672.
19663 
1336.
60195 
891.4
0373 
668.8
0462 
P 444.2
5653 
222.6
3190 
148.7
5703 
111.8
1959 
4 
2
2 
2715.
23884 
1358.
12306 
905.7
5113 
679.5
6517 
2743.
23375 
1372.
12051 
915.0
8277 
686.5
6390 
A 347.2
0376 
174.1
0552 
116.4
0610 
87.55
640 
3 
2
3 
2871.
33996 
1436.
17362 
957.7
8484 
718.5
9045 
2899.
33487 
1450.
17107 
967.1
1647 
725.5
8918 
R 276.1
6664 
138.5
8696 
92.72
706 
69.79
712 
2 
2
4 
                T 120.0
6552 
60.53
640 
40.69
336 
30.77
184 
1 
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263-IQT*YLPCIMTVIL*SQV-278 
  
#
1   a⁺   a²⁺   a³⁺   a⁴⁺   b⁺   b²⁺   b³⁺   b⁴⁺   Seq.   y⁺   y²⁺   y³⁺   y⁴⁺  
#
2  
1 86.09
643 
43.55
185 
29.37
033 
22.27
957 
114.0
9135 
57.54
931 
38.70
197 
29.27
829 
I         1
6 
2 214.1
5501 
107.5
8114 
72.05
652 
54.29
421 
242.1
4993 
121.5
7860 
81.38
816 
61.29
294 
Q 2157.
86562 
1079.
43645 
719.9
6006 
540.2
2186 
1
5 
3 511.1
7413 
256.0
9070 
171.0
6289 
128.5
4899 
539.1
6904 
270.0
8816 
180.3
9453 
135.5
4772 
T-AziIso 2029.
80704 
1015.
40716 
677.2
7387 
508.2
0722 
1
4 
4 674.2
3745 
337.6
2236 
225.4
1733 
169.3
1482 
702.2
3236 
351.6
1982 
234.7
4897 
176.3
1355 
Y 1732.
78793 
866.8
9760 
578.2
6749 
433.9
5244 
1
3 
5 787.3
2152 
394.1
6440 
263.1
1202 
197.5
8584 
815.3
1643 
408.1
6185 
272.4
4366 
204.5
8457 
L 1569.
72461 
785.3
6594 
523.9
1305 
393.1
8661 
1
2 
6 884.3
7429 
442.6
9078 
295.4
6295 
221.8
4903 
912.3
6920 
456.6
8824 
304.7
9458 
228.8
4776 
P 1456.
64054 
728.8
2391 
486.2
1836 
364.9
1559 
1
1 
7 1044.
40494 
522.7
0611 
348.8
0650 
261.8
5669 
1072.
39985 
536.7
0357 
358.1
3814 
268.8
5542 
C-
Carbamido
methyl 
1359.
58777 
680.2
9752 
453.8
6744 
340.6
5240 
1
0 
8 1157.
48901 
579.2
4814 
386.5
0119 
290.1
2771 
1185.
48392 
593.2
4560 
395.8
3283 
297.1
2644 
I 1199.
55712 
600.2
8220 
400.5
2389 
300.6
4474 
9 
9 1288.
52951 
644.7
6839 
430.1
8135 
322.8
8783 
1316.
52442 
658.7
6585 
439.5
1299 
329.8
8656 
M 1086.
47305 
543.7
4016 
362.8
2920 
272.3
7372 
8 
1
0 
1389.
57719 
695.2
9223 
463.8
6391 
348.1
4975 
1417.
57210 
709.2
8969 
473.1
9555 
355.1
4848 
T 955.4
3255 
478.2
1991 
319.1
4903 
239.6
1359 
7 
1
1 
1488.
64561 
744.8
2644 
496.8
8672 
372.9
1686 
1516.
64052 
758.8
2390 
506.2
1836 
379.9
1559 
V 854.3
8487 
427.6
9607 
285.4
6647 
214.3
5167 
6 
1
2 
1601.
72968 
801.3
6848 
534.5
8141 
401.1
8788 
1629.
72459 
815.3
6594 
543.9
1305 
408.1
8661 
I 755.3
1645 
378.1
6186 
252.4
4367 
189.5
8457 
5 
1
3 
1910.
78518 
955.8
9623 
637.5
9991 
478.4
5175 
1938.
78010 
969.8
9369 
646.9
3155 
485.4
5048 
L-AziIso 642.2
3238 
321.6
1983 
214.7
4898 
161.3
1355 
4 
1
4 
1997.
81721 
999.4
1225 
666.6
1059 
500.2
0976 
2025.
81213 
1013.
40970 
675.9
4223 
507.2
0849 
S 333.1
7687 
167.0
9207 
111.7
3047 
84.04
968 
3 
1
5 
2125.
87579 
1063.
44154 
709.2
9678 
532.2
2441 
2153.
87071 
1077.
43899 
718.6
2842 
539.2
2313 
Q 246.1
4484 
123.5
7606 
82.71
980 
62.29
167 
2 
1
6 
                V 118.0
8626 
59.54
677 
40.03
360 
30.27
702 
1 
 
286-V*PARTVFGVTTVLTMTTLSIS*ARNSLP-313  
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#
1  
a⁺   a²⁺   a³⁺   a⁴⁺   b⁺   b²⁺   b³⁺   b⁴⁺   Seq.   y⁺   y²⁺   y³⁺   y⁴⁺  
#
2  
1 268.05
222 
134.52
975 
90.022
26 
67.76
851 
296.04
713 
148.52
720 
99.353
89 
74.76
724 
V-
AziIs
o 
        2
7 
2 365.10
499 
183.05
613 
122.37
318 
92.03
170 
393.09
990 
197.05
359 
131.70
482 
99.03
043 
P 2929.4
6833 
1465.2
3780 
977.1
6096 
733.1
2254 
2
6 
3 436.14
211 
218.57
469 
146.05
222 
109.7
9098 
464.13
702 
232.57
215 
155.38
386 
116.7
8971 
A 2832.4
1556 
1416.7
1142 
944.8
1004 
708.8
5935 
2
5 
4 592.24
323 
296.62
525 
198.08
593 
148.8
1626 
620.23
814 
310.62
271 
207.41
756 
155.8
1499 
R 2761.3
7844 
1381.1
9286 
921.1
3100 
691.1
0007 
2
4 
5 693.29
091 
347.14
909 
231.76
849 
174.0
7818 
721.28
582 
361.14
655 
241.10
012 
181.0
7691 
T 2605.2
7732 
1303.1
4230 
869.0
9729 
652.0
7479 
2
3 
6 792.35
933 
396.68
330 
264.79
129 
198.8
4529 
820.35
424 
410.68
076 
274.12
293 
205.8
4402 
V 2504.2
2964 
1252.6
1846 
835.4
1473 
626.8
1287 
2
2 
7 939.42
775 
470.21
751 
313.81
410 
235.6
1239 
967.42
266 
484.21
497 
323.14
574 
242.6
1112 
F 2405.1
6122 
1203.0
8425 
802.3
9192 
602.0
4576 
2
1 
8 996.44
922 
498.72
825 
332.82
126 
249.8
6776 
1024.4
4413 
512.72
570 
342.15
289 
256.8
6649 
G 2258.0
9280 
1129.5
5004 
753.3
6912 
565.2
7866 
2
0 
9 1095.5
1764 
548.26
246 
365.84
406 
274.6
3487 
1123.5
1255 
562.25
991 
375.17
570 
281.6
3360 
V 2201.0
7133 
1101.0
3930 
734.3
6196 
551.0
2329 
1
9 
1
0 
1196.5
6532 
598.78
630 
399.52
662 
299.8
9679 
1224.5
6023 
612.78
375 
408.85
826 
306.8
9552 
T 2102.0
0291 
1051.5
0509 
701.3
3915 
526.2
5618 
1
8 
1
1 
1297.6
1300 
649.31
014 
433.20
918 
325.1
5871 
1325.6
0791 
663.30
759 
442.54
082 
332.1
5744 
T 2000.9
5523 
1000.9
8125 
667.6
5659 
500.9
9426 
1
7 
1
2 
1396.6
8142 
698.84
435 
466.23
199 
349.9
2581 
1424.6
7633 
712.84
180 
475.56
363 
356.9
2454 
V 1899.9
0755 
950.45
741 
633.9
7403 
475.7
3234 
1
6 
1
3 
1509.7
6549 
755.38
638 
503.92
668 
378.1
9683 
1537.7
6040 
769.38
384 
513.25
832 
385.1
9556 
L 1800.8
3913 
900.92
320 
600.9
5123 
450.9
6524 
1
5 
1
4 
1610.8
1317 
805.91
022 
537.60
924 
403.4
5875 
1638.8
0808 
819.90
768 
546.94
088 
410.4
5748 
T 1687.7
5506 
844.38
117 
563.2
5654 
422.6
9422 
1
4 
1
5 
1741.8
5367 
871.43
047 
581.28
941 
436.2
1887 
1769.8
4858 
885.42
793 
590.62
104 
443.2
1760 
M 1586.7
0738 
793.85
733 
529.5
7398 
397.4
3230 
1
3 
1
6 
1842.9
0135 
921.95
431 
614.97
197 
461.4
8079 
1870.8
9626 
935.95
177 
624.30
360 
468.4
7952 
T 1455.6
6688 
728.33
708 
485.8
9381 
364.6
7218 
1
2 
1
7 
1943.9
4903 
972.47
815 
648.65
453 
486.7
4271 
1971.9
4394 
986.47
561 
657.98
616 
493.7
4144 
T 1354.6
1920 
677.81
324 
452.2
1125 
339.4
1026 
1
1 
1
8 
2057.0
3310 
1029.0
2019 
686.34
922 
515.0
1373 
2085.0
2801 
1043.0
1764 
695.68
085 
522.0
1246 
L 1253.5
7152 
627.28
940 
418.5
2869 
314.1
4834 
1
0 
1
9 
2144.0
6513 
1072.5
3620 
715.35
989 
536.7
7174 
2172.0
6004 
1086.5
3366 
724.69
153 
543.7
7047 
S 1140.4
8745 
570.74
736 
380.8
3400 
285.8
7732 
9 
2
0 
2257.1
4920 
1129.0
7824 
753.05
458 
565.0
4276 
2285.1
4411 
1143.0
7569 
762.38
622 
572.0
4149 
I 1053.4
5542 
527.23
135 
351.8
2332 
264.1
1931 
8 
2
1 
2540.1
5266 
1270.5
7997 
847.38
907 
635.7
9362 
2568.1
4757 
1284.5
7743 
856.72
071 
642.7
9235 
S-
AziIs
o 
940.37
135 
470.68
931 
314.1
2863 
235.8
4829 
7 
2
2 
2611.1
8978 
1306.0
9853 
871.06
811 
653.5
5290 
2639.1
8469 
1320.0
9599 
880.39
975 
660.5
5163 
A 657.36
788 
329.18
758 
219.7
9414 
165.0
9743 
6 
2
3 
2767.2
9090 
1384.1
4909 
923.10
182 
692.5
7818 
2795.2
8581 
1398.1
4655 
932.43
346 
699.5
7691 
R 586.33
076 
293.66
902 
196.1
1510 
147.3
3815 
5 
2
4 
2881.3
3383 
1441.1
7055 
961.11
613 
721.0
8891 
2909.3
2874 
1455.1
6801 
970.44
777 
728.0
8764 
N 430.22
964 
215.61
846 
144.0
8140 
108.3
1287 
4 
2
5 
2968.3
6586 
1484.6
8657 
990.12
680 
742.8
4692 
2996.3
6077 
1498.6
8403 
999.45
844 
749.8
4565 
S 316.18
671 
158.59
699 
106.0
6709 
79.80
214 
3 
2
6 
3081.4
4993 
1541.2
2860 
1027.8
2149 
771.1
1794 
3109.4
4484 
1555.2
2606 
1037.1
5313 
778.1
1667 
L 229.15
468 
115.08
098 
77.05
641 
58.04
413 
2 
2                 P 116.07 58.538 39.36 29.77 1 
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7 061 94 172 311 
295-VTTVLTMTTLSI*SARNSLPKVAYATAMD-322  
 
#
1  
a⁺   a²⁺   a³⁺   a⁴⁺   b⁺   b²⁺   b³⁺   b⁴⁺   Seq.   y⁺   y²⁺   y³⁺   y⁴⁺  
#
2  
1 72.08
078 
36.54
403 
24.69
845 
18.77
565 
100.0
7570 
50.54
149 
34.03
008 
25.77
438 
V         2
8 
2 173.1
2846 
87.06
787 
58.38
101 
44.03
757 
201.1
2338 
101.0
6533 
67.71
264 
51.03
630 
T 3053.
44012 
1527.
22370 
1018.
48489 
764.1
1549 
2
7 
3 274.1
7614 
137.5
9171 
92.06
357 
69.29
949 
302.1
7106 
151.5
8917 
101.3
9520 
76.29
822 
T 2952.
39244 
1476.
69986 
984.8
0233 
738.8
5357 
2
6 
4 373.2
4456 
187.1
2592 
125.0
8637 
94.06
660 
401.2
3948 
201.1
2338 
134.4
1801 
101.0
6533 
V 2851.
34476 
1426.
17602 
951.1
1977 
713.5
9165 
2
5 
5 486.3
2863 
243.6
6795 
162.7
8106 
122.3
3762 
514.3
2355 
257.6
6541 
172.1
1270 
129.3
3634 
L 2752.
27634 
1376.
64181 
918.0
9696 
688.8
2454 
2
4 
6 587.3
7631 
294.1
9179 
196.4
6362 
147.5
9954 
615.3
7123 
308.1
8925 
205.7
9526 
154.5
9826 
T 2639.
19227 
1320.
09977 
880.4
0227 
660.5
5353 
2
3 
7 718.4
1681 
359.7
1204 
240.1
4379 
180.3
5966 
746.4
1173 
373.7
0950 
249.4
7543 
187.3
5839 
M 2538.
14459 
1269.
57593 
846.7
1971 
635.2
9161 
2
2 
8 819.4
6449 
410.2
3588 
273.8
2635 
205.6
2158 
847.4
5941 
424.2
3334 
283.1
5799 
212.6
2031 
T 2407.
10409 
1204.
05568 
803.0
3955 
602.5
3148 
2
1 
9 920.5
1217 
460.7
5972 
307.5
0891 
230.8
8350 
948.5
0709 
474.7
5718 
316.8
4055 
237.8
8223 
T 2306.
05641 
1153.
53184 
769.3
5699 
577.2
6956 
2
0 
1
0 
1033.
59624 
517.3
0176 
345.2
0360 
259.1
5452 
1061.
59116 
531.2
9922 
354.5
3524 
266.1
5325 
L 2205.
00873 
1103.
00800 
735.6
7443 
552.0
0764 
1
9 
1
1 
1120.
62827 
560.8
1777 
374.2
1428 
280.9
1253 
1148.
62319 
574.8
1523 
383.5
4591 
287.9
1125 
S 2091.
92466 
1046.
46597 
697.9
7974 
523.7
3662 
1
8 
1
2 
1429.
68378 
715.3
4553 
477.2
3278 
358.1
7640 
1457.
67869 
729.3
4298 
486.5
6441 
365.1
7513 
I-AziIso 2004.
89263 
1002.
94995 
668.9
6906 
501.9
7862 
1
7 
1
3 
1516.
71581 
758.8
6154 
506.2
4345 
379.9
3441 
1544.
71072 
772.8
5900 
515.5
7509 
386.9
3314 
S 1695.
83713 
848.4
2220 
565.9
5056 
424.7
1474 
1
6 
1
4 
1587.
75293 
794.3
8010 
529.9
2249 
397.6
9369 
1615.
74784 
808.3
7756 
539.2
5413 
404.6
9242 
A 1608.
80510 
804.9
0619 
536.9
3988 
402.9
5673 
1
5 
1
5 
1743.
85405 
872.4
3066 
581.9
5620 
436.7
1897 
1771.
84896 
886.4
2812 
591.2
8784 
443.7
1770 
R 1537.
76798 
769.3
8763 
513.2
6084 
385.1
9745 
1
4 
1
6 
1858.
88099 
929.9
4413 
620.2
9852 
465.4
7571 
1886.
87591 
943.9
4159 
629.6
3015 
472.4
7443 
N-
Deamid
ated 
1381.
66686 
691.3
3707 
461.2
2714 
346.1
7217 
1
3 
1
7 
1945.
91302 
973.4
6015 
649.3
0919 
487.2
3371 
1973.
90794 
987.4
5761 
658.6
4083 
494.2
3244 
S 1266.
63991 
633.8
2359 
422.8
8482 
317.4
1544 
1
2 
1
8 
2058.
99709 
1030.
00218 
687.0
0388 
515.5
0473 
2086.
99201 
1043.
99964 
696.3
3552 
522.5
0346 
L 1179.
60788 
590.3
0758 
393.8
7414 
295.6
5743 
1
1 
1
9 
2156.
04986 
1078.
52857 
719.3
5481 
539.7
6792 
2184.
04478 
1092.
52603 
728.6
8644 
546.7
6665 
P 1066.
52381 
533.7
6554 
356.1
7945 
267.3
8641 
1
0 
2
0 
2284.
14483 
1142.
57605 
762.0
5313 
571.7
9167 
2312.
13975 
1156.
57351 
771.3
8477 
578.7
9039 
K 969.4
7104 
485.2
3916 
323.8
2853 
243.1
2322 
9 
2
1 
2383.
21325 
1192.
11026 
795.0
7594 
596.5
5877 
2411.
20817 
1206.
10772 
804.4
0757 
603.5
5750 
V 841.3
7607 
421.1
9167 
281.1
3021 
211.0
9948 
8 
2
2 
2454.
25037 
1227.
62882 
818.7
5498 
614.3
1805 
2482.
24529 
1241.
62628 
828.0
8661 
621.3
1678 
A 742.3
0765 
371.6
5746 
248.1
0740 
186.3
3237 
7 
2
3 
2617.
31369 
1309.
16048 
873.1
0942 
655.0
8388 
2645.
30861 
1323.
15794 
882.4
4105 
662.0
8261 
Y 671.2
7053 
336.1
3890 
224.4
2836 
168.5
7309 
6 
2
4 
2688.
35081 
1344.
67904 
896.7
8846 
672.8
4316 
2716.
34573 
1358.
67650 
906.1
2009 
679.8
4189 
A 508.2
0721 
254.6
0724 
170.0
7392 
127.8
0726 
5 
2
5 
2789.
39849 
1395.
20288 
930.4
7102 
698.1
0508 
2817.
39341 
1409.
20034 
939.8
0265 
705.1
0381 
T 437.1
7009 
219.0
8868 
146.3
9488 
110.0
4798 
4 
173 
 
2
6 
2860.
43561 
1430.
72144 
954.1
5006 
715.8
6436 
2888.
43053 
1444.
71890 
963.4
8169 
722.8
6309 
A 336.1
2241 
168.5
6484 
112.7
1232 
84.78
606 
3 
2
7 
2991.
47611 
1496.
24169 
997.8
3022 
748.6
2449 
3019.
47103 
1510.
23915 
1007.
16186 
755.6
2321 
M 265.0
8529 
133.0
4628 
89.03
328 
67.02
678 
2 
2
8 
                D 134.0
4479 
67.52
603 
45.35
311 
34.26
666 
1 
 
β3 GABAA receptor subunit 
65-MNIDIA*SIDMVSEVNM-80 
  
#
1  
a⁺   a²⁺   a³⁺   b⁺   b²⁺   b³⁺   Seq.   y⁺   y²⁺   y³⁺  
#
2  
1 120.0477
8 
60.5275
3 
40.6874
4 
148.0426
9 
74.5249
8 
50.0190
8 
M-
Oxidation 
      1
6 
2 234.0907
1 
117.548
99 
78.7017
5 
262.0856
2 
131.546
45 
88.0333
9 
N 1862.737
78 
931.872
53 
621.584
11 
1
5 
3 347.1747
8 
174.091
03 
116.396
44 
375.1696
9 
188.088
48 
125.728
08 
I 1748.694
85 
874.851
06 
583.569
80 
1
4 
4 462.2017
3 
231.604
50 
154.738
76 
490.1966
4 
245.601
96 
164.070
40 
D 1635.610
78 
818.309
03 
545.875
11 
1
3 
5 575.2858
0 
288.146
54 
192.433
45 
603.2807
1 
302.143
99 
201.765
09 
I 1520.583
83 
760.795
55 
507.532
79 
1
2 
6 842.2943
5 
421.650
81 
281.436
30 
870.2892
7 
435.648
27 
290.767
94 
A-AziIso 1407.499
76 
704.253
52 
469.838
10 
1
1 
7 929.3263
8 
465.166
83 
310.446
98 
957.3213
0 
479.164
29 
319.778
62 
S 1140.491
21 
570.749
24 
380.835
25 
1
0 
8 1042.410
45 
521.708
86 
348.141
67 
1070.405
37 
535.706
32 
357.473
31 
I 1053.459
18 
527.233
23 
351.824
58 
9 
9 1157.437
40 
579.222
34 
386.483
98 
1185.432
32 
593.219
80 
395.815
62 
D 940.3751
1 
470.691
19 
314.129
89 
8 
1
0 
1288.477
90 
644.742
59 
430.164
15 
1316.472
82 
658.740
05 
439.495
79 
M 825.3481
6 
413.177
72 
275.787
57 
7 
1
1 
1387.546
32 
694.276
80 
463.186
96 
1415.541
24 
708.274
26 
472.518
60 
V 694.3076
6 
347.657
47 
232.107
40 
6 
1
2 
1474.578
35 
737.792
81 
492.197
63 
1502.573
27 
751.790
27 
501.529
27 
S 595.2392
4 
298.123
26 
199.084
60 
5 
1
3 
1603.620
95 
802.314
11 
535.211
83 
1631.615
87 
816.311
57 
544.543
47 
E 508.2072
1 
254.607
24 
170.073
92 
4 
1
4 
1702.689
37 
851.848
32 
568.234
64 
1730.684
29 
865.845
78 
577.566
28 
V 379.1646
1 
190.085
94 
127.059
72 
3 
1
5 
1816.732
30 
908.869
79 
606.248
95 
1844.727
22 
922.867
25 
615.580
59 
N 280.0961
9 
140.551
73 
94.0369
1 
2 
1
6 
            M-
Oxidation 
166.0532
6 
83.5302
7 
56.0226
0 
1 
 
315-V*FVFLALLEYAFVNY-329 
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#
1  
a⁺   a²⁺   a³⁺   a⁴⁺   b⁺   b²⁺   b³⁺   b⁴⁺   Seq.   y⁺   y²⁺   y³⁺   y⁴⁺  
#
2  
1 268.05
222 
134.5
2975 
90.02
226 
67.76
851 
296.04
713 
148.5
2720 
99.35
389 
74.76
724 
V-AziIso         1
5 
2 415.12
064 
208.0
6396 
139.0
4506 
104.5
3562 
443.11
555 
222.0
6141 
148.3
7670 
111.5
3435 
F 1709.8
8258 
855.4
4493 
570.6
3238 
428.2
2610 
1
4 
3 514.18
906 
257.5
9817 
172.0
6787 
129.3
0272 
542.18
397 
271.5
9562 
181.3
9951 
136.3
0145 
V 1562.8
1416 
781.9
1072 
521.6
0957 
391.4
5900 
1
3 
4 661.25
748 
331.1
3238 
221.0
9068 
166.0
6983 
689.25
239 
345.1
2983 
230.4
2231 
173.0
6856 
F 1463.7
4574 
732.3
7651 
488.5
8676 
366.6
9189 
1
2 
5 774.34
155 
387.6
7441 
258.7
8537 
194.3
4084 
802.33
646 
401.6
7187 
268.1
1700 
201.3
3957 
L 1316.6
7732 
658.8
4230 
439.5
6396 
329.9
2479 
1
1 
6 845.37
867 
423.1
9297 
282.4
6441 
212.1
0012 
873.37
358 
437.1
9043 
291.7
9604 
219.0
9885 
A 1203.5
9325 
602.3
0026 
401.8
6927 
301.6
5377 
1
0 
7 958.46
274 
479.7
3501 
320.1
5910 
240.3
7114 
986.45
765 
493.7
3246 
329.4
9073 
247.3
6987 
L 1132.5
5613 
566.7
8170 
378.1
9023 
283.8
9449 
9 
8 1071.5
4681 
536.2
7704 
357.8
5379 
268.6
4216 
1099.5
4172 
550.2
7450 
367.1
8542 
275.6
4089 
L 1019.4
7206 
510.2
3967 
340.4
9554 
255.6
2347 
8 
9 1200.5
8941 
600.7
9834 
400.8
6799 
300.9
0281 
1228.5
8432 
614.7
9580 
410.1
9962 
307.9
0154 
E 906.38
799 
453.6
9763 
302.8
0085 
227.3
5245 
7 
1
0 
1363.6
5273 
682.3
3000 
455.2
2243 
341.6
6864 
1391.6
4764 
696.3
2746 
464.5
5406 
348.6
6737 
Y 777.34
539 
389.1
7633 
259.7
8665 
195.0
9180 
6 
1
1 
1434.6
8985 
717.8
4856 
478.9
0147 
359.4
2792 
1462.6
8476 
731.8
4602 
488.2
3310 
366.4
2665 
A 614.28
207 
307.6
4467 
205.4
3221 
154.3
2597 
5 
1
2 
1581.7
5827 
791.3
8277 
527.9
2427 
396.1
9502 
1609.7
5318 
805.3
8023 
537.2
5591 
403.1
9375 
F 543.24
495 
272.1
2611 
181.7
5317 
136.5
6669 
4 
1
3 
1680.8
2669 
840.9
1698 
560.9
4708 
420.9
6213 
1708.8
2160 
854.9
1444 
570.2
7872 
427.9
6086 
V 396.17
653 
198.5
9190 
132.7
3036 
99.79
959 
3 
1
4 
1795.8
5363 
898.4
3045 
599.2
8940 
449.7
1887 
1823.8
4855 
912.4
2791 
608.6
2103 
456.7
1759 
N-
Deamid
ated 
297.10
811 
149.0
5769 
99.70
755 
75.03
248 
2 
1
5 
                Y 182.08
116 
91.54
422 
61.36
524 
46.27
575 
1 
 
280-ITTVLTMTTINT*-291  
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#1   a⁺   a²⁺   a³⁺   b⁺   b²⁺   b³⁺   Seq.   y⁺   y²⁺   y³⁺   #2  
1 86.09643 43.55185 29.37033 114.0913
5 
57.54931 38.70197 I       1
2 
2 187.1441
1 
94.07569 63.05289 215.1390
3 
108.0731
5 
72.38453 T 1391.595
35 
696.3013
1 
464.5366
3 
1
1 
3 288.1917
9 
144.5995
3 
96.73545 316.1867
1 
158.5969
9 
106.0670
9 
T 1290.547
67 
645.7774
7 
430.8540
7 
1
0 
4 387.2602
1 
194.1337
4 
129.7582
6 
415.2551
3 
208.1312
0 
139.0898
9 
V 1189.499
99 
595.2536
3 
397.1715
1 
9 
5 500.3442
8 
250.6757
8 
167.4529
5 
528.3392
0 
264.6732
4 
176.7845
8 
L 1090.431
57 
545.7194
2 
364.1487
1 
8 
6 601.3919
6 
301.1996
2 
201.1355
1 
629.3868
8 
315.1970
8 
210.4671
4 
T 977.3475
0 
489.1773
9 
326.4540
2 
7 
7 732.4324
6 
366.7198
7 
244.8156
7 
760.4273
8 
380.7173
3 
254.1473
1 
M 876.2998
2 
438.6535
5 
292.7714
6 
6 
8 833.4801
4 
417.2437
1 
278.4982
3 
861.4750
6 
431.2411
7 
287.8298
7 
T 745.2593
2 
373.1333
0 
249.0912
9 
5 
9 934.5278
2 
467.7675
5 
312.1807
9 
962.5227
4 
481.7650
1 
321.5124
3 
T 644.2116
4 
322.6094
6 
215.4087
3 
4 
1
0 
1047.611
89 
524.3095
8 
349.8754
8 
1075.606
81 
538.3070
4 
359.2071
2 
I 543.1639
6 
272.0856
2 
181.7261
7 
3 
1
1 
1161.654
82 
581.3310
5 
387.8897
9 
1189.649
74 
595.3285
1 
397.2214
3 
N 430.0798
9 
215.5435
8 
144.0314
8 
2 
1
2 
            T-
AziIso 
316.0369
6 
158.5221
2 
106.0171
7 
1 
  
176 
 
A.5. Table of Propofol-specific proteome as determined by AziPm-click(1c)  activity-
based protein profiling  
*Please Refer to Associated excel file (A.5. Table of Propofol-specific proteome as 
determined by AziPm-click(1c)  activity-based protein profiling) for table A.5.* 
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